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mmol      millimole(s) 
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1 General Introduction 
1.1 Nuclear Medicine 
In 1934, Irene and Frederic Joliot-Curie discovered the artificial radioactivity, 
representing the most significant milestone in nuclear medicine.(1) Nuclear medicine 
gained public recognition only after December 7, 1946, when an article was published 
in the Journal of the American Medical Association (JAMA) by S.M Seidlin.(2) The 
article described a successful treatment of a patient with thyroid cancer using 
radioactive iodine (I-131). Widespread clinical use of nuclear medicine, however, did 
not start until the early 1950s, as knowledge expanded about radionuclides, detection 
of radioactivity, and using certain radionuclides to trace biochemical processes. 
Despite considerable advances in knowledge about the application of radiotracer 
technique for interrogating physiologic and pathophysiologic cardiopulmonary 
conditions in the early twentieth century, the spatial resolution of the scintigraphic 
instruments used to measure tracer concentration in different organs was limited. The 
development of single photon emission computed tomography (SPECT) in the late 
1970s and PET in the 1980s dramatically changed the clinical utility of radiotracer 
techniques for the assessment of myocardial perfusion, and since that time, nuclear 
medicine has changed rapidly as a result of these technological developments.(3-7) 
1.1.1 Radionuclide  
A radioactive nuclide is an atom with an unstable nucleus that decays, emitting alpha, 
beta, or gamma rays. In alpha decay, the nucleus ejects a helium nucleus composed of 
two neutrons and two protons, dropping the mass of the original nucleus by four mass 
units. Atoms emit beta particles through a process known as beta decay. Beta decay 
occurs when an atom has either too many protons or too many neutrons in its nucleus. 
Two types of beta decay can occur. One type (β+ decay) releases a positively charged 
beta particle called a positron, and a neutrino; the other type (β- decay) releases a 
Chapter 1 
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negatively charged beta particle called an electron, and an antineutrino. The neutrino 
and the antineutrino are high energy elementary particles with little or no mass and 
are released in order to conserve energy during the decay process. Gamma decay 
occurs because the nucleus is at too high an energy. The nucleus falls down to a lower 
energy state and, in the process, emits a high energy photon known as a gamma 
particle (Table 1.1).  
 
Table 1.1 Common isotopes used in nuclear medicinea 
 
isotope symbol T1/2 decay gamma (keV) positron (keV) 
Imaging: 
fluorine-18 18F 109.77 m β+ 511 (193%) 249.8 (97%) 
gallium-67 67Ga 3.26 d ec 93 (39%), 
185 (21%), 
300 (17%) 
- 
krypton-81m 81mKr 13.1 s IT 190 (68%) - 
rubidium-82 82Rb 1.27 m β+ 511 (191%) 3.379 (95%) 
nitrogen-13 13N 9.97 m β+ 511 (200%) 1190 (100%) 
technetium-99m 99mTc 6.01 h IT 140 (89%) - 
indium-111 111In 2.80 d ec 171 (90%), 
245 (94%) 
- 
iodine-123 123I 13.3 h ec 159 (83%) - 
xenon-133 133Xe 5.24 d β- 81 (31%) 0.364 (99%) 
thallium-201 201Tl 3.04 d ec 69–83 (94%),
167 (10%) 
- 
Therapy: 
yttrium-90 90Y 2.67 d β- - 2.280 (100%) 
iodine-131 131I 8.02 d β- 364 (81%) 0.807 (100%) 
T1/2 = half-life; β+ = β+ decay; β- = β- decay; IT = isomeric transition; ec = electron capture 
a) Retrieved from Wikipedia 
 
Radiation can be absorbed by matter in its path. For example, alpha radiation travels 
only a few centimeters in air, beta radiation travels tens of centimeters in air, while 
gamma radiation travels many meters. Alpha and beta particles are effective only for a 
short distance because they use up their energy when they hit other atoms. Hence, 
these particles can cause internal radiation exposure hazard and affect health when 
they cause changes in the cells of the human body. These types of radiation can be 
used to kill cancer cells for therapeutic purpose. Gamma rays have a relatively long 
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range of penetration in air and matter and are not as ionizing as alpha or beta particles, 
hence, they can be detected outside the body and cause minimum damage to the 
patient. This type of radiation can be used to image the cancer cells for diagnosis 
purpose.(8) 
1.1.2 Therapeutic nuclear medicine 
Nuclear medicine treatments are technically a form of radiation therapy. Targeted 
tumor radiotherapy is a kind of radiation therapy that the radionuclides, which have 
high linear energy transfer particle emissions, are carried to a malignant site by 
appropriate carrier molecules in order to deliver lethal radiation dose to the tumors 
with minimal injury to normal tissue. There are three main types of radiation that can 
be emitted by radioactive particles (Table 1.2). They are called alpha, beta, and 
gamma and all three types of radiation come from the nucleus of the atom.(9) 
Physical characteristics include type and range of emissions, half-life, and chemical 
characteristics considered important for the selection of an appropriate therapy 
radioisotope. Most therapy agents utilize β-particle emissions for their ability to 
penetrate tissues. The ultimate target to achieve cell damage is the nucleus. The β 
emitter selected must therefore have an appropriate path length to reach the nucleus. 
There are several choices with respect to energy of the β emission. Lower energy β 
particles are desirable because they deposit all of their kinetic energy within a few cell 
diameters. These may be useful for microscopic targets and reducing damage to 
healthy tissue. Carrier molecules that target the cell surface require a longer particle 
path length to achieve nuclear damage and are ideally labeled with high energy β 
emitters such as P-32, Y-90, and Ho-166, which have excellent tissue penetration with 
a range beyond the source of several millimeters. Medium energy β particles such as 
those from iodine-131 have a shorter path length and may result in less dose 
homogeneity to the tissue, but still retain excellent therapeutic results.(10) 
Although pre-clinical research and clinical trials suffer from limited availability of 
alpha emitters, there has been growing interest in alpha-particle emitters for targeted 
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radionuclide therapy over the past several years because of their high linear energy 
transfer and relative biological efficiency. The path length of alpha-particles in tissues 
only has a few cell diameters so that they can destroy tumor cells with minimal 
damage to surrounding healthy tissue. Cell damage essentially results from ionization 
and rupture of chemical bonds due to the kinetic energy transfer of alpha particles. 
 
Table 1.2 Three Types of Radioactive Decay 
 
Type        Symbol     Type of energy    Characteristics      Representative 
                                                          radionuclide 
Alpha decay    α          Particle     Release of 2 protons,      211At, 212Bi 
2 neutrons               
 
Beta decay     β　       Particle      Release of 1 electron       131I, 90Y 
 
Gamma decay  γ      Electromagnetic  Release of photons           111In 
 
Ultra short-lived radioisotope of bismuth, Bi-213 has been studied for antibody 
mediated tumor targeting. Because of its short half-life (46 min), Bi-213 must be 
produced at the place of utilization. Radioisotopes with longer half-life, 225Ac and 
212Pb, may be suitable for use in systemic treatment. 225Ac has a sufficiently long 
half-life (10 days) that results in optimal pharmacokinetics and is conveniently 
produced from Thorium 229 generators. 212Pb with half-life of 10.6 hours can be 
attached to monoclonal antibodies for cancer treatment.(10) 
1.1.3 Diagnostic nuclear medicine 
Diagnostic nuclear medicine generally uses small amounts of radioisotopes given 
intravenously or orally, and then external detectors capture and form images from the 
radiation emitted by the radiopharmaceuticals.(11-13). This diagnostic test helps 
evaluate different organ systems, including kidneys, liver, heart, lungs, thyroid, and 
bones. For many diseases, nuclear medicine is the most reliable method for making 
diagnoses. 
Positron emission tomography (PET) and single-photon emission computed 
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tomography (SPECT) are noninvasive nuclear imaging modalities that provide 
clinical information regarding the living tissue in patients. In PET the radionuclides 
emit positrons (positively charged electrons) when they decay. The emitted positron 
travels in tissue until it interacts with an electron, resulting in the annihilation of both 
particles and the creation of two gamma rays which are used to create a tomographic 
image. The most important radiopharmaceutical used in the medical imaging modality 
PET is 2-18F-fluoro-2-deoxyglucose (FDG), in which the hydroxyl group in the 
2-position of D-glucose is replaced by 18F. It can be used for the assessment of 
glucose metabolism in the heart, lungs, and the brain in PET imaging.(14-17) Unlike 
PET, radionuclides used in SPECT emit gamma rays, which are then recorded on 
cameras and reconstructed to determine the location of the decay events.(18) 99mTc is 
the most commonly used radionuclide for SPECT and the advantages of using this 
radionuclide are discussed in section 1.2. The ideal nuclear characteristics and its 
wide range availability are the main reason for widespread application of 99mTc based 
radiopharmercuticals.(19, 20) One widely used example in nuclear medicine imaging 
is technetium sestamibi (trade name Cardiolite), which is a lipophilic cation consisting 
of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile ligands. 
The drug is mainly used to image the myocardium (heart muscle) and its lipophilicity 
leads to a favorable accumulation in the tissues.(21-23)  
 
Table 1.3 Comparison of PET versus SPECT for imaging in nuclear medicine 
 
Imaging 
modality 
Radiation type  Type of energy  Characteristics  Representative 
radiotracer 
 
SPECT   
 
 
PET 
 
γ      Electromagnetic  Release of photons   99mTc 111In 
123I 
 
β+          Particle        Release of positively    18F 11C 
   charged electrons      13N 15O 
 
The comparison of the two imaging modalities, PET and SPECT, are shown in Table 
1.3. One advantage of PET imaging is that there are more biologically relevant 
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isotopes available such as F-18, C-11, which can be covalently incorporated into a 
molecule.(24, 25) The main disadvantage is its high cost and not widely available. Up 
to now, there are only 3 FDA (U.S. Federal Drug Administration)-approved PET 
radiopharmaceuticals, 18F-FDG (see Figure 1.1), 18F-FDOPA (3,4-dihydroxy- 
6-fluoro- phenylalanine), and 18F-Fluoride. This thesis focuses on the design of new 
SPECT based imaging agents. SPECT isotopes are generally cheaper than PET 
isotopes, and the gamma ray tracers used for SPECT usually have a longer half-life, 
like 6 hours for 99mTc, than the β+ tracers used for PET, like 1.9 hours for 18F. In 
addition, SPECT is based on much cheaper technology when compared to PET, 
Short-lived PET radiopharmaceuticals need to be produced by an expensive onsite 
cyclotron. SPECT, in contrast, produce images using gamma cameras which are 
available to most clinicians. These combined properties make SPECT much more 
widely applicable than PET.(26-28) 
 
O
HO
HO
18F
OH
OH
 
 
Figure 1.1 Structure of 18F-FDG ( 2-deoxy-2-fluoro-glucose) 
 
1.2 Tc-99m in diagnostic nuclear medicine 
The most commonly used radioisotope in nuclear medicine is technetium-99m, a 
metastable nuclear isomer  of technetium-99, used in over 85 percent of all nuclear 
medicine scans worldwide.(20) Technetium-99m was first discovered in 1938 as a 
product of cyclotron bombardment of molybdenum. This procedure produced a 
radionuclide molybdenum-99(99Mo, t1/2=66h), which decays to Tc-99m. As an ideal 
radionuclide for diagnostic imaging, 99mTc only emits gamma rays with energy of 141 
keV and these are of an energy that is easily detected by a gamma camera. It has an 
ideal half life (6 h) which is long enough that the labeling synthesis of 
the radiopharmaceutical can be performed without significant loss of radioactivity but 
Chapter 1 
Page | 17   
short enough that the radioactivity administered to the body decreases rapidly with 
time, producing a radiation exposure equivalent to that obtained from a single normal 
X-ray.(29)  
Technetium does not have any nonradioactive isotopes that permit the convenient 
characterization of compounds prepared by the new chemical methods. Rhenium (Re) 
is also a group VIIB transition metal that shares similar coordination geometries with 
technetium, thus it can be used as a nonradioactive surrogate for characterization of 
99mTc radiopharmaceuticals. HPLC retention time comparison of the rhenium and 
technetium complexes derived from the same ligand is used as the primary method for 
identification of 99mTc complexes. If coinjection of both complexes shows the 
identical retention time, this is considered evidence of the technetium complex 
formation. 
 
Tc
H2O CO
H2O CO
CO
OH2  
 
Figure 1.2 The structure of technetium (I) tricarbonyl core 
 
Aside from traditional approach based on coordination chemistry for radiolabeling 
small molecules with 99mTc via stabilization of the [TcVO]3+ metal core with ligands 
containing N or S chelating donors, organometallic labeling strategy  has been 
investigated.(30, 31) The most well-known approach is using Alberto’s reagent 
[99mTc(CO)3(OH2)3]+ (Figure 1.2).(32) The three aqua ligands can be readily replaced 
by many other donor atoms. Previous work from our laboratory has established the 
organometallic chemistry of Tc(I) and Re(I) tricarbonyl complexes containing the 
fac-M(CO)3 moiety.(33-37) This core is of particular interest, not only because it is 
very small and stable over a wide range of pH values, but also because it provides 
excellent labeling efficiencies with a number of donor atoms. The new organometallic 
precursor [99mTc(CO)3(OH2)3]+ has been successfully used for radiolabeling  of 
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biomolecules with low-valent 99mTc.(38-46) Our group previously reported the 
radiolabel Neurotensin by functionalizing the NH2 terminus of Neurotensin with 
histidine or (N-histidinyl)acetic acid and obtained relatively high specific activity 
radiocomplexes, more importantly, the biological activity of the peptide was 
maintained.(47) In this thesis, we designed and synthesized several small tripod 
chelates with different number of nitrogen and oxygen donor atoms for 
[99mTc(CO)3(OH2)3]+ core. The reasons for this interest is that the tripod ligands have 
strong coordination ability with Alberto’s reagent and the resulting complexes are 
quite small and hydrophilic, which are essential for the biological behavior of 
radiopharmaceuticals  
1.3 Carbohydrate-based radiopharmaceuticals 
1.3.1 Designing of diagnostic radiopharmaceuticals 
Diagnostic radiopharmaceuticals are radiolabelled tracers that target specific organs 
or functions whose activity kinetics in tissue can be detected externally by specialised 
imaging systems such as gamma cameras and positron emission tomography scanners. 
An important part of the design of diagnostic radiopharmaceuticals is the chelating 
portion capable of strongly binding radioactive metals. The target-specific 
biomolecule itself usually does not bind strongly to metals, so a chelating portion 
needs to be introduced to the target molecule. This is bifunctional chelating agent 
(BFCA) approach for designing a targeted metal radiopharmaceutical, as illustrated in 
Figure 1.3. There are three essential parts designed into bioconjugates of this type: (i) 
Chelate (ii) Biomolecule (carrier) (iii) Linker or spacer. The primary function of the 
chelate is to produce radiometal complexes that are stable in vitro and in vivo. 
Biomolecules such as peptides, monoclonal antibodies and other receptor avid 
molecules carries a radionuclide as a payload and results in specific delivery of 
radioactivity to the desired site while sparing nearby organs from unnecessary 
radiation dose. The function of a linker is to prevents chelate’s interference with 
biomolecule and adjust the lipophilic property of the bifunctional chelating agent. 
Chapter 1 
Page | 19   
 
Receptor
Biomolecule
Radionuclide
Chelate
Linker
 
 
Figure 1.3 BFCA approach for the design of diagnostic radiopharmaceuticals 
 
Biomolecules are molecules that occur naturally in living organisms and there are four 
major classes of biomolecules: Carbohydrates; Lipids; Proteins; Nucleic acids. The 
carbohydrates based bifunctional chelates that are the focus of this thesis are a class of 
attractive bioconjugates for the development of diagnostic radiopharmaceuticals due 
to the biological importance of carbohydrates that will be discussed in section 1.3.2. 
99mTc is one of the most important medical radioisotopes in nuclear medicine 
applications due to its easy availability and ideal nuclear decay characteristics and 
therefore, the design of a 99mTc labeled glucose derivative as a SPECT analogue of the 
well established PET tracer [18F]FDG is considered to be of great interest.(48, 49) 
Although some were recognized with relatively good affinity by hexokinase, the 
intracellular enzyme, the major problem to overcome is to effectuate transport through 
the cell membrane actively mediated by GLUT1.  
In our endeavour for designing new carbohydrate derivatives able to be transported by 
GLUT1, we designed for this PhD project a number of new glucose derivatives, 
which are functionalized at different positions via a PEG spacer with the 
1,2-diamino-propionic acid (Dap) chelator. Dap, replacing the ε-NH2 group in Lysine 
was shown to yield a molecular imaging agent actively transported by the L-type 
amino acid transporter LAT1. Furthermore, we identified in previous work that Dap is 
a very strong chelator for the [99mTc(CO)3]+ core, yielding small and hydrophilic 
complexes.(50-53) 
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1.3.2 Carbohydrate metabolism in Vivo    
Carbohydrates are a class of interesting building-block molecules for organic 
chemistry and drug development due to their involvement in various biological 
systems.(54, 55) Some carbohydrates are relatively small molecules. The most 
important to us is glucose, a simple sugar that is metabolized by nearly all known 
organisms. The breakdown of glucose to provide energy begins with the metabolic 
process called glycolysis. The free energy released in this process is used to form ATP 
(adenosine triphosphate) - the biological energy currency. Another important 
metabolic pathway is called oxidative phosphorylation that involves the conversion of 
ADP to ATP by the electron transport system in aerobic respiration. This pathway is a 
highly efficient way of releasing energy, generating 33.6 ATP per glucose molecule, 
compared to 2 ATP per glucose molecule for anaerobic glycolysis. Cancer cells have 
an altered cellular metabolism that promotes tumor survival and growth, which led to 
a high rate of glucose consumption compared with normal cells. This phenomenon, 
known as aerobic glycolysis or the Warburg effect, has important medical 
applications for the diagnosis and monitoring treatment responses of cancers by 
imaging uptake of 2-18F-2-deoxyglucose (FDG) with positron emission tomography 
(PET).(56) Thus glucose was widely used as a targeting vector for designing of 
diagnostic or therapeutic radiopharmaceuticals. 
Hexokinase was first described by Meyerhof, who prepared the enzyme from baker's 
yeast.(57) It has a molecular weight of 100 kDa and is composed of an N-terminal 
regulatory domain a C-terminal catalytic domain. Each domain weighs about 50kD 
and contains a glucose binding site. It is an important enzyme that catalyzes the 
ATP-dependent phosphorylation of hexose to hexose-6-phosphate.The enzyme can 
catalyse this reaction on glucose, fructose, sorbitol and glucosamine as the first 
reaction in glycolysis pathway. The addition of a charged phosphate group at the 
6-position of hexoses acts to trap it in a cell, since charged hexose phosphates cannot 
easily cross the cell membrane (Figure 1.4). 
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Figure.1.4 Phosphorylation of Glucose by hexokinase 
 
Four different isozymes of hexokinase have been identified in mammals and each 
isozyme display distinct catalytic and regulatory properties. In contrast to normal cells, 
most malignant cells display increased expression and activity of hexokinase 2, which 
play a important role in tumor development by enhancing aerobic glycolysis.(58) 
There are many inhibitors of hexokinase that are being investigated as potential 
therapeutic agent in cancer treatment. Geschwind et al.(59) reported a novel 
therapeutic strategy for liver cancer by direct intraarterial injection of 
3-bromopyruvate (3-BrPA), a potent inhibitor of cell ATP production, to 
liver-implanted rabbit tumors. The result showed that this strategy is highly effective, 
reducing the total number of viable cells to as low as 10% in a single injection without 
doing any apparent harm to the animals. Bertoni et al tested N-Appended glucosamine 
derivatives and found that several compounds exhibited competitive inhibition of 
hexokinase.(60) 
Glucose is a uncharged polar molecule that is unable to cross the plasma membrane 
by passive diffusion and therefore requires specific carrier proteins to mediate its 
specific transport into the cell. Glucose transporters (GLUT) are a wide group of 
membrane proteins that facilitates glucose transport across these tissue barriers.(61) 
The human GLUTs family consists of 14 members and these facilitative glucose 
transporters are functionally distinct from the Na+-dependent transporters which 
contribute to renal glucose reabsorption. The molecular weight of all Glut proteins 
range from 40 to 60 kDa and they are all glycosylated at or near the C terminus and 
are present on either cell surface or in intracellular sites. Tumor cells usually exhibit 
an altered metabolism characterized by exhanced aerobic glycolysis. Increases in 
glucose consumption help supply the energy for tumour cell proliferation and survival 
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that necessitate the overexpression of GLUTs. For example, GLUT1 appears to be the 
predominant glucose transporter in many types of cancer cells that include the breast, 
liver, pancreas, lung, thyroid, bone, cervix. Thus, metabolic changes of tumours can 
be used in the designing a carbohydrate based imaging agent.(62) 
Glucose transporter type 1(GLUT1), a member of GLUTs family, is a major glucose 
transporter in the mammalian blood-brain barrier and is present at high levels in 
primate erythrocytes and brain endothelial cells. Although it has been proved that 
GLUT1 exhibits substrate specificity for glucose and galactose, the transport of 
non-natural substrates across biological membranes have been observed.(63, 64) 
When designing the glucose based imaging agents, it is important to keep the 
substrate specificity of glucose transporters and enhance the cell permeability. Zheng 
et al. described the synthesis of a porphyrin-glucosamine derivative (Figure 1.5a) and 
found that the compound was transported into cells.(65)  
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Figure 1.5 Functionalized glucose derivatives that exhibit GLUT glucose transporter activity: (a) 
porphyrin-appended glucosamine (b) 6-NBDG (c) 2-NBDG 
 
Speizer and coworkers reported a fluorescent derivative of glucose 6-NBDG (Figure 
1.5b) which was transported into human erythrocytes. It was found that the cellular 
uptake was competitively inhibited by D-glucose and that suggested the involvement 
of a glucose transporter in erythrocyte membrane.(66) 2-NBDG (Figure 1.5c) was 
also synthesized by Yoshioka et al,(67) it was shown that this compound is not only 
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transported into cells by GLUTs, but also phosphorylated by hexokinase.  
18F-FDG, as a glucose analogue, is actively transported into cells by GLUT 
transporters and subsequently phosphorylated by hexokinase to FDG 6-phosphate. 
The negative charged FDG 6-phosphate is unable to permeate the cell membrane and 
therefore accumulates once it has been absorbed. In addition, due to the absence of C2 
hydroxyl group, 18F-FDG-6-phosphate can not be further metabolized in cells. These 
properties make FDG a perfect imaging agent for glucose metabolism and give us 
inspiration in designing new carbohydrate based imaging agents. 
1.4 Peptide-based radiopharmaceuticals 
Peptide-based targeting vectors as carriers for radionuclides are in the focus of finding 
and developing new radiolabeled compounds for molecular imaging purposes. Since 
distinct peptide receptors are strongly overexpressed in many tumor cells, they 
represent attractive targets for radionuclide based diagnosis and therapy in 
oncology.(68-74) Most peptide radiopharmaceuticals, which are either used in clinical 
studies or currently under preclinical evaluation, are structurally derived from 
naturally occurring peptide ligands. These have intrinsically evolved to be highly 
active ligands, but also, being mostly peptide hormones, to be rapidly degraded in 
vivo.(69) For the applicability of a radiolabeled peptide probe for in vivo imaging, 
however, high metabolic stability, suitable pharmacokinetics (e.g. fast clearance from 
the blood pool, low binding to plasma proteins or non-target tissues, fast renal 
excretion) and high receptor affinity are crucial. Even if all these issues have been 
carefully addressed and an “optimized” small and metabolically stable peptide 
sequence with high affinity towards the target receptor is available, introduction of the 
radiolabel may represent a serious challenge on both receptor affinity and in vivo 
pharmacokinetics, depending on the radionuclide and labeling method chosen. For 
example, the use of radiometals requires the functionalization of the biomolecule with 
an usually bulky chelator for radiometal complexation. Even if this modification is 
well tolerated in a given position of the peptide sequence and does not seriously 
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challenge receptor affinity, it may still have substantial impact on the overall 
pharmacokinetics of the peptide radiopharmaceutical. This problem has been 
repeatedly observed for 99mTc-labeled peptides, and recent research has therefore been 
focused on the development of suitable bifunctional chelators (BFC) allowing 
99mTc-labeling with high efficiency, leading to complexes with high stability. The 
influence of the type of chelator on labeling efficiencies and complex stabilities has 
recently been reviewed comprehensively several times.(75-79) However, in some 
cases, coordination chemistry and physicochemical characteristics such as 
lipophilicity of the complexes were not optimally compatible with the requirements 
for in vivo imaging applications. 
1.4.1 Peptide synthesis 
Chemical synthesis is one way for the production of peptides, by which unnatural 
amino acids can be incorporated and obtain larger peptides of the desired 
sequence.(80) There are two strategies for the chemical peptide synthesis: 
solution-phase and solid-phase peptide synthesis (SPPS) (Figure 1.6). Classical 
solution synthesis of peptides has been only used for the synthesis of small peptides 
due to the requirement of purification or work-up after each step. Bruce Merrifield 
developed in 1963 a method for peptide synthesis, based on reaction on a solid phase, 
for which he was awarded the Nobel Prize in Chemistry 1984.(81) The development 
of solid phase peptide synthesis was a major breakthrough allowing for the chemical 
synthesis of large complex peptides.  
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Figure 1.6 Solid Phase Peptide Synthesis using Fmoc methodology 
 
Two major chemistries used for SPPS are Fmoc (base labile protecting group) and 
Boc (acid labile protecting group).(82) Unlike ribosome protein synthesis, SPPS is 
traditionally carried out in a C-terminal to N-terminal direction. The N-termini of 
amino acid monomers are protected by either of these two groups and introduced into 
a deprotected amino acid chain. Fmoc chemistry is known for peptide synthesis of 
avoidance of hydrofluoric acid and good yield compared with Boc chemistry and it is 
therefore used for most routine synthesis. In general, Solid phase peptide synthesis 
consists of three steps: 1) assembly of a protected peptide chain on a polymeric 
support 2) cleavage and deprotection of the resin-bound, fully protected peptide chain 
3) chromatographic purification of the crude peptide. The selectivity of amino 
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protecting group for each amino acid monomer is the key point for the effectiveness 
of the peptide assembly process. Most widely used amino protecting groups for 
peptide synthesis have centered around three groups: Carboxybenzyl (abbreviated as 
Cbz or Z), removed by catalytic hydrogenation; tert-butoxycarbonyl (abbreviated as 
Boc or t-Boc), removed by mild acidolysis; and 9-fluorenylmethoxycarbonyl 
(abbreviated as Fmoc), removed by secondary amines. These groups are orthogonal to 
each other that the Boc group is stable to secondary amines and catalytic 
hydrogenation, the Fmoc group is stable to acidolysis, and the Cbz group is stable to 
secondary amines and mild acidolysis. Each of these protecting groups has found its 
place in SPPS. 
1.4.2 Bombesin peptide analogues 
Bombesin is a 14-amino acid peptide (pGlu1-Gln2-Arg3-Leu4-Gly5-Asn6-Gln7- 
Trp8-Ala9-Val10-Gly11-His12-Leu13-Met14-NH2) (Figure 1.7), originally isolated 
from the skin of the oriental fire-bellied toad (Bombina orientalis). It shows high 
affinity and specificity for GRP (gastrin-releasing peptide) receptors, which is 
overexpressed on a variety of human cancer cells, like prostate, breast, lung, and 
pancreatic cancers.(83) To date, Four BN/GRP receptor subtypes have been 
characterized: the GRP preferring subtype (BRS-1), the neuromedin B preferring 
subtype (BRS-2) and the bombesin receptor subtype 3 (BRS-3) and the receptor 
subtype 4 (BRS-4). High expression of BBN/GRP receptors on a variety of human 
tumours provides an attractive target for molecular imaging and internal radiotherapy. 
It has been show that 7-14 amino acid sequence of BBN with amidated C-terminus 
(Gln7-Trp8-Ala9-Val10-Gly11-His12-Leu13-Met14-NH2) is critical for receptor 
binding affinity and biological activity.(84) Most reported BBN analogues therefore 
are based on 7-14 amino acid sequence, coupled with a chelator through a spacer 
group at the N-terminus of the peptide.(84, 85) As 99mTc is most commonly used 
radionuclide for diagnostic Nuclear Medicine, much attention has been focused on 
developing 99mTc-labeled BBN analogues with different types of chelators, such as 
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SN3(triamidethiol), N4 (tetraamine), P2S2(dithiadiphospine). In this work, we mainly 
focused on the small tripod chelators based on N2O and NO2 ligands due to their 
favourable properties as discussed in section 1.3. 
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Figure 1.7 Structure of BBN (7-14) 
 
Volkert et al. described the synthesis and the radiolabeling of P2S2 (dithiadiphosphine) 
-based BBN analogue. The 99mTc-P2S2-BBN (7-14) conjugate in vivo exhibited a 
favourable biodistribution profile after injection in normal mice. The radiopeptide was 
rapidly cleared from the blood and non-target tissues and more importantly, 
significant uptake of radioactivity was observed in the pancreas where acini cells 
express GRP receptors.(86) 
Wiele et al. reported a 99mTc-labeled BBN (7-14) analogue based on SN3 chelator 
(99mTc-RP-527). In vitro evaluation showed that this compound was rapidly and 
specifically bound and internalised by both PC-3 and CF-PAC-1 cells. In SCID mice 
with tumour xenografts study, the radiopeptide accumulated in tumour resulting in 
high tumour-to-muscle ratios. The preliminary clinical studies indicate that 
99mTc-RP527 is a pharmacologically safe radioligand and the low brain, lung, and 
myocardial uptake and rapid hepatobiliary excretion of 99mTc-RP527 resulted in 
excellent imaging conditions for the supradiaphragmatic region.(87, 88) 
Maina and co-workers reported the synthesis of tetraamine (N4) bombesin analogue, 
which is derived from the potent bombesin antagonist, wherein a tetraamine chelating 
unit was covalently attached to D-Phe residue through a benzylaminodiglycolic acid 
spacer. Preclinical study showed that the 99mTc-labeled BBN analogue exhibited high 
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affinity for the GRP-R and high specific uptake in PC-3 xenografts and pancreas in 
mice.(89) 
1.4.3 RGD cyclic peptide 
Integrins are heterodimeric transmembrane receptors containing the α (alpha) and β 
(beta) subunits that mediate the attachment between a cell and its surroundings. In 
mammals, eighteen α and eight β subunits have been characterized and the different 
combinations of them generate 24 unique integrins, although the number varies 
according to different studies.(90, 91) 
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Figure 1.8 99mTc-apcitide approved by FDA 
 
The most studied αIIbβ3 or αvβ3 integrin-binding motif is the sequence 
arginine-glycine-aspartic acid (RGD), which is present in many extracellular matrix 
proteins and intracellular proteins. αIIbβ3 integrin-receptor is expressed only on 
activated platelets and many synthetic peptides targeting this integrin have been 
successfully radiolabeled with 99mTc. A successful example of such radio-imaging 
agent is 99mTc-apticide (AcuTect ® P280, Diatide, Nycomed Amersham) (Figure 1.8), 
which was the first RGD-mimicking peptide studied in humans.(92, 93) It is approved 
by the Food and Drug Administration and can be used for the detection of acute 
venous thrombosis. 
The integrin receptor αvβ3 is highly expressed on tumor cells, endothelial cells and 
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stromal cells. It is involved in angiogenesis, osteoclast-mediated bone resorption and 
tumor metastasis and is being investigated intensively. Linear as well as cyclic RGD 
peptides targeting the αvβ3 integrin have been studied for many years. Cyclic 
pentapeptides such as cyclo(RGDfV), cyclo(RGDfE), c(RGDfK) and c(RGDyK), 
showed high binding affinity for integrin αvβ3. Among these peptides, the most 
commonly used for the delivery of diagnostic and therapeutic agents are c(RGDfK) 
and c(RGDyK), on which the ε-amino group of the L-Lysine is an ideal site for 
further modification. Thus, these RGD containing peptides are very useful tool for the 
targeting of imaging agents to αvβ3-integring expressing tumor vasculature.  
Decristoforoa et al. reported the biological evaluation of [99mTc] labeled 
[c(RGDyK(HYNIC))].(94) The derivatization of c(RGDyK) with HYNIC at the 
ε-amino group of the Lysine gave the HYNIC RGD, which was radiolabeled using 
tricine, tricine–nicotinic acid (NA) or EDDA as coligands. Among these 
99mTc-peptide conjugates, [99mTc]EDDA/HYNIC-RGD shows most favorable 
properties to target αvβ3 receptors with high stability in vivo. Thus, this RGD analogue 
was considered as a good candidate for imaging αvβ3 integrin receptor expression in 
tumors. 
Smith and co-workers described the design and synthesis of a new cyclic RGD 
analogue [c(RGDyK(PZ))] (PZ =3,5-Me2-pz(CH2)2N((CH2)3COOH)-(CH2)2NH2) that 
can be radiolabeled with the metal precursor [99mTc(CO)3(H2O)3]+.(95) In vivo study 
showed a specific accumulation of radiolabeled peptide on αvβ3 receptor-positive 
melanoma cancer cells suggesting the potential utility of this new cyclic RGD 
derivative to image angiogenesis and tumor formation. 
1.5 Conclusion 
The design and synthesis of radiolabeled-biomolecule conjugates for receptor 
targeting is playing an increasingly important role in development of 
radiopharmaceuticals. Bifunctional chelator (BFC) approach is mainly used to design 
target specific radiopharmaceutical. In this approach, a suitable bifunctional chelate 
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was used to form a stable conjugate with the biomolecule and at the same time hold 
the radionuclide tightly. In the design of radiopharmaceuticals for the molecular 
imaging and targeted radiotherapy of disease, many important issues have to be 
considered including radioisotopes, bifunctional chelating agents, and targeting 
molecules. In this thesis, we chose to use 99mTc as the radionuclide, small tripod 
ligands as the chelating agents, and glucose and peptides as the targeting 
biomolecules. These units were assembled to build up the final radiopharmaceutical 
by using BFC approach. 
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2 Aims and Objectives 
Although we have made huge progress in medicine, cancer remains the most feared 
disease, with more than 10 million new cases every year. Current 
radiopharmaceuticals for cancer imaging and treatment also detect and kill healthy 
cells and cause toxicity to the patient. It would therefore be desirable to develop more 
target-specific agents for molecular imaging and radiation therapy of tumours. 
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Figure 2.1 Design of peptide based radiopharmaceuticals for targeted tumor diagnosis 
 
As discussed in section 1.3 and 1.4, Receptor-binding peptides and Glut1-mediated 
glucose are a class of useful biomolecules for the development of such tumor-specific 
radiopharmaceuticals. Hence, the design and evaluation of radiolabeled biomolecules 
for early diagnosis or systemic radiotherapy of tumors is very meaningful in nuclear 
medical research. In previous work in our group, it has already been shown that 1, 
2-diamino-propionic acid (Dap) is a very strong tripod chelator for 
[99mTc(H2O)3(CO)3]+ core, providing very small and hydrophilic complexes. The 
main goal of this PhD thesis is the design, synthesis and biological evaluation of 
metal tripod chelate-containing biomolecule conjugates. Towards this goal, cyclic as 
well as linear peptide and glucose were selected to be modified with different small 
tripod ligands and their analogues.  
For the synthesis of peptide conjugates, the objective was to incorporate the 
bifunctional chelates into the peptide sequence such as BBN analogues, RGD cyclic 
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peptides (Figure 2.2). The resulting peptides were then labeled with organometallic 
tricarbonyl precursor[99mTc(H2O)3(CO)3]+, yielding very hydrophilic metal-peptide 
conjugates, which were then finally evaluated in vitro and in vivo as potential peptide 
radiopharmaceuticals (Figure 2.1).  
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Figure 2.2 Synthetic strategies for bifunctional chelate-peptide conjugates 
 
Carbohydrates are a class of interesting building blocks due to their involvement in 
various biological systems. PET Imaging of glucose metabolism has gained 
considerable interest in recent years.(96-100) 2-[18F]-fluoro-2-deoxy-D-glucose 
([18F]-FDG) is the most successful and widely used imaging agent in PET in clinical 
routine so far. Since 18F has some disadvantages, especially cost and half life time, 
there has been growing interest in the design of 99mTc labeled glucose derivatives as 
surrogates of [18F]-2-fluoro-desoxy glucose ([18F]-FDG). We therefore designed for 
this PhD project a number of new glucose derivatives. Such derivatives are 
functionalized at position C1, C2, C3, C6 via a PEG spacer with the Dap chelator 
(Figure 2.3). Our approach involved i) radioactive labeling of these promising 
candidates at low concentration (10-5M) and ii) testing of 99mTc complexes for cell 
internalization and transport via Glut1. 
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3 Synthesis of N2O, NO2, and N3 bifunctional chelate ligands 
containing PEG spacers 
3.2 Results and discussion 
PEG is the abbreviation for polyethylene glycol. Conjugation of a biomolecule with 
poly (ethylene glycol) polymers is designed to improve the pharmacological 
properties of a drug molecule. It enhances aqueous solubilities and give minimal loss 
of biological activity. To couple PEG to a biomolecule, the modification of PEG 
molecule with different functional group at one or both termini is necessary. In this 
work, we choose triethylene glycol as the spacer, which one end was attached to the 
small tripod chelate and the other end was a biomolecule. 
3.1.1 α-amination of ethyl or methyl cyanoacetate 
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Scheme 3.1 Synthesis of cyanoacetate derivatives; (a) AcOH, NaNO2/H2O (b) i) Na2S2O4, 
NaHCO3/H2O ii) TsOH, EtOH/Ether (c) Boc2O, Toluene (d) Boc2O, CH2Cl2/H2O 
 
The total synthesis of small tripod ligands ethyl or methyl 2-(tert-butoxy 
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carbonylamino)-2-cyanoacetate is shown in Scheme 3.1. The nitrosylation of ethyl or 
methyl acetate using sodium nitrite in aqueous acetic acid afford oxime 3.1. Sodium 
dithionite reduction of 3.1 followed by treatment with p-toluenesulfonic acid gives the 
tosylate of ethyl or methyl aminocyanoacetate 3.2. The final Boc protection of 3.2 
afforded the desired compound 3.3 in 20% overall yield for the three steps. The 
commercial available aminomalonate hydrochloride was protected as its N-Boc 
derivative 3.4 in 88% yield (Scheme 3.1). The 1H spectra of 3.4 agreed well with 
literature data.(101) 
3.1.2 Synthesis of triethylene glycol derivatives 
For conjugation to other molecules, we synthesized mesylate 3.6 and iodide 3.7 
(Scheme 2). Benzyl protected alcohol 3.5 was synthesized from triethylene glycol; the 
free hydroxyl group was then mesylated to afford compound 3.6 in 90% yield. The 
formation of 3.6 was confirmed by 1H NMR spectroscopy, with the presence of a 
singlet at about 3.00 ppm (integrating as three proton in total) corresponding to the 
proton of the methyl group.The displacement of mesylate group with sodium iodide 
gave pure compound 3.7 (90% yield). Iodide and mesylate are both good leaving 
groups in nucleophilic substitution reactions that facilitate the attachment of binding 
site to one end of PEG linker. 
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Scheme 3.2 Synthesis of mesylate 3.6 and iodide 3.7; (a) BnBr, K2CO3, acetone (b) MeSO2Cl, 
Et3N, CH2Cl2 (c) NaI, 2-butanone 
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3.1.3 Synthesis of protected N2O bifunctional chelate ligands 
Bifunctional chelate ligand 3.11 and 3.13: The synthesis of protected N2O 
bifunctional chelate ligands 3.11 and 3.13 starting from mesylate 3.6 was shown in 
scheme 3.3. In a first step, the deprotonation of methyl 
2-(tert-butoxycarbonylamino)-2-cyanoacetate with sodium methylate (freshly 
prepared by dissolving sodium in MeOH) gave the corresponding sodium salt, which 
was then treated with mesylate 3.6 in DMSO at 70° to afford 3.8 in excellent yield. 
We found that nucleophilic displacement of mesylate by the sodium salt in THF was 
difficult but proceed in good yield when carried out in DMSO.(102) Reduction of 
nitrile 3.8 employing catalytic quantities of nickel (II) chloride with excess sodium 
borohydride gave Boc protected amine 3.9. The removal of benzyl group using 
catalytic hydrogenation gave the desired alcohol 3.10, which was then converted to 
bromide 3.11 by triphenylphosphine and CBr4 in THF.  
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Scheme 3.3 Synthesis of fully protected N2O bifunctional chelate ligand 3.11 and 3.13; (a) 3.3, 
NaOMe, DMF (b) NaBH4, Boc2O, MeOH (c) Pd/C, EtOH (d) Ph3P, CBr4,THF (e) i) TFA/DCM ii) 
Tfa2O, Et3N (f) Pd/C, MeOH 
 
Both Boc protecting groups of 3.9 were replaced with base labile group trifluoroacetyl 
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(TFA) followed by removing of benzyl group to produce alcohol 3.13 in 63% overall 
yield after two steps. The successful formation of 3.12 was confirmed by 1H NMR 
spectroscopy in CDCl3, with two broad singlets at 8.63 and 7.56 ppm corresponding 
to the NH hydrogen. 
Bifunctional chelate ligand 3.18: The ligand 3.18 was synthesized from methyl ester 
3.9, as summarized in scheme 3.4. Direct reduction of 3.9 gave alcohol 3.14 by using 
LiBH4 in THF in 70% yield. The protection of hydroxyl group in the compound 3.14 
was accomplished with TBSCl in the presence of imidazole, followed by removal of 
the benzyl protecting group by hydrogenolysis, furnishing the desired alcohol 3.16. 
Formation of the product 3.15 was confirmed by 1H NMR spectroscopy, with two 
singlets at 0.86 and 0.03 ppm corresponding to the methyl protons of the TBS group. 
Mesylation of the OH of 3.16 with methanesulfonyl chloride in the presence of TEA 
and followed by an SN2 substitution using NaN3 in DMF, led to the desired azide 3.17 
in 79% yield. Finally, reduction of the azide group in 3.17, accomplished by catalytic 
hydrogenation, resulted in the formation of the desired bifunctional chelate ligand 
3.18 in 80% yield.  
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Scheme 3.4 Synthesis of fully protected N2O bifunctional chelate ligand 3.18; (a) LiBH4, THF 
(b)TBSCl, imidazole, DMF (c) Pd/C, MeOH (d) i) MsCl, CH2Cl2, Et3N ii)NaN3, DMF (e) Pd/C, 
EtOH 
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We initially tried to use triphenylphosphine (Staudinger reduction) to reduce the azido 
group, but it proved difficult to separate the reaction mixture. Thus, we tried to reduce 
the azide 3.17 via catalytic hydrogenation over 10% palladium on carbon under 2 bar. 
hydrogen at room temperature, a general method for the reduction of azides, but the 
yield of the target amine 3.18 was only 30% due to the formation of secondary amine 
(Scheme 3.5).(103) When the reaction was conducted at 0° C over 10% palladium on 
carbon at an initial hydrogen pressure of 2 bar, the yield of 3.18 increased to 80% and 
the production of secondary amine was negligible. 
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Scheme 3.5 The dimerization of azide 3.17 by catalytic hydrogenation 
 
3.1.4 Synthesis of protected NO2 and N3 bifunctional chelate ligands 
Bifunctional chelate ligand 3.22 and 3.27: The preparation of ligand 3.22 and 3.27 
are summarized in Scheme 3.6. Nucleophilic displacement of the mesylate 3.6 by 
using the sodium salt of diethyl 2-(tert-butoxycarbonyl)malonate in DMSO had only 
marginal success. Instead, iodide 3.7 was used for the nucleophilic displacement by 
the sodium salt of diethyl 2-(tert-butoxycarbonyl)malonate in dry THF, furnishing 
diester 3.19 in excellent yield (90%). The removal of benzyl protection group in the 
diester 3.19 provided alcohol 3.20, which was then converted to amine 23 using 
procedures analogous to those described for 3.18. Removal of Boc protecting groups 
in diester 3.19, followed by reaction with aq NH3 in MeOH, furnished amide 3.23 in 
76% yield.  
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Scheme 3.6 Synthesis of fully protected N2O bifunctional chelate ligand 3.22 and 3.27; (a) 3.4, 
NaH, THF (b) Pd/C, MeOH (c) i) TFA/CH2Cl2 ii) aq NH3, MeOH (d)i) LiAlH4, THF ii) Boc2O, 
dioxane, NaHCO3 (e) i) MsCl, CH2Cl2, Et3N ii) NaN3, DMF (f) Pd/C, EtOH 
 
The 1H NMR spectrum of 3.23 exhibited additional broad singlets corresponding to 
the amino group. Two singlets at 7.83 and 6.43 ppm with an integration of 2H for 
each were assigned to the amide groups and one singlet at 2.57 ppm to the terminal 
NH2 group. Reduction of 3.23 using LiAlH4 in THF followed by Boc protection 
afforded target compound 3.24. The desired alcohol 3.25 was then obtained by 
catalytic hydrogenation. Conversion of the alcohol 3.25 to the amine 3.27 was 
accomplished by employing conditions similar to those used for the preparation of 
3.18 in Scheme 3.4.  
Bifunctional chelate ligand 3.31: The ligand 3.31 was prepared using the protocol as 
outlined in Scheme 3.7. Selective hydrolysis of the diester 3.19 by LiOH in 
THF/Water gave the carboxylic acid, which was converted to the HOBt ester with 
BOP reagent and DIPEA (Caution: highly carcinogenic HMPA formed).The active 
ester was then reacted with NaBH4 to give the alcohol 3.28 (54% yield), followed by 
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the protection of the hydroxyl group with TBS to produce 3.29 in 87% yield.  
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Scheme 3.7 Synthesis of protected N2O bifunctional chelate ligand 3.31; (a) i) LiOH, H2O THF 
ii)BOP, NaBH4, THF(b) TBSCl, imidazole, DMF (c) Pd/C, MeOH (d) sodium iodoacetate, 
NaH/DMF 
 
1H NMR spectroscopy of 3.29 showed the signals of to the protection groups, two 
singlets at 0.81 and 0.03 ppm due to the methyl protons of the TBS group, a triplet at 
1.23 ppm with an integration of 3H for the methyl protons of the ester group, a singlet 
at 1.39 ppm with an integration of 9H for the methyl protons of the Boc group. The 
alkylation of alcohol 3.30 with sodium iodoacetate provide the carboxylic acid 3.31 
(77% yield).  
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Scheme 3.8. Reduction of Carboxylic acid by BOP reagent and NaBH4 
 
Scheme 3.8 illustrates the reduction process of carboxylic acid using BOP reagent. In 
comparison with other reductants (eq, LiAlH4, Borane) for carboxylic acids, this 
method can tolerate many functional groups, such as esters, nitriles, amides, halides, 
Chapter 3 
Page | 42   
azides. Therefore, this protocol offers a wide range of applications for reduction of 
carboxylic acids.(104) 
 
3.2 Conclusion 
In this chapter, synthetic strategies for bifunctional chelate ligands containing 
triethylene glycol spacer are described. Small tripod chelating agents with different 
nitrogen, oxygen donor atoms were successfully introduced to one end of triethylene 
glycol spacer. The other terminus contains chemical reactive functional groups, 
through which these newly synthesized bifunctional chelate ligands could be 
introduced to the biomolecules. 
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4 Synthesis of orthogonally protected artificial amino acid as 
bifunctional chelators 
4.1 Results and discussion 
The design of single amino acid chelates, designed from derivatized amino acids or 
amino acid analogues, was considered suitable for development of novel 
radiopharmaceuticals, since the introduction of the single amino acid chelates does 
not result in significant alterations of the structure and function of the biomolecules. 
To introduce the single amino acid chelates into the peptide by solid phase synthesis, 
Fmoc protected amino acid with chelating agents were designed. In our study, 
L-Lysine was selected for the modification, and a series of Fmoc-protected amino 
acids with small tripod chelators carrying acid-labile side chain protecting groups 
were synthesized. 
4.1.1 Synthesis of L-Lysine derivatives 
Starting from L-Lysine, iodide 4.6, 4.10 and mesylate 4.5, 4.9 were synthesized as 
shown in Scheme 4.1. In the first step, ε-amino group of Lysine was masked by 
formation of the benzylidene imine 4.1. Benzyloxycarbonyl was then introduced to 
protect the α-amino group. Hydrolytic in situ cleavage of the ε-imine gave 
N-α-benzyloxycarbonyl-L-Lysine 4.2. For the conversion of ε-amino group to a 
hydroxyl group, two different approaches were adopted. The first approach was to use 
NaNO2 in acetic acid at 40° C. The amino group was converted to an acetyl protected 
alcohol which was then treated with Boc2O in the presence of 4-DMAP to afford 
tert-butyl ester 4.3. After hydrolytic removal of the acetyl group, the alcohol 4.4 was 
treated with methanesulfonyl chloride. The resulting mesylate 4.5 was finally 
converted to iodide 4.6. The other approach was with sodium nitroprusside at pH 9.5. 
The resulting alcohol was extracted as yellow oil after removal of complex 
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decomposition products and used without purification in the next step.(105, 106) The 
carboxylic acid was then protected to give the benzyl ester 4.8, followed by the 
synthesis of iodide 4.10 which was achieved by mesylation and displacement with 
sodium iodide. In contrast to compound 4.9, the 1H-NMR spectrum of 4.10 exhibited 
a triplet at 3.13 ppm, assigned to the methylene protons adjacent to iodide. 
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Scheme 4.1 Synthesis of L-Lysine derivatives; (a) LiOH, benzaldehyde (b) EtOH/1M NaOH, 
Benzyl chloroformate (c) 4M NaOH, sodium nitroprusside (d) i) HOAc, NaOAc, NaNO2 ii) 
Boc2O, DMAP, t-BuOH (e) K2CO3, MeOH/water (f) MsCl, Et3N (g) NaI, 2-butanone (h) BnBr, 
TEA, Acetone. 
 
4.1.2 Synthesis of L-Lysine based bifunctional chelators  
Scheme 4.2 illustrates the synthesis of tridentate single amino acid chelates (SAAC) 
derived from L-Lysine. Compound 4.11, 4.16 and 4.12, 4.17 were prepared by using 
the same conditions as described for 3.8 and 3.9 in chapter 3. Formation of the 
products was confirmed by ESI-MS and NMR spectroscopy was in agreement with 
the presence of the tripod ligand moiety. Deprotection of the carboxybenzyl (Cbz) and 
benzyl (Bn) protecting group in 4.17 was accomplished by hydrogenolysis with 10% 
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Pd/C to furnish amino acid 4.18, which was protected as its N-Fmoc derivative 4.19 
(87% yield). Hydrolysis of the methyl ester functionality of 4.12, followed by the 
reduction of the carboxylic acid using BOP reagent and Na[BH4], gave the desired 
compound 4.13 (50% yield).  Selective deprotection of the tert-butyl ester in the 
presence of N-Boc protecting group under the described conditions (ZnBr2/CH2Cl2, 
CeCl3/CH3CN) failed to get the desired compound 4.14. (107, 108) LC-MS analysis 
showed that simultaneous removal of Boc and tert-butyl protecting group occurred in 
the presence of these Lewis acids. On the other hand, a two-step reaction sequence 
involving acid deprotection of both tert-butyl and Boc group followed by 
re-introduction of N-Boc function provided 4.14 in excellent yield (87%).  
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Scheme 4.2 Synthesis of orthogonally protected BFC based on L-Lysine; (a) 3.3, NaOMe, DMF 
or 3.3a, NaOEt, DMF (b) NaBH4, NiCl2 6H2O (c) i) LiOH,THF/H2O ii) BOP, NaBH4,THF (d) 
Pd/C, EtOH (e) FmocCl, NaHCO3, dioxane/H2O ii)NaN3, DMF (f) i)TFA, CH2Cl2, ii) TMAH, 
Boc2O, CH3CN (g) i)Pd/C, MeOH ii) FmocOSu, acetone, DIEA 
 
We found that the re-introduction of N-Boc group did not succeed with standard 
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conditions (NaHCO3, Boc2O, and H2O/dioxane) after stirring for 24h due to the steric 
hindrance of one amino group. Employing another, more efficient method for 
N-tert-butoxycarbonyl protection with TMAH in acetonitrile, provided 4.14 in good 
yields.(109) After hydrogenolytic cleavage of the Cbz-protecting group and Fmoc 
protection using the more reactive Fmoc-OSu instead of Fmoc-Cl, 4.15 was obtained 
in 90% yield.  
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Scheme 4.3 Synthesis of orthogonally protected BFC based on L-Lysine; (a) 3.4, NaH, THF (b) i) 
Pd/C, MeOH ii) FmocOSu, acetone, DIEA (c) i) LiOH, THF/H2O ii) BOP, NaBH4, THF (d) i) 
TFA, CH2Cl2 ii) TMAH, Boc2O, CH3CN 
 
Bifunctional chelators 4.25 and 4.23 were synthesized as summarized in Scheme 4.3. 
After extensive experimentation with various bases and conditions, the nucleophilic 
displacement of iodide in 4.6 and 4.10 with sodium salt of diethyl 
2-(tert-butoxycarbonyl)malonate (deprotonated by sodium hydride) in THF (refluxing 
overnight), afforded pure diesters 4.20 and 4.24, respectively, in yields from 85 to 
95%. The 1H NMR spectrum of both compounds showed signals corresponding to the 
N-protected amino acid; a doublet at 5.21 ppm with an integration of 1H was assigned 
to NH proton adjacent to Cbz protecting group and a broad singlet at 5.87 ppm to the 
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NH proton adjacent to Boc protecting group. The simultaneous removal of the benzyl 
and benzyloxycarbonyl groups in 4.24, followed by the 9-fluorenylmethoxycarbonyl 
(Fmoc) protection of the amino group led to the desired bifunctional chelator 4.25 in 
92% yield. Conversion of 4.20 to the primary alcohol 4.21 by using similar conditions 
as described for 4.13, followed by the acid deprotection and re-introduction of Boc 
protecting group, provided carboxylic acid 4.22 (74% yield). The formation of 4.21 
was confirmed by HR-MS (ESI), with a peak at m/z = 575.2939 corresponding to [M 
+ Na]+. 1H NMR spectroscopy showed a doublet at 3.71 ppm with an integration of 
1H that was assigned to one of the methylene protons adjacent to hydroxyl group. For 
the re-introduction of the Boc group, no reaction was observed with standard 
conditions (NaHCO3, Boc2O, H2O/dioxane), probably due to steric hindrance of the 
amino group. Thus, we employed the same methodology (TMAH, acetonitrile, Boc2 O) 
as used for preparation of 4.14. Under this condition and as previously observed, the 
solubility of the [N(CH3)4]+ salt proved to be crucial for the success of the 
reaction.(110) In our reaction, the precipitation of the amino acid [N(CH3)4]+ salt 
dissolved rapidly in acetonitrile so that the reaction proceeded very quickly and gave 
good yields. Final removal of Cbz group followed by Fmoc protection provided the 
desired bifunctional chelator 4.23 in 78% yields. 
4.1.3 Synthesis of D-Tyrosine based bifunctional chelators  
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Scheme 4.4 Synthesis of orthogonally protected BFC based on D-Tyrosine; (a) DEAD, Ph3P, 
toluene (b) Pd(PPh3)4, N-methylaniline, THF 
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The carboxylic acid 4.27a was synthesized from D-Tyrosine derived compound 4.26 
(Scheme 4.4), which was prepared according to a known literature procedure.(111) 
The coupling of 4.26 with alcohol 3.16 under Mitsunobu protocol provided compound 
4.27 in 50% yield. Interestingly, the reaction did not go to completion and compound 
4.26 was recovered.(112)  
4.1.4 Synthesis of L-Glutamic acid based bifunctional chelators  
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Scheme 4.5 Synthesis of orthogonally protected BFC based on L-Glutamic acid; (a) EDC, HOBt, 
NMM, THF (b) (Ph3P)4Pd, N-methylaniline, THF 
 
Three L-Glutamic acid based bifunctional chelators 4.29a, 4.30a, 4.31a were prepared 
from the known L-Glutamic acid-derived compound 4.28, as shown in scheme 4.5. 
Thus, the commercially available Fmoc-L-Glutamic acid 5-tert-butyl ester was 
converted to the corresponding allyl ester and then to the carboxylic acid 4.28, 
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according to a published procedures.(113) The coupling of the carboxylic acid 4.28 
with amine by EDC·HCl and HOBt in THF, followed by removal of allyl protecting 
group in the presence of tetrakis(triphenylphosphine)palladium(0), led to the desired 
building block 4.29a, 4.30a, 4.31a, respectively.  
4.2 Conclusion 
Multistep syntheses of single amino acid chelates (SAAC) based on L-Lysine, 
L-Glutamic acid and D-Tyrosine was described in this chapter. These artificial amino 
acids offer the possibility for conjugation to biomolecules via the carboxylic acid 
group without significant effect on the structure and function. Deprotection of these 
ligands produce very strong chelators with different donor atoms for the 
[99mTc(CO3)]+ moiety.  
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5 Synthesis and in vitro evaluation of 99mTc-Carbohydrate conjugates 
5.1 Results and discussion 
Glucose plays an important role in human metabolism as one of the primary 
molecules which serve as energy sources for plants and animals. Tracers for imaging 
of glucose metabolism have gained considerable interest in recent years. In this work，
a small tridentate chelate was introduced to the different position of glucose via a 
PEG spacer. Radiolabeling of these glucose derivatives was performed and the 
resulting tehcnetium complexes were tested for their transport through cancer cell 
membranes via Glut1. 
5.1.1 Synthesis of glucose derivatives 
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Scheme 5.1 Synthesis of a glucose analogue substituted at the C1 position; (a) 3.13, BF3·Et2O, 
CH2Cl2 (b) i) LiOH, THF/H2O ii) [NEt4]2[Re(CO)3Br3], H2O 
 
Substitution at C1 position The synthesis of metal glucoconjugate 5.2 is shown in 
Scheme 5.1. In a first step, glycosylation of 3.13 with beta glucose pentaacetate in the 
presence of BF3·OEt2 in dichloromethane afford compound 5.1 in 82% yield. Only the 
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beta-anomere was observed under these conditions, in agreement with literature 
reports.(114, 115) Simultaneous removal of all the protection group by LiOH in 
water/THF, followed by the reaction with [99mTc(CO)3(H2O)3]+ or [ReBr3(CO)3]2-, 
furnished the metal complex 5.2 (99mTc-G1) and 5.2a, respectively. The successful 
formation of 5.2a was confirmed by 1H NMR spectroscopy in D2O. Although an 
unambiguous assignment of the signals is difficult, a doublet signal for C-l β proton 
can be clearly seen at 4.53 ppm. The synthetic strategy described here has many 
advantages for the preparation of glucose analogues substituted at C1 position. For 
instance, the starting material -glucose-pentaacetate is easily prepared and even 
commercially available. The coupling of -glucose-pentaacetate with alcohol 3.13 
afforded compound 5.1 in high yields. This method is simpler and more convenient 
than those previously reported in view of the easiness of the synthetic method for 
substitution at C1 position.(116, 117) Moreover, the use of base labile N-protecting 
trifluoroacetyl group remarkably simplified the synthetic procedures and greatly 
enhanced the overall yield. 
Substitution at C2 position: Unlike the synthesis of 5.1, the synthesis of glucose 
analogue 5.5 started with the protected glucofuranose instead of glucopyranose as 
shown in Scheme 5.2. According to the previous study, an effort to alkylate the 
unprotected C2 hydroxyl group of benzyl protected glucopyranose in the presence of 
different bases with an alkylbromide failed to give the desired products.(118) The 
most probable explanation for the synthetic problem is the steric hindrance of C2 
hydroxy groups on the sugar in pyranose form with the bulky benzyl groups. However, 
the protected furanose ring is considered as planar, with the C2 hydroxyl group below 
and the protecting group above the plane. The steric hindrance was thus reduced and 
the alkylation became much easier.(118) Our synthetic approach is therefore to 
alkylate the hydroxyl group at C2 position of the benzyl protected glucofuranose, 
followed by the conversion of furanose to pyranose and complexation with Re or 
99mTc. 
The benzyl protected glucofuranose 5.3, with an unprotected hydroxyl group at C2 
position was synthesized from 1, 2-O-isopropylidene-α-D- glucofuranose.(119) The 
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latter was protected to yield O-benzylated glucofuranose, which was then converted to 
5.3 by treatment with acidic ion exchange resin in MeOH. The alkylation of 5.3 using 
NaH in DMF with the bromide 3.11 (56% yield), followed by the replacement of acid 
labile amino-protecting group Boc with acid stable TFA group, furnished derivative 
5.6 (73% yield). After the reductive removal of benzyl groups, the substitution of the 
methoxy by an acetoxy group occurred in the presence of TMSOtf and acetic 
anhydride.(118, 120) Simultaneous removal of all the protecting groups by basic 
hydrolysis give the unprotected glucose derivative, which was sufficiently pure to be 
directly used for the synthesis of Re and 99mTc complexes (99mTc-G2). In 1H NMR 
spectroscopy of 5.8a, two doublets were observed at 5.25 and 4.62 ppm (with a 
coupling constant of 3.5 Hz, 8.0 Hz, respectively) and assigned to the anomeric 
protons at the C-1 position. 
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Scheme 5.2 Synthesis of glucose analogue substituted at C2 position; (a) BnBr, NaH, DMF (b) 
AmberliteH+, MeOH (c) 3.11, NaH, DMF (d) i) TFA/CH2Cl2 ii) Tfa2O, Et3N (e) i) Pd/C, MeOH ii) 
TMSOtf, Ac2O (f) i) LiOH, THF/H2O ii) [NEt4]2[Re(CO)3Br3], H2O 
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Substitution at C3 position: Scheme 5.3 illustrates the synthesis of glycoconjugate 
5.11. Acetonation of D-glucose to 1,2:5,6-diisopropylidene-α-D-glucofuranose and 
the alkylation of the latter with bromide 3.11 to 5.10 have been accomplished in 70% 
yield. Final removal of Boc protecting group and the acetone substituent, followed by 
treatment with the transition metal precursor [99mTc(OH2)3(CO)3]+ and 
[Re(OH2)3(CO)3]+, provided the sugar-metal complex 5.11(99mTc-G3) and 5.11a, 
respectively. In 1H NMR spectroscopy of the rhenium compex 5.11a, the signals of 
anomeric proton occur at 4.60 (J = 8Hz) and 5.18(J = 3Hz), respectively, due to the 
presence of a mixture of α- and β-anomers. 
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Scheme 5.3 Synthesis of glucose analogue substituted at C3 position; (a) Con H2SO4, acetone (b) 
3.11, NaH, DMF (c) i) CF3COOH, H2O ii) (NEt4)2[Re(CO)3Br3], H2O 
 
Substitution at C6 position: The technetium and rhenium glucoconjugates 5.16, 
5.16a were synthesized starting from D-glucose as shown in Scheme 5.4. Conversion 
of D-glucose to alcohol 5.14 began with the benzylation of all hydroxyl groups using 
benzyl bromide to provide 5.12 in 60% yield. Selective acetolysis of the benzyl 
protecting group at C-6 took place when 5.12 was treated with a mixture of 
HOAc-Ac2O in the presence of ZnCl2.(121) Deacetylation of 5.13 under “Zemplen” 
conditions (catalytic amount of sodium methoxide in methanol) afforded alcohol 5.14, 
which was subjected to an alkylation of the hydroxyl group with bromide 3.11 to give 
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compound 5.15 (52% yield). Acidic removal of the tert-butyloxycarbonyl group and 
reductive removal of the benzyl group in 5.15, followed by strong coordination to Tc(I) 
and Re(I) using the same condition as for preparation of 5.2, led to the desired metal 
glucoconjugate 5.16 (99mTc-G4) and 5.16a, respectively. Elementary analysis of 5.16a 
confirmed the composition. The 1H NMR spectrum clearly exhibited a doublet at 4.58 
ppm with a coupling constant of 8.0 Hz that was assigned to the C1β proton. 
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Scheme 5.4 Synthesis of glucose analogue substituted at C6 position; (a) BnBr, KOH, DMSO (b) 
ZnCl2 HOAc-Ac2O (c) NaOMe, MeOH (d) 3.11, NaH, DMF (e) i) CF3COOH, CH2Cl2 ii) Pd/C, 
MeOH iii) (NEt4)2[Re(CO)3Br3], H2O 
 
5.2 Hexokinase inhibition studies 
Hexokinase is an important enzyme that phosphorylates glucose by ATP, forming 
glucose-6-phosphate and ADP. Glucose-6-phosphate dehydrogenase (G6PDH) 
catalyzes the oxidation of G6P by NADP+ to form 6-phosphogluconate and NADPH 
(Scheme 5.5), which is determined by measuring the increase in absorbance at 340 
nm. Thus, the rate of glucose phosphorylation can be monitored 
spectrophotometrically in the presence and absence of inhibitory 
compounds.(122-124) 
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ATP + glucose
hexokinase
glucose-6-phosphate + ADP
Glucose-6-phosphate + NADP+
G6PDH
6-phosphogluconate + NADPH + H+  
 
Scheme 5.5 Test principle of the rate of glucose phosphorylation 
 
The Re complexes 5.2a, 5.8a and 5.16a have been tested for competitive inhibition of 
yeast hexokinase: 5.2a: Ki = 2.38±0.05 mM, 5.8a: Ki = 0.81±0.06 mM, the 
inhibition of 5.16a was not observed. The Lineweaver-Burk plot, also known as the 
double reciprocal plot, was used to calculate the inhibition constant Ki. For 
comparison, the known hexokinase inhibitor N-acetyl-glucosamine has an inhibition 
constant of 3.5 mM in this assay (literature value 2.72±0.05 mM).(123) The Ki 
values of these two rhenium complexes suggest that they may have interaction with 
hexokinase. It is worth noting that the C-1 functionalized rhenium glucose analogues 
have the comparable Ki value to the one of glucosamine. To the best of our 
knowledge, none of the C-1 functionalized glucose Re derivatives showing inhibition 
of hexokinase, was previously reported in the literature.(125, 126) One possible 
reason for 5.2a exhibiting interaction with hexokinase is that a PEGylated linker 
increases the water solubility of the complexes. This can also explain the result that 
no inhibition was observed for the C-1 functionalized glucose rhenium complex with 
a alkyl linker.(125) 
5.3 Cellular uptake of 99mTc-labeled glucose derivatives 
5.3.1 99mTc labelling 
The small tridentate ligands have strong coordination ability with the[99mTc(CO)3]+ 
core. The labeling traces are shown in Figure 5.1. Over a concentration range of 
10-3-10-5 M, the labeling of glucose derivatives with [99mTc(CO)3]+ was achieved in 
very good yields (>99%) by heating a buffered solution (pH 7.4) of the corresponding 
peptide and 99mTc-tricarbonyl precursor at 70° C for 15-30 min. The rhenium 
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complexes were synthesized by heating each ligand with the [Re(OH2)3(CO)3]+ 
precursor in water at 70℃ for 6 h. The identity of complexes was confirmed by 
HPLC coinjection with the corresponding rhenium complexes, due to the well-known 
chemical similarities between rhenium and technetium complexes.  
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Figure 5.1 HPLC traces of 99mTc-labelled glucose derivatives; Retention time (Gradient B): 
99mTc-G1: 13.60 min; 99mTc-G2: 13.48 min; 99mTc-G3: 13.27 min; 99mTc-G4: 14.17 min 
5.3.2 Cellular uptake 
Glucose transporter 1 is an integral membrane protein used to facilitate transport of 
glucose and other sugars. In this study, we tested all four technetium complexes for 
transport through the cell membrane via Glut1. Five different cell lines were used for 
these experiments (Figure 5.1). Low to moderate cellular uptake was observed for all 
radiolabeled glucose derivatives. The uptake was quite rapid as no significant increase 
was observed for higher incubation periods. The highest values of uptake were 
observed for MDA-MB-231 breast carcinoma cells, probably because the cells are 
bigger and have epithelial-like morphology that phenotypically appear as spindle 
shaped cells which may facilitate the uptake of glucose derivative. 
In vitro, the MDA-MB-231 cell line has a high invasive phenotype, displaying a 
relatively high colony forming efficiency (cells grow quite fast), which can also 
contribute for the highest uptake glucose. We could also think about an eventual 
higher expression of glucose transporters, namely Glut1, in the cells MDA-MB-231 
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that could, and will be, evaluated by western blot analysis. However, such eventual 
higher expression is probably not the responsible for the higher uptake observed as 
the uptake appeared to be not Glut1 mediated.   
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Figure5.3 Cellular uptake of 99mTc Glucose derivatives in different cells 
 
Effect of assay medium in the uptake of radiolabeled glucose derivatives: The 
assay medium used in the uptake assays is very important and strongly influences the 
results of such assays. The modified Eagles Medium (MEM) with 25 mM of HEPES 
is frequently used and herein was used it as a first attempt. Compared to the 
high-glucose culture mediums like DMEM with glutamax (4500 mg/L D-glucose, 
Gibco 61965-026), MEM is a low-glucose medium (1000 mg/L D-glucose).  
However, such low amounts of glucose may compete with the radiolabeled glucose 
derivatives to the binding to glucose transporters, reducing thereby their uptake. Thus, 
other assays mediums were applied as well: MEM (Gibco: 21090-022) with 25mM 
HEPES (glucose conc.: 1000 mg/L, 5.5 mM), Opti-MEM (Gibco: 31985) (glucose 
conc.: 2500 mg/L) , Dulbecco’s PBS (without glucose), Hanks Balanced Salt Solution 
(without glucose). The cellular uptakes of 99mTc-G2 in different assay mediums are 
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shown in Figure 5.4. 
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Figure 5.4 Cellular uptake of 99mTc-G2 in different assay mediums 
 
The highest values of uptake were obtained for MEM with 25 mM Hepes and for 
Dulbecco’s PBS. However, the morphology of cells incubated in DPBS changed 
during the incubation and it is believed that labeled compounds entered in the cells 
because cell membrane is damaged. Indeed, PBS or DPBS is not recommended as 
assay mediums for long incubation periods, but often used for washing steps.  
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Figure 5.5 Cellular uptake of 99mTc-G1 in different assay mediums 
 
Since the radiolabeled glucose derivatives are in a very low concentration, orders of 
magnitude lower than the 5.5 mM of glucose in MEM medium. Since our aim was to 
minimize the competition/saturation of glucose transporter Glut1 with cold glucose to 
maximize the uptake of radiolabeled compounds, the use of an assay medium without 
glucose, but richer than PBS or glucose-free HBSS could improved that uptake. 
Therfore, the effect of two different no-glucose mediums (DMEM, no glucose and 
RPMI 1640, no glucose) was evaluated in the uptake of 99mTc-G1 in A2780, MCF-7 
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and MDA-MB-231 cells, at 15 and 30 min (Figure 5.5), and compared with MEM 
with low glucose (5.5 mM), all mediums with 25 mM HEPES. The uptake of 
99mTc-G1 was not improved with these assay mediums without glucose as compared 
to assay medium with low glucose concentration (5.5 mM). These results suggested 
that uptake was probably not mediated by transporters of glucose. 
Effect of Cytochalasin B (Glut1 inhibitor) in the uptake of 99mTc-labeled glucose 
derivatives 
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Figure 5.6 Cellular uptake of 99mTc-G1 in different concentration of Cytochalasin B 
 
In a previous study the uptake of 99mTc-G2 in MDA-MB-231, cells were challenged in 
the presence of different concentrations (0, 5, 10 and 20 µM) of the potent Glut1 
inhibitor cytochalasin B to verify specific transport via Glut1. The radiolabeled 
complexes and cytochalasin B were added to the cells simultaneously and the uptake 
was evaluated after 15 and 60 min at 37ºC. No inhibition of the uptake was observed. 
The effect of higher concentrations of cytochalasin B (0-100µM) was herein 
evaluated in the uptake of 99mTc-G1 in A431 cells at 37ºC during 15 min. 
Cytochalasin (400 L) was added to the cells 15 min before the radiolabeled glucose 
derivative (100 L). However, no significant uptake inhibition of 99mTc-G1 was 
observed in the presence of cytochalasin B (Figure 5.6). 
Effect of high concentrations of glucose in the uptake of 99mTc-labeled glucose 
derivatives: Since cytochalasin B binds intracellularly to Glut1, it could still be 
speculated that the 99mTc-glucose derivatives are interacting at different binding sites, 
at the extracellular binding site of glucose. Therefore, the uptake (after 15 min) of 
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radiolabeled compounds was also evaluated in the presence of increasing 
concentrations of 2-deoxy-D-glucose (0-20 mM) (Figure 5.7).  
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Figure 5.7 Cellular uptake of 99mTc-G1 in different concentration of 2-deoxy-D-glucose 
 
MDA-MB-231 and A431 cells were incubated with 2-deoxy-D-glucose 15 min before 
the addition of the radiocomplexes. A large excess of 2-deoxy-D-glucose did not 
reduce internalization of 99mTc-G1 and 99mTc-G2, giving final evidence that they do 
not compete with 2-deoxy-D-glucose for a common binding site.  
These complexes appeared to be transported into the cells by an unspecific uptake 
mechanism (e.g. passive diffusion) rather than by active transport via the 
sodium-independent Glut1 transporter. It is likely that the 99mTc-complexes are 
sterically too demanding for recognition at the extracellular binding site and/or 
transportation via Glut1. 
5.4 Conclusion 
In this Chapter, glucose derivatives functionalized at position C1, C2, C3, C6 with the 
Dap chelators were successully synthesized and radiolabeled. The rhenium complexes 
were accessed for competitive inhibition of hexokinase. The cellular uptakes of the 
corresponding 99mTc-complexes have been test in different tumor cells. No significant 
uptake inhibition of the radiocomplexes observed in the presence of cytochalasin B or 
2-deoxy-D-glucose suggest that the cellular uptake is not mediated by GLUT-1. 
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6 Solid phase synthesis and biological evaluation of Peptide-99mTc 
conjugates 
6.1 Results and discussion 
The overexpression of many peptide-targeted receptor proteins provides the basis for 
new imaging methods. Radiolabeled peptides that bind with high affinity and 
specificity to receptors on tumor cells have emerged as an important class of 
radiopharmaceuticals. In this chapter, we described the design and synthesis of 
radiolabeled linear peptide and cyclic RGD peptides that target GRPrs, v3 receptor, 
respectively. In vitro and in vivo studies of RGD peptide based conjugates were 
carried out for assessing binding affinity and internalization.  
6.1.1 BBN analogues synthesis  
To assess the utility of SAAC 4.19, three different peptide sequences, each containing 
nine residues but with a variable L-lys(Dap) position, were selected for the synthesis 
of BBN analogues. In those sequences, the single amino acid chelate L-lys(Dap) was 
introduced at the N-, the C-terminus or near the centre of the peptide. Dap containing 
peptide L1 was prepared by solid phase peptide synthesis (Scheme 6.1). In this BBN 
derivative, the tripod chelate was introduced into N-terminus of BBN (7-14). For the 
solid phase synthesis, Rink amide MBHA resin was used as the solid support, which 
consists of the Rink amide linker attached to MBHA resin and is an ideal tool for the 
Fmoc SPPS of peptide amides with high yields and purities.(127) After removal of 
Fmoc protecting groups on the resin, the first amino acid Fmoc-Met-OH was 
immobilized on the resin by the reaction of HBTU activated carboxyl groups with the 
amino group. The protected amino acids were assembled sequentially on the Rink 
amide resin using a standard HOBt/HBTU/DIPEA coupling protocol. Each coupling 
was performed once for 50 min using a fourfold excess of the amino acid and 
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coupling reagents. Two equivalents of SAAC 4.19 were coupled manually to the 
growing peptide using a more expensive HATU coupling protocol which is preferred 
to HBTU due to the faster reaction with less epimerization during coupling. After 
final Fmoc deprotection, peptides were cleaved from the resin with simultaneous Boc 
protecting group removal using a cocktail consisting of 85% TFA, 5% thioanisole, 5% 
phenol and 5% water. At this point, the carboxylate group in the Dap unit was still 
esterified.  
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Scheme 6.1 Solid-Phase Synthesis of peptide conjugate 6.1 and peptide metal complex 6.1a,b 
 
Coordination to the {Re(CO)3}+ or to the {99mTc(CO)3}+ moiety hydrolyzes this group 
concomitantly. It is important to exclude oxygen during the cleavage reaction in order 
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to avoid oxidation of the methionine containing peptides.(128) Following 
precipitation with cold methyl-t-butyl ether and centrifugation, the peptide-chelator 
conjugate 6.1 was purified by RP-HPLC and obtained in overall yields of 46% based 
on the initial resin loading of 0.69 mmol g-1. Aqueous solution of the target peptide 
was treated with [M(OH2)3(CO)3]+ [M=Re, 99mTc] in H2O under N2 at 70°C for 20 h 
to give the corresponding metal bound peptide conjugates in quantitative yields. 
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Scheme 6.2 Solid-Phase Synthesis of peptide conjugate 6.2 and peptide metal complex 6.2a,b 
 
The same approach was used to prepare the Dap containing peptide L2, in which the 
Chapter 6 
Page | 66   
tripod chelate was introduced into middle position of BBN (7-14) (Scheme 6.2). Two 
equivalents of SAAC 4.19 were coupled after the completion of cycle 4 by using two 
equivalents of coupling reagents (HATU/DIEA). After deprotection and resin 
cleavage, the final peptide 6.2 was treated with metal precursor [M(OH2)3(CO)3]+ 
[M=Re, 99mTc] to give the corresponding metal-peptide conjugates 6.2a, b. 
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Scheme 6.3 Solid-Phase Synthesis of peptide conjugate 6.3 and peptide metal complex 6.3a,b. 
 
In the synthesis of peptide L3 (Scheme 6.3), the SAAC 4.19 was first immobilized on 
the rink amide resin, and the remaining Fmoc-amino acids (4 equiv) were sequentially 
coupled with standard HBTU protocol. The final product was cleaved from the resin 
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and precipitated into cold MTBE. The metal bound peptide conjugates 6.3a, b were 
obtained by the same method for preparation of 6.1 a, b. 
6.1.2 Cyclic RGD peptide analogues synthesis  
The synthetic strategy for preparation of the cyclic RGD peptide L4 is shown in 
Scheme 6.4. Essentially, the synthesis involved three key steps: (1) attachment to the 
solid support via the α-carboxyl of Fmoc-Gly-OH, (2) linear chain formation, and (3) 
head-to-tail cyclization in solution through amide bond formation between the 
α-carboxyl group of Gly and the α-amino group of Asp. 
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Scheme 6.4 Synthesis of cyclic RGD peptide 6.6 and its complexes 
 
SPPS was performed using 2-chlorotrityl chloride resin and standard Fmoc chemistry. 
The resin is a super acid-labile resin for the solid phase immobilization of carboxylic 
acids that provides the possibility of selective cleavage of peptide from the resin in the 
presence of moderate acid-labile protecting groups.(129) To initiate the synthesis, 
Fmoc-gly-OH was immobilized onto 2-chlorotrityl chloride resin via its carboxylic 
acid and then the linear, side-chain-protected peptide was assembled with the glycine 
at the C-terminus using HBTU/HOBt activation in the presence of DIPEA in DMF. 
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The completion of each coupling cycle was monitored after 50 min of agitation by 
means of the Kaiser test.(130) Cleavage from the resin was accomplished under 
mildly acidic conditions (0.8% TFA in DCM) to give the fully protected linear 
peptide which was then subjected to intramolecular head-to-tail cyclization in solution 
to furnish the macrocycle 6.5. Side chain deprotection was achieved in almost 
quantitative yield by treating the product with TFA in the presence of free radical 
scavenger (triisopropylsilane). Purification of the crude products with preparative 
reverse-phase HPLC gave the target compound L4 in 20% overall yield, with >95% 
purity (as determined by analytical HPLC with monitoring at 226 nm). 
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Scheme 6.5 Cyclic RGD peptide analogues 
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cyclo(Arg-Gly-Asp-D-Tyr-Glu(NO2))(L5),cyclo(Arg-Gly-Asp-D-Tyr-Glu(N3))(L6),c
yclo(Arg-Gly-Asp-D-Tyr-Glu(N2O))(L7),cyclo(Arg-Gly-Asp-D-Tyr-Lys(NO2))(L8),
cyclo(Arg-Gly-Asp-D-Tyr(N2O)-Val)(L9) (Scheme 6.5) were prepared using the 
same strategy as for the preparation for peptide L4. All the couplings were performed 
manually using a DMF solution of HOBt/HBTU in the presence of DIPEA. Each 
coupling was performed once for 60 min using a fourfold excess of Fmoc-amino acids 
and activating reagents. In the case of SAAC, the coupling was performed for 90 min 
by using two equivalents of the amino acids. After purification by preparative HPLC, 
peptides were obtained in overall yields of 20-25%.  
6.1.3 Rhenium complexes 
The complexes were synthesized as references for the corresponding 99mTc labeled 
peptides. Aqueous solutions of peptides (L1-L4) were reacted with [Re(OH2)3(CO)3]+ 
in H2O under N2 at 70°C for 6-20 h to give the Re compounds in quantitative yields. 
The synthesis of complexes 6.7-6.10 (Scheme 6.5) were performed using a 
microwave reactor. The reactions were complete in 2 min at 120 °C. The metallated 
conjugates were purified by reverse-phase HPLC and lyophilized. Electrospray mass 
spectrometry allowed for the determination of the molecular ion of the nonradioactive 
Re(I) conjugates. No dissociation between the fac-{Re(CO)3}+ moiety and the ligand 
framework was observed, demonstrating the stability of the M(I)-N2O coordinate 
bond. 
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Firgure 6.1 a) HPLC traces of N terminus of BBN(7-14)-Metal(M=Re, 99mTc) conjugates 
b)HPLC trace of [M(CO)3-cyclo-(Arg-Gly-Asp-D-Tyr-Lys(DAP))](M=Re,99mTc) 
6.1.4 99mTc-labeling studies 
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Scheme 6.5 Synthesis of Re and [99mTc] chelator-cyclic RGD peptide conjugates 
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[99mTc(OH2)3(CO)3]+ was prepared from Na99mTcO4 according to literature methods. 
Aqueous 99mTc solutions in the concentration range of 10-6 to 10-9 M were adjusted to 
pH=7 with 1 M HCl and labeling efficiencies determined by reacting these stock 
solutions with peptide concentration from 10-3-10-5M. Over this range, these peptides 
could be labeled with [99mTc(OH2)3(CO)3]+ at 90°C after 30 min in yields better than 
98%. Even at a concentration of 10-6 M, the peptides could be labeled in 85% yield 
after 70 min, underlining the efficacy of the Dap chelator. In the presence of 0.1 M 
cysteine or histidine at 37°C, no trans-metallation was found after 24h further 
confirming the chemical robustness of the Dap complex. 
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Figure 6.2 HPLC traces of cyclic RGD peptides without metal complex and the 99mTc conjugates 
(a) L5(dash line), [99mTc(L5)(CO)3] (red line), (b) L7(dash line), [99mTc(L7)(CO)3](red line), (c) 
L8(dash line), [99mTc(L8)(CO)3](red line), (d) L6(dash line), [99mTc(L6)(CO)3]+(red line). 
 
It should be emphasized at this point that the labeling yield did not depend on the 
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absolute amount of 99mTc activity, an observation in agreement with the pseudo first 
order labeling kinetics in Dap. Typical specific activities as achieved in our labeling 
studies were in the order of 1.1TBq/μmol. Dap is, thus, suitable for labeling 
biomolecules to very high specific activities. The identities of the 99mTc labeled 
conjugates were confirmed by HPLC co-injection with the corresponding rhenium 
analogues (Figure 6.1). Due to the close structural similarity between Re and Tc 
homologues, retention times should be close to identical. It was found that if the 
labeling was conducted using a microwave reactor instead of normal heating, the 
labeling reactions were complete in 1 to 2 min at 120° C (Scheme 6.5). All the RGD 
peptides with the tridentate ligands have relatively high reaction rates with the 
[99mTc(OH2)3(CO)3]+ moiety as compared with those tridentate ligand frameworks 
containing bulky coordinating functional groups. The radioactive HPLC traces are 
shown in Figure 6.2, and the biological evaluation of these labelled peptide conjugates 
are still under investigation. 
6.2 Biological evaluation 
In vitro evaluation: For an exemplary evaluation of the effect of Lys by Lys(Dap) 
substitution on receptor binding affinity of cyclic RGD analogs, we investigated the 
binding affinity of [Re(L4)(CO)3] to different clinically relevant integrin receptor 
subtypes.(131, 132)  
The integrins with the highest documented relevance for imaging applications contain 
the v subunit, especially the v and v subtype. The former is known to be 
overexpressed on many tumor types and tumor neovasculature, but is also expressed 
at lower levels in non-cancerous tissues.(133) Table 6.1 summarizes the binding 
affinities (IC50 in nM) of [Re(L4)(CO)3] as well as of the uncomplexed labeling 
precursor L4 to these and three other integrin receptor subtypes. 
The rhenium reference peptide [Re(L4)(CO)3] and the uncomplexed labeling 
precursor L4 display similar IC50 values for all integrin subtypes investigated. 
However, in the case of the v, v and v integrins, complexation with the 
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[Re(CO)3]+ fragment leads to a loss in binding affinity by a factor of 2. Nevertheless, 
binding affinity of L4 integrates well into a series of different RGD-based precursors 
for 99mTc-labeling such as Pz1-RGD, HYNIC-RGD, Cys-RGD and L2-cRGD with 
IC50 values of 3, 6, 6.6, and 11.8 nM, respectively, in a comparable assay.(134) The 
v-integrin affinity of [Re(L4)(CO)3] is comparable to that of other clinically used 
radiolabeled RGD-analogs such as [18F]Galacto-RGD. [18F]Galacto-RGD shows an 
affinity of 5 nM to the immobilized v receptor, but significantly higher v 
selectivity (IC50 (v) = 1000 nM, IC50 (b) = 6000 nM) than the peptides 
investigated in this study.(135) 
 
Table 6.1 Competitive binding affinities of L4 and [Re(L4)(CO)3] to different solubilized 
integrins determined via ELISA. Data represent IC50 values [nM] (mean of duplicate experiments 
(SD))  
 
  va  　vb  　 vc  　bd    　v e   
reference peptide*  30 (3.5)  6.1(0.5) 41(1.2)  1.5 (0.3)  0.2 (0.02) 
L4  254 (4.1) 41 (1.9) 30 (3.1)  440 (8.3)  3.4 (0.05) 
[Re(L4)(CO)3]  540 (3.9) 42 (1.4) 72 (1.2)  432 (5.1)  7.1(1.2) 
* data for the respective reference peptides are cited from the literature; Reference peptides are a) 
RTDlinear IC50=30 nM (136), b) Cilengitide IC50=15 nM (137), c) Cilengitide IC50=50 nM 
(138), d) Tirofiban IC50=0.6 nM (137), e) Cilengitide IC50=0.5 nM (139, 140) 
 
The results obtained in the binding study using M21 cells and [125I]echistatin as the 
radioligand show the same tendency: Re(CO)3-complexation of L4 leads to a loss in 
binding affinity (IC50 (L4) = 242 nM, IC50 ([Re(L4)(CO)3]) = 866 nM), albeit 
somewhat more pronounced than observed when using immobilized integrin. The 
affinity determined for [18F]Galacto-RGD in the same assay is 319 nM.(141) 
In vivo biodistribution study: The biodistribution data obtained for [99mTc(L4)(CO)3] 
in M21 melanoma bearing nude mice are summarized in Table 6.2.  
[99mTc(L4)(CO)3] shows rapid clearance from the circulation and no particular 
predominance of renal vs. hepatobiliary clearance or vice versa, but modest 
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accumulation in all excretion organs. This represents a major advantage of this new 
Lys(Dap)-coupled RGD analog over previous derivatives using other BFC’s for 
[99mTc(CO)3]+ complexation.(142) For example, [99mTc(CO)3]Pz1-cRGD, in which 
pyrazolyl functionalities serves for [99mTc(CO)3]+ complexation, shows fivefold 
higher hepatic and intestinal accumulation. This may be due to the significantly 
reduced lipophilicity of [99mTc(L4)(CO)3] as compared to [99mTc(CO)3]Pz1-cRGD 
(log P = -1.82 vs -0.92). Surprisingly, the accumulation of [99mTc(L4)(CO)3] in the 
excretion organs is as low as or even lower than that of [99mTc]EDDA/HYNIC-cRGD, 
which shows an even lower log P of -3.57.(134) This underlines once more the 
observation, that especially in the case of 99mTc-labeled peptide radiopharmaceuticals, 
the labeling method itself rather than the physical parameter “hydrophilicity” governs 
excretion pathways from the circulation.  
 
Table 6.2: Biodistribution of [99mTc(L4)(CO)3] in M21 melanoma bearing nude mice 60 min p.i.. 
Control animals (n = 5) were injected with tracer only, for the blocking study (n = 3), the tracer 
and 590 µg Cilengitide per mouse (23.5 mg/kg body weight) were coinjected. Data are given 
as %ID/g and are means ± SD. 
 
Organ Control Blocking study Tumor/organ ratio 
blood 0.37 ± 0.02 0.31 ± 0.25 3.8 ± 0.5 
heart 0.34 ± 0.02 0.20 ± 0.04 4.2 ± 0.5 
lung 0.78 ± 0.13 0.41 ± 0.06 1.8 ± 0.4 
spleen 0.63 ± 0.13 0.22 ± 0.04 2.3 ± 0.5 
pancreas 0.24 ± 0.01 0.10 ± 0.01 5.9 ± 0.7 
liver 2.10 ± 0.50 1.42 ± 0.27 0.7 ± 0.2 
stomach 1.02 ± 0.15 0.35 ± 0.23 1.4 ± 0.3 
intestines 1.89 ± 0.45 1.31 ± 0.77 0.8 ± 0.2 
kidney 2.02 ± 0.29 1.22 ± 0.22 0.7 ± 0.1 
muscle 0.18 ± 0.01 0.07 ± 0.02 7.7 ± 1.0 
tumor 1.41 ± 0.16 0.25 ± 0.14  
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Absolute tumor accumulation of [99mTc(L4)(CO)3] is lower than that observed for 
[99mTc(CO)3]Pz1-cRGD or [99mTc]EDDA/HYNIC-cRGD in the same tumor model at 
1 h p.i. (2.5 and 2.7 %ID/g, respectively). However, as demonstrated by the blocking 
experiment (coinjection of an excess of unlabeled Cilengitide), tumor uptake is almost 
exclusively integrin-mediated, which highlights the integrin targeting efficiency of 
[99mTc(L4)(CO)3].  
Due to its comparably low accumulation in non-target tissues, [99mTc(L4)(CO)3] 
shows reasonable tumor-to-background ratios (Table 6.2), which approximates or 
even exceeds those previously achieved with 99mTc-labeled monomeric RGD peptides 
with higher tumor accumulation such as [99mTc]EDDA/HYNIC-cRGD (t/blood: 2.8, 
t/liver: 1.0, t/intestines: 1.3, t/kidney: 0.7, t/muscle: 3.6). These features make 
[99mTc(L4)(CO)3] a promising candidate for future evaluation in small animal 
SPECT-imaging of integrin expression.  
6.3 Conclusion 
Orthogonally protected L-Lys(NxOy) and L-Glu(NxOy) represent artificial, single 
amino acid chelates which can be implemented into solid phase peptide syntheses. 
Being orthogonally protected amino acids, incorporation into any desired position in 
the peptide sequence is possible and thus enables facile preparation of libraries of 
peptides including a single amino acid chelate at any position. We have demonstrated 
this concept by conjugating L-Lys(Dap) to three different positions in BBN(7-14). In 
addition, we have replaced the original L-Lysine in the c-RGDyK sequence or 
glutamine in the c-RGDyE sequence . As shown in a receptor binding study, both 
introduction of the Lys(Dap)-moiety as well as complex formation with [Re(CO)3]+ 
do not seriously affect binding affinity of the peptide to different integrin subtypes, in 
particular to the vreceptor. Labeling of L-Lys(Dap)-functionalized peptides with 
the [99mTc(CO)3]+ core usually proceeds quantitatively at around 10 M 
concentrations, leading to 99mTc-labeled peptide radiopharmaceuticals with high 
specific activities. Overall, the investigated NxOy-based tripod ligand is one of the 
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smallest and most efficient tridentate ligands for [99mTc(CO)3]+ complexation 
described so far, and is not only suited for labeling of peptides but also of other 
biomolecules or pharmacophores. As HYNIC, it has the potential to become a 
standard in 99mTc-based molecular imaging, but unlike for HYNIC-based 99mTc 
complexes, the authenticity of the conjugates is well defined.  
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7 Summary and Outlook 
In this work, we designed and synthesized a series of small tripod ligands which have 
very low molecular weight with different hydrophilic functional groups including 
amino groups, carboxyl groups, hydroxyl groups (Figure 7.1). These tripod ligands 
are strong chelators for the [99mTc(CO)3]+ core and the resulting complexes are 
therefore very small and hydrophilic. 
 
NH2
OH
OH
O
O
NH2
NH2
NH2
NH2
NH2
OH
NH2
NH2
OHO
NH2
OH
OH
O  
 
Figure 7.1 Small tripod chelates with different donor atoms 
 
In order to introduce these tripod chelators into the peptide sequence, we prepared the 
L-Lysine derivatives in which the -NH2 group was replaced by the tripod through 
conjugation to its -carbon and glutamic acid derivatives in which the γ-COOH group 
was conjugated with the tripod via PEG linker. The synthetic strategy produced 
orthogonally protected single amino acid chelates (SAACs). The -NH2 group of the 
-amino acid portion is Fmoc- and the -NH2 groups of the tripod are Boc-protected. 
Fmoc-L-Lys(N2O(Boc)) was either conjugated to the N- and C-terminus of bombesin 
BBN(7-14) or integrated into the sequence using solid phase peptide synthesis (SPPS). 
We also replaced the amino acid at position 5 in a cyclic RGD peptide with L-Lysine 
or L-Glutamic acid based chelators. For all peptides, quantitative labeling was 
achieved with the [99mTc(CO)3]+ core at 10 M concentrations in PBS buffer (pH=7.4). 
For comparison, the rhenium homologues were prepared from [Re(OH2)3(CO)3]+ and 
Lys(N2O)-BBN(7-14) or cyclo-(RGDyK(N2O)) or cyclo-(RGDyE(NxOy)) respectively. 
Chapter 7 
Page | 78   
Determination of integrin receptor binding showed low to medium nM affinities for 
various receptor subtypes. The IC50 of cyclo-(RGDyK(N2O[Re(CO)3])) for v3 is 7.1 
nM as compared to 3.1 nM for non-ligated RGD derivative. Biodistribution studies in 
M21 melanoma bearing nude mice showed reasonable v3-integrin specific tumor 
uptake. Altogether, orthogonally protected L-Lys(N2O) represents a highly versatile 
building block for integration in any peptide sequence. Lys(N2O)-precursors allow 
high yield 99mTc-labeling with [99mTc(H2O)3(CO)3]+, forming small and hydrophilic 
complexes, which in turn leads to peptide radiopharmaceuticals with excellent in vivo 
characteristics.   
The design of a 99mTc labeled glucose derivatives as SPECT imaging analogues of the 
well established PET tracer [18F]FDG is considered to be of great interest. In our 
endeavor for designing new carbohydrate derivatives able to be transported by 
GLUT1, we designed a number of new glucose derivatives. In this work, we present 
the synthesis of glucose derivatives which are functionalized at position C1, C2, C3, 
C6 via a PEG spacer with the 1, 2-diamino-propionic acid (Dap) chelator. Labeling 
studies showed quantitative labeling at low glucose concentrations. Inhibition studies 
with hexokinase showed good affinity with inhibition values in the range of 0.8 to 2.3 
mM which are comparable to one of the standard inhibitor glucosamine (3.5 mM). 
The cellular uptakes of the corresponding Tc complexes have been test in different 
tumour cells. Low to moderate cellular uptakes were observed for all radiolabeled 
glucose derivatives. Since no significant uptake inhibition of the radiocomplexes was 
observed in the presence of cytochalasin B or 2-deoxy-D-glucose, it is evident that 
these complexes are transported into the cells by an unspecific uptake mechanism 
rather than by active transport via the sodium-independent Glut1 transporter. 
The small size of these tripod chelators as well as their strong coordination with the 
[99mTc(CO)3]+ core make them attractive building blocks in the design of 99mTc based 
radiopharmaceuticals. The new methodologies developed for the synthesis of these 
metal-biomolecule conjugates will facilitate forthcoming studies that would have to 
extend investigations to the correlation of structure and properties. The investigation 
should include the incorporation of longer spacer into the metal-biomolecule 
Chapter 7 
Page | 79   
conjugates to reduce the interaction between the biomolecules and ligand binding 
sites and provide favourable binding characteristics in vivo. An amphiphilic 
polyethylene glycol (PEG) linker was incorporated into the cyclic RGD peptide to 
improve the pharmacokinetics, it may also reduce the receptor binding affinity, we 
will report on the overall effect of the introduction of PEG linkers in due course. 
Furthermore, the synthesis of 99mTc labeled glucose derivatives transported by Glut1, 
would be of importance for the design of carbohydrate-based radiopharmaceuticals. 
Important future tasks are to find out the transport mechanism of the glucose 
derivatives we reported in this work and develop more promising glucose analogues 
that would be probably used as surrogates of [18F]-2-fluoro-desoxy glucose 
([18F]-FDG). 
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Zusammenfassung 
Im Rahmen dieser Arbeit wurde eine Reihe von kleinen, tripodalen Liganden mit 
verschiedenen funktionellen Gruppen konzipiert und synthetisiert. Die resultierenden 
Komplexe mit der [99mTc(CO)3]+ Einheit sind klein und hydrophil. 
Des Weiteren wurden diverse Glucose Derivate synthetisiert, welche an den 
Positionen C1, C2, C3 und C6 über einen PEG Linker mit dem 
1,2-Diaminopropionsäure Chelator funktionalisiert sind. Markierungs-Studien mit 
99mTc waren selbst bei tiefen Glucose Konzentrationen möglich. Die Zellaufnahme 
von den entsprechenden 99mTc Komplexen wurde in verschiedenen Tumorzelllinien 
untersucht. Dabei wurde eine schlechte bis moderate Zellaufnahme für die 
verschiedenen Glucose Derivate beobachtet. Aufgrund der Tatsachte, dass keine 
signifikante Hemmung der Zellaufnahme in der Gegenwart von Cytochalasin B oder 
2-Deoxy-D-Glucose gefunden wurde, ist eine unspezifische Zellaufnahme 
offensichtlich und nicht ein aktiver Transport in die Zelle über den GLUT-1 
Transporter. 
Um die Chelatoren in Peptidsequenzen einzufügen, wurde die Aminogruppe an der 
-Position von L-Lysine durch die tripodalen Liganden ersetzt oder die Carbonsäure 
γ-Position von Glutaminsäure über einen PEG Linker mit dem tripodalen Liganden 
verbunden. Die sogenannten orthogonal geschützten „Single Amino Acid Chelates 
(SAACs)“ wurden entweder an den N- und C-Terminus von Bombesin angehängt 
oder direkt in die Sequenz integriert mittels Festphasenpeptidsynthese. Ausserdem 
wurden die Aminosäurederivate in ein zyklisches RGD Peptid inkorporiert. Die 
verschiedenen Peptide konnten bei M-Konzentrationen quantitative mit der 
[99mTc(CO)3]+ Einheit markiert werden. Die Bestimmung der Affinität zum Integrin 
Rezeptor zeigte geringe bis mittelmässige Werte im nM Bereich für diverse 
Rezeptor-Subtypen. Die Biodistributionsstudien in Nacktmäusen mit einem M21 
Melanom ergab eine vernünftige v3-Integrin spezifische Tumoraufnahme.
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8 Experimental part 
8.1 General information, materials and instrumentation 
All reagents and organic solvents were purchased from Aldrich, Acros, or ABCR in 
reagent grade or better and used without further purification. Dry DMF, acetonitrile 
were purchased from Aldrich. Dry ethanol, methanol and THF were freshly distilled. 
Yeast hexokinase, glucose, Adenosine triphosphate (ATP), Nicotinamide adenine 
dinucleotide phosphate (NADP), glucose-6- phosphate-dehydrogenase (G6PDH) were 
purchased from Roche diagnostics. Thin-layer chromatography (TLC) was carried out 
using Merck silica gel 60, F254 with a thickness of 0.25 mm. Column 
chromatography was accomplished on silica gel 60 (20-40 mesh). Electrospray 
ionization mass spectrometry (ESI-MS) spectra were recorded a Bruker HCT 
spectrometer, NMR spectra on a Bruker 400 or 500 MHz spectrometer in CDCl3 
solutions. All NMR chemical shifts are in ppm, coupling constants (J) are given in Hz. 
High-resolution electrospray ionization mass spectrometry was performed on a 
FinniganMAT 900 (Finnigan MAT95, San Jose, CA; USA) double-focusing magnetic 
sector mass spectrometer (geometry BE). Compoud 3.1-3.5, 4.1-4.3, 4.7-4.8, 5.3-5.4, 
5.9, 5.12-5.14 were synthesized by slightly modified literature procedures.(105, 119, 
121, 143-149) 
HPLC-MS (ESI) spectra were measured on a Bruker HCT spectrometer (Bruker) with 
Aquinity UPLC (Waters), using either a Macherey-Nagel EC 250/3 Nucleodur C18 
Gravity 5 µm or a Macherey-Nagel EC 250/3 Nucleosil C18 Gravity 5 µm. HPLC 
solvents were 0.1% formic acid (solvent A) and methanol or acetonitrile(solvent B), 
The following gradient was used: Gradient A: 0% B for 2 min, and increased to 100% 
in 10 min, and held at 100% for 5 min and then back to 0% in 8 min, flow 0.3 
mL.min-1. HPLC analyses were performed on a Merck-Hitachi L-7000 system 
equipped with a diode array UV/Vis spectrometer and Macherey Nagel Nucleosil C18 
columns (5μm particle size, 100 Å pore size, 250 x 3 mm) for radioactive compounds. 
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HPLC solvents were acetonitrile(0.1% TFA, solvent B) in water (0.1%TFA, solvent 
A). Gradient B: 0-3 min 0% B, 3-20 min 0-100% B, 20-25 min 100% B, 25-30 min 
100%-0% B, flow 0.3 mL.min-1; Gradient C: 0-3 min 0% B, 3-40 min 0-100% B, 
40-42 min 100% B, 42-45 min 100%-0% B, Gradient D: 0-5 min 5% B, 5-20 min 
5-18% B, 20-30 min 18% B, 30-35 min 18%-5% B, flow 0.5 mL.min-1. Gradient E: 
0-3 min 5% B, 3-20 min 5-20% B, 20-30 min 20%, flow 0.5 mL.min-1. Gradient F: 
0-3 min 5% B, 3-20 min 5-30% B, 20-30 min 30%, flow 0.5 mL.min-1. Preparative 
HPLC was performed on a Varian ProStar system by using a Macherey-Nagel VP 
250/40 Nucleosil 100-7 C18 column with a flow rate of 40 mL.min-1. The mobile 
phase for preparative HPLC consisted of 0.1% aqueous trifluoroacetic acid (A) and 
acetonitrile (B). Samples were purified with a linear gradient (100% solvent A to 20% 
or 30% solvent B over 70min). 
8.2 General procedures 
8.2.1 In vitro evaluation of glucose derivatives 
Hexokinase assay: The cold rhenium complexes were tested for their ability to 
inhibit glucose phosphorylation by hexokinase. Commercial yeast hexokinase has 
been used instead of human HK1. The phosphotransferase activity was followed 
spectrophotometrically by reduction of NADP+ in the presence of an excess of 
G6PDH. Our assay was validated and confirmed using a known HK inhibitor 
2-N-acetyl glucosamine. Stock solution of 10-2 M of the complexes 5.2a, 5.8a, 5.16a 
in triethanolamine hydrochloride buffer (TEOA; Ph=7.6) have been prepared. 
Inhibition with respect to glucose was studied at three different concentrations. The 
reagent for the determination of inhibitory effect of the compounds on HK was a 
reaction mixture composed of 0.1 M TEOA, 100 μL of 10 mM NADP, 50 μL of 0.66 
mM ATP, 200 μL of 10 mM MgCl2, 100-200 μL of 1 mM glucose, 5 μL of a stock 
solution of glucose-6-phosphate dehydrogenase (G6PDH; 140 U/mL). After 5 min of 
pre-incubation of the enzyme with the compound in the assay buffer, the reaction 
mixture was added to trigger off the reaction (The final total volume was 1 ml). The 
Chapter 8 
Page | 85   
rate of NADPH formation was determined by measuring the increase in absorbance at 
340 nm.  
Protocol for the uptake studies: 
The uptake of radiolabeled glucose derivatives was evaluated in five cancer cell lines, 
for different incubation periods (5, 15, 30 and 60 min) at 37ºC 
‐ A431 vulva carcinoma cells 
‐ HT-29 colon carcinoma cells 
‐ MDA-MB-231 breast carcinoma cells 
‐ MCF-7 breast carcinoma cells  
‐ A2780 ovarian carcinoma cells 
Radiolabeling of glucose derivatives with 99mTc(I) for cell upake: Na[99mTcO4] was 
eluted from a 99Mo/99mTc generator, using 0.9% saline. Using a Covidean kit, the 
precursor fac-[99mTc(CO)3(H2O)3]+ was prepared and its radiochemical purity checked 
by RP-HPLC. Radioconjugates 99mTc-G1, 99mTc-G2, 99mTc-G3 and 99mTc-G4 were 
obtained by reaction of the conjugates G1-G4 with fac-[99mTc(H2O)3(CO)3]+. Briefly, 
a solution of fac-[99mTc(H2O)3(CO)3]+ (450 μL) was added to a capped vial, 
previously flushed with N2, containing conjugates G1-G4 (50-60 μL, 10-4 M). The 
mixture reacted for 20-40 min, at 90ºC and the radiochemical purity of radiolabeled 
glucose derivatives was checked by RP-HPLC in a C18 Nucleosil column (250/4 mm, 
10 μm) eluted with flow rate of 1.0 mL min-1 and using the following method: (mobile 
phase A, 0.1% TFA aq; mobile phase B, CH3CN) 0–3 min, 100% A; 3-20 min, 0–100% 
B; 20–28 min, 100% B; 28-29 min, 100–0% B; 29-30 min, 100% A. 
Cell culture: Cells were grown in DMEM containing GlutaMax I or RPMI 1640 
supplemented with 10% heat-inactivated fetal bovine serum and 1% 
penicillin/streptomycin antibiotic solution (all from Gibco-Invitrogen). Cells were 
cultured in a humidified atmosphere of 95% air and 5% CO2 at 37°C with the medium 
changed every other day. The cells were adherent in monolayers and, when confluent, 
were harvested from the cell culture flasks with trypsin EDTA and seeded farther 
apart. 
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Uptake assays: cells were seeded at a density of 0.2 million per well in plates of 24 
wells and allowed to attach overnight. The cells were incubated at 37 ºC for a period 
of 5, 15, 30 and 60 min with about 200,000 cpm of the 99mTc-labeled glucose 
derivatives in 0.5 mL of assay medium (MEM with 25 mM 
N-(2-hydroxyethyl)piperazine-N-ethanesulfonic acid). Incubation was terminated by 
removing the radiocomplexes and washing the cells with ice-cold assay medium. The 
cells were subsequently lysed by 10 min incubation with 1 M NaOH at 37 ºC and the 
radioactivity in the lysate fraction was measured in a gamma counter. 
8.2.2 Determination of binding affinity and specificity using solubilized integrins 
The inhibitory activity and selectivity of L4 and [Re(L4)(CO)3] were determined 
using  an ELISA assays based on previously reported methods with some 
optimizations.(150, 151) 
Human integrins αvβ3 and αvβ5 were purchased from Millipore, αIIbβ3 from Enzyme 
Research Laboratories, α5β1 and αvβ3 from R&D Systems. Vitronectin was purchased 
from Millipore, fibronectin from Sigma, fibrinogen from Calbiochem and LAP 
protein from R&D Systems.  
Blocking and binding steps were always performed with TS buffer (20 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, and 1 mM MnCl2) containing 1% 
BSA (TSB-buffer). Washing steps after the incubation time were done with PBST 
buffer (10mM Na2HPO4, pH 7.5, 150 mM NaCl, and 0.01% Tween 20). 
For the integrins αvβ3 and αvβ5, the binding was visualized using a Mouse anti-human 
integrin α-V monoclonal antibody for αv subunit (MAB 1978 purchased from 
Chemicon); for α5β1 and αIIbβ3 were used antibodies from BD Biosciences (mouse 
anti-human CD49e for α5β1 and mouse antihuman CD41b for αIIbβ3) and Sigma 
(anti-mouse IgG-peroxidase). Peroxidase development was performed using the 
substrate solution 3,3,5,5’-tetramethylethylenediamine (TMB from Seramun 
Diagnostic GmbH) and 3 M H2SO4 to stop the reaction. 
The absorbance (450, 492 nm) was recorded with a POLARstar Galaxy plate reader 
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(BMG Labtechnologies). Every concentration was analyzed in duplicate and the 
resulting inhibition curves were analyzed using OriginPro 7.5G software. Each plate 
also contained either Tirofiban (152) or Cilengitide (139) as reference compounds.  
αvβ3 assay. Flat-bottom 96-well ELISA plates (from Brand) were coated with 100 µL 
of vitronectin (2µg/mL) overnight at 4 °C in 15 mM of Na2CO3, 35 mM NaHCO3, pH 
9.6 (carbonate buffer). 
After removal of the coating solution, the wells were blocked for 1h at R.T. with 150 
μL/well of TSB. Plates were then washed three times with 200 μL/well of PBST.  
Next, 4.0 μg/mL of soluble integrin αvβ3 and a serial dilution of integrin inhibitors and 
the control cilengitide were incubated in the coated wells for 2 h at r.t.  
After washing three times, the plate was treated with 100 μL/well of primary antibody 
(MAB1978 diluted 1:500 in TSB) and the secondary antibody (antimouse 
IgG-peroxidase) at 2.0 μg/mL for 1 h at r.t. After three washing steps, integrin binding 
was visualized with TMB. The oxidation was allowed to proceed for 5 min, and the 
product absorbance was measured at 450 nm.  
αvβ6 assay. For this assay, ELISA plates were coated with 100 µL of LAP protein (0.4 
µg/mL) overnight at 4 °C in coating TS buffer. Blocking and washing steps were 
performed as described for αvβ3. Next, 0.5 μg/mL of soluble integrin αvβ6 and a serial 
dilution of integrin inhibitors and the control cilengitide were incubated in the coated 
wells for 1 h at r.t. All subsequent steps were performed as described for αvβ3. 
αvβ5 assay. ELISA plates were coated with 100 µL of vitronectin (5µg/mL) 
overnight at 4 °C in coating TS buffer. Blocking and washing steps were performed as 
described for αvβ3. Next, 3.0 μg/mL of soluble integrin αvβ5 and a serial dilution of 
integrin inhibitors and the control cilengitide were incubated in the coated wells for 1 
h at r.t. After washing three times, the plate was incubated with 100 μL/well of 
primary antibody (MAB1978) diluted 1:500 in TSB and secondary antibody 
(antimouse IgG-peroxidase) at 1.0 μg/mL for 1 h at r.t. All subsequent steps were 
performed as described for αvβ3. 
α5β1 assay. Flat-bottom 96-well ELISA plates were coated overnight at 4 °C with 100 
μL/well of 0.50 μg/mL of fibronectin in carbonate buffer (see αvβ3). Blocking and 
Chapter 8 
Page | 88   
washing steps were performed as described. Next, 1.0 μg/mL of soluble integrin α5β1 
and a serial dilution of integrin inhibitors and the control cilengitide were incubated in 
the coated wells for 1 h at r.t. After washing three times, the plate was treated with 
100 μL/well of primary antibody (CD49e) at 1.0 μg/mL (1:500 dilution) and 
secondary antibody (antimouse IgG-peroxidase) at 2.0 μg/mL (1:385 dilution) for 1 h 
at r.t. All subsequent steps were performed as described for αvβ3 
αIIbβ3 assay. ELISA plates were coated overnight at 4 °C with 100 μL/well of 10.0 
μg/mL of fibrinogen in carbonate buffer. After washing and blocking, 2.5 μg/mL of 
soluble integrin αIIbβ3 and a serial dilution of integrin inhibitors and the control 
molecules cilengitide and tirofiban were incubated in the coated wells for 1 h at r.t. 
After three washing steps, wells were treated with 100 μL/well of primary antibody 
(CD41b) at 2.0 μg/mL (1:250 dilution) and secondary antibody (anti-mouse 
IgG-peroxidase) at 1.0 μg/mL (1:770 dilution) for 1 h at r.t. All subsequent steps were 
performed as described for αvβ3. 
8.2.3 Determination of binding affinity using M21 cells 
The in vitro integrin binding affinities were assessed via a cellular displacement assay 
using 125I-echistatin as an integrin specific radioligand on M21 human melanoma 
cells. One day prior to the experiment M21 cells were harvested using trypsin/EDTA 
(0.05 % and 0.02 %) in PBS (Biochrom), centrifuged and re-suspended in culture 
medium. The cells were transferred into 24-well plates (approx. 200'000 cells per well 
in 1 mL) and placed in the incubator overnight. The plates were used when 
confluence reached approx. 80 %. Before the experiment the culture medium was 
removed and binding buffer (20 mM tris(hydroxymethyl)aminomethane (Tris) pH 7.4, 
150 mM NaCl, 2 mM CaCl2·2H2O, 1 mM MgCl2·6H2O, 1 mM MnCl2·4H2O, 0.1 % 
(m/m) BSA) was added. The cells were incubated with 125I-echistatin (120.000 – 
140.000 cpm/well) and increasing concentrations of the RGD ligands (10-11 – 
10-4 mol/L), both dissolved in binding buffer. The total incubation volume was 
adjusted to 500L by addition of binding buffer. After the cells were incubated for 2 h 
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at r.t. the supernatant was removed and the cells were washed twice with cold PBS. 
The cells were lysed with 1 M sodium hydroxide solution and transferred to vials. 
Quantification of bound radioactivity was performed using a gamma counter. The 
experiments were performed in duplicate and repeated three times. The best-fit IC50 
(inhibitory concentration of 50 %) values were calculated by fitting the data by 
nonlinear regression using GraphPad Prism (GraphPad Software, Inc.). 
8.2.4 In vivo biodistribution study 
To establish tumor growth, 1.5·107 M21 melanoma cells were injected 
subcutaneously into the shoulder of female CD1 nu/nu mice (Charles River, Sulzfeld, 
Germany).(153) At the time of the experiment (app. 6 weeks after cell inoculation), 
tumor masses ranged from 32-250 mg. For the biodistribution study, 740 kBq of 
[99mTc(L4)(CO)3] in 100 µL of PBS were injected intravenously into the tail vein of 
the M21 tumor bearing nude mice (n=5). To demonstrate αvβ3 integrin specificity of 
tumor accumulation, mice (n=3) were co-injected with 590 µg Cilengitide per mouse 
(23.5 mg/kg body weight). At 60 min post injection (p.i.) mice were sacrificed, and 
the organs of interest were dissected, weighed and counted in a Gamma counter 
(Wallach, Turku). Data are given in percent of injected dose per gram tissue [%ID/g] 
and represent means ± standard deviation.  
8.3 Synthesis and characterization of compounds in Chapter 3 
Ethyl (hydroxyimino)cyanoacetate (3.1a) To a solution of NaNO2 (7.5g, 0.1 mol) in 
water (40 ml) cooled in an ice bath was added ethyl cyanoacetate (10.2 g, 0.09 mol), 
followed by acetic acid (7.5 g, 0.12 mmol). The reaction mixture was stirred at 0 °C 
for two hours. The solution was filtered, and the yellow solid was treated with 12 % 
aq. HCl (22.5 ml). The resulting solution was extracted with diethyl ether, dried with 
anhydrous CaCl2, and evaporated. The resulting white precipitate was recrystallized 
from water to yield (10 g, 78 %) of the product. 1H NMR (200 MHz, D2O): δ 4.32(q, 
2H, J = 7.2 Hz), 1.25(t, 3H, J = 7.2 Hz). 
Ethyl-2-amino-2-cyanoacetate (p-TsOH salt) (3.2a) To a solution of ethyl 
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(hydroxyimino)cyanoacetate (10 g, 70.4 mmol) in water (50 ml) and sat aq. NaHCO3 
(40 ml) was added Na2S2O4 (15 g) and the resulting mixture was stirred at 35°C for 
30 min. The mixture was extracted with CH2Cl2.The combined organic phase was 
then washed with brine and dried over MgSO4, and the volatiles were removed under 
reduced pressure. The residue was dissolved in Et2O and the solution treated with 
TsOH (9 g, 47.3 mmol) in EtOH. After addition of Et2O and cooling, the precipitate 
was removed by filtration, washed with cold Et2O, and dried under reduced pressure 
to provide (6.4 g, 30%) of compound 3.2 as a white solid. 1H NMR (200 MHz, 
CD3OD): δ 7.67-7.72(m, 2H), 7.20-7.25(m, 2H), 4.41(q, 2H, J = 7.2Hz), 2.36(s, 3H), 
1.36(t, 3H, J = 7.2 Hz). 
Ethyl 2-(tert-butoxycarbonylamino)-2-cyanoacetate (3.3a) To a solution of 
Ethyl-2-amino-2-cyanoacetate (p-TsOH salt) (4.80 g, 16 mmol) in toluene (17 ml) 
was added Boc2O (6.11 g, 28 mmol) and DIPEA (2.07 g, 16 mmol).The reaction 
mixture was heated at 100 ºC in an oil bath for 5 h and was then cooled to room 
temperature, water(15 ml) was added and the mixture was extracted with EtOAc. The 
organic layer was separated, washed with aq.NaHCO3, H2O, and brine, dried 
(MgSO4), and concentrated. Purification on silica gel eluting gradually with 20% 
EtOAc/hexanes, 50% EtOAc/hexanes provided compound 3.3 (3.1 g, 13.6 mmol, 
85%) as a white solid. 1H NMR (200 MHz, CDCl3): δ 5.33(s, 1H), 5.27(s, 1H), 4.35(q, 
2H, J = 7.2 Hz), 1.47(s, 9H), 1.34(t, 3H, J = 7.2Hz). 
Compound 3.3 was synthesized according to the analogous procedure described for 
3.3a. Compound 3.4, 3.5 were prepared according to the literature procedure.(146, 
147) 
Methanesulfonic acid 2-[2-(2-benzyloxy-ethoxy)-ethoxy]-ethylester (3.6) To a 
stirred solution of compound 3.5 (5 g, 0.02 mol) and methanesulfonylchloride (2.52, 
0.022 mol) in dichloromethane (30 ml) cooled to 0 °C was slowly added TEA (2.22 g, 
0.022 mol). The mixture was allowed to warm to room temperature, and stirring was 
continued for 2 h. The solution was diluted with 20ml dichloromethane and washed 
with water, brine, dried (MgSO4), and concentrated to give a pale yellow oil (6.24 g, 
98%). 1H NMR (200 MHz, CDCl3): 7.31-7.34(m, 5H), 4.53(s, 2H), 3.60-3.75(m, 
12H), 3.00(s, 3H). 13C NMR (50 MHz, CDCl3): 138.17, 128.38, 127.75, 127.65,  
73.20, 70.60, 70.54, 69.40, 68.98, 37.63.  
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1-((2-(2-(2-iodoethoxy)ethoxy)ethoxy)methyl)benzene (3.7) To a solution of 3.6 (8 
g, 25.1 mmol) in 2-butanone (150 mL) was added sodium iodide (4.48 g, 29.9 mmol). 
The solution was refluxed for 6 h, concentrated, diluted with water, and extracted with 
EtOAc. The organic layer was separated, washed with 10% Na2S2O3 and brine, dried, 
and evaporated. Silica gel chromatography, eluting with hexane-EtOAc (6:1), gave 
3.7 (7.9 g, 90%) as a colourless oil. 1H NMR (400 MHz, CDCl3): δ 7.32-7.34(m, 5H), 
4.55(s, 2H), 5.40(s, 1H), 3.75(t, 2H, J = 7.0 Hz), 3.62-3.68(m, 8H), 3.23(t, 2H, J = 6.8 
Hz). 13C NMR (100 MHz, CDCl3): δ 138.31, 128.40, 127.75, 127.62, 73.27, 72.01, 
70.77, 70.69, 70.28, 69.51, 3.12. 
Methyl4-(2-(2-(benzyloxy)ethoxy)ethoxy)-2-(tert-butoxycarbonylamino)-2-cyano
butanoate (3.8) Metallic sodium (0.23 g, 10 mmol) was dissolved in absolute 
methanol, and methyl 2-(tert-butoxycarbonylamino)-2-cyanoacetate (2.14g, 10 mmol) 
was added. After being stirred at 60°C for 30 min, all the methanol was removed 
under vacuum, the residue was dissolved in 30 ml DMSO, mesylate 3.6 (3.18 g, 10 
mmol) was then added, the mixture was stirred at 70°C for 10 h. The DMSO was 
removed under high vacuum, the remaining material was taken into EtOAc and the 
solution washed with water, brine and dried over magnesium sulfate, and the volatiles 
were removed under reduced pressure. The resulting material was chromatographed 
on silica gel to afford 3.45 g (79%) of 3.8. 1H NMR (400 MHz, CDCl3): δ 
7.28-7.29(m, 5H), 6.63(s, 1H), 4.51(s, 2H), 3.57-3.77(m, 13H), 2.21-2.26(m, 2H), 
1.40(s, 9H)  13C NMR (100 MHz, CDCl3) δ 167.08, 154.13, 138.17, 128.25, 128.23, 
127.59, 127.49, 127.44, 116.86, 81.21, 73.09, 70.54, 70.45, 70.20, 69.43, 66.84, 58.84, 
53.78, 35.78, 28.06, 27.91. HRMS (ESI): Calcd. for [M + Na]+, 459.2102; Found, 
459.2106. 
Methyl4-(2-(2-(benzyloxy)ethoxy)ethoxy)-2-(tert-butoxycarbonylamino)-2-((tert-
butoxycarbonylamino)methyl)butanoate (3.9) To a solution of 3.8 (1.75 g, 4 mmol) 
in dry MeOH (30 ml) cooled in an ice bath were added Boc2O (1.74g, 8mmol)and 
NiCl2.6H2O (0.096 g, 0.4 mmol). NaBH4 (1.2 g, 32 mmol) was then added in small 
portions over 30 min. The solution was allowed to warm to room temperature, and 
stirring was continued for 3 h. The mixture was filtered through celite and the filtrate 
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evaporated to dryness in vacuo. The residue was taken up in EtOAc and washed with 
water, brine, dried (MgSO4), and concentrated. Purification on a silica gel column 
with 33% EtOAc/hexane provided 3.9 (1.58 g, 73%)as a colorless oil. 1H NMR (400 
MHz, CDCl3): δ 7.26-7.31(m, 5H), 6.00(s, 1H), 5.07(s, 1H), 4.54(s, 2H), 3.51-3.65(m, 
15H), 2.24(s, 1H), 2.11(s, 1H), 1.40(s, 18H). 13C NMR (100 MHz, CDCl3): δ 173.21, 
155.72, 154.61, 138.20, 128.32, 127.69, 127.56, 79.59, 79.27, 73.19, 70.58, 70.39, 
70.29, 69.42, 66.83, 62.26, 52.47, 44.69, 32.62, 28.29. HRMS (ESI): Calcd. for [M + 
Na]+, 563.2939; Found, 563.2936. 
Methyl2-(tert-butoxycarbonylamino)-2-((tert-butoxycarbonyl)methylamino)-4-(2
-(2-hydroxyethoxy)ethoxy)butanoate (3.10) To an anhydrous EtOH (50 ml) solution 
of 3.9 (2.5 g, 4.6 mmol)was added 10% palladium on carbon (150 mg), the resulting 
solution was constantly bubbled with hydrogen for 24 hours at room temperature. The 
catalyst was filtered off, and the solvent was removed under reduced pressure. The 
residue was purified by silica gel chromatography to yield 3.10 (1.87 g, 90%) as a 
colorless oil. 1H NMR (400 MHz, CDCl3): δ 6.00(s, 1H), 5.03(s, 1H), 3.51-3.68(m, 
15H), 2.77(s, 1H), 2.23(s, 1H), 2.10(s, 1H), 1.38(s, 18H). 13C NMR (100 MHz, 
CDCl3): δ 173.38, 155.88, 154.58, 79.68, 79.38, 72.47, 70.21, 70.16, 66.73, 62.27, 
61.69, 52.54, 44.58, 32.61, 28.28. HRMS (ESI): Calcd. for [M + Na]+, 473.2470; 
Found, 473.2471. 
Methyl4-(2-(2-bromoethoxy)ethoxy)-2-(tert-butoxycarbonylamino)-2-((tert-buto
xycarbonylamino)methyl)butanoate (3.11) Compound 3.10 (1.5g, 3.3mmol) was 
dissolved in dry THF (10 ml), PPh3 (0.95 g, 3.63 mmol) was added to the solution 
followed by CBr4 (1.2 g, 3.63 mmol). The resulting mixture was stirred at RT for 3 h. 
The solvent was removed in vacuo and the residue was purified by silica gel 
chromatography with 4:1 hexane/ethyl acetate to give 1.05 g (62 %) of product as a 
colorless oil. 1H NMR (400 MHz, CDCl3): δ 5.96(s, 1H), 5.02(s, 1H), 3.41-3.77(m, 
15H), 2.23(s, 1H), 2.10(s, 1H), 1.39(s, 18H)  13C NMR (100 MHz, CDCl3) δ 173.72, 
156.40, 155.08, 1, 81.16, 79.83, 71.64, 70.78, 70.69, 67.42, 62.78, 53.00, 45.17, 33.17, 
30.61, 28.80. HRMS (ESI): Calcd. for [M + Na]+, 535.1626; Found, 535.1630. 
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Methyl4-(2-(2-(benzyloxy)ethoxy)ethoxy)-2-(2,2,2-trifluoroacetamido)-2-((2,2,2-t
rifluoroacetamido)methyl)butanoate (3.12) To a solution of compound 3.9 (810 mg, 
1.5 mmol) in DCM (12 ml) was added dropwise TFA (4 mL). After stirring at room 
temperature for 3 h, the reaction mixture was concentrated in vacuo to give yellow oil 
that was used in the next step without further purification. 
To a solution of the crude product in dichloromethane were added NEt3 (0.8 mL) and 
trifluoroacetic anhydride (0.8 mL) at 0 °C. The reaction mixture was allowed to warm 
to room temperature and stirred for 40 min. The solvent was removed in vacuo, and 
the crude product was purified using flash column chromatography (silica gel, 
DCM/acetone, 60:1) to afford 3.12 as a colorless oil (510 mg, 0.96 mmol, 64%). 1H 
NMR (400 MHz, CDCl3): δ 8.63(br, 1H), 7.56(br, 1H), 7.33-7.25(m, 5H), 4.55(s, 2H), 
3.61-3.98(m, 15H), 2.15-2.19(m, 2H).  13C NMR (100 MHz, CDCl3) δ 170.91, 
157.62(q, 2×COCF3), 138.07, 128.39, 127.77, 127.70, 116.96(q, 2×COCF3), 73.27, 
70.65, 70.58, 70.10, 69.35, 66.93, 63.01, 53.35, 42.98, 32.82. HRMS (ESI): Calcd. for 
[M+Na]+, 555.1536; Found, 555.1537. 
Methyl4-(2-(2-hydroxyethoxy)ethoxy)-2-(2,2,2-trifluoroacetamido)-2-((2,2,2-trifl
uoroacetamido)methyl)butanoate (3.13) To a solution of 3.12 (500 mg, 0.94 mmol) 
in ethanol (20 ml) was added 10% Pd/C (100 mg) and the suspension was stirred 
under hydrogen for 24 h. The suspension was then filtered and the filtrate was 
concentrated under reduced pressure to give 3.13 as a white solid (407 mg, 98 %). 1H 
NMR (400 MHz, CDCl3): δ 8.47(br, 1H), 7.68(br, 1H), 3.53-3.99(m, 15H), 2.21(s, 
2H).  13C NMR (100 MHz, CDCl3) δ 170.73, 157.42(q, 2×COCF3), 116.82(q, 
2×COCF3), 72.18, 70.45, 69.85, 66.64, 62.87, 61.46, 53.21, 42.82, 32.54. HRMS 
(ESI): Calcd. for [M + H]+, 443.1248; Found, 443.1251. 
4-(2-(2-(benzyloxy)ethoxy)ethoxy)-2-(tert-butoxycarbonylamino)-2-((tert-butoxy
carbonylamino)methyl)butan-1-ol (3.14) To a solution of 3.9 (810 mg, 1.50 mmol) 
in THF (10.0 mL) was added lithium borohydride (66 mg, 3.03 mmol) at 0°C, The 
reaction mixture was stirred at room temperature for 20 h, and then treated with 
saturated aqueous ammonium chloride solution , followed by extraction with CH2Cl2, 
dried over MgSO4 and filtrated. After evaporation of the solvent, the residue was 
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purified by chromatography on a silica gel column with AcOEt-n-hexane (1:2) to 
afford compound 3.14 (538 mg, 70% yield) as a colorless oil. 1H NMR (400 MHz, 
CDCl3): δ 7.31-7.32(m, 5H), 5.52(s, 1H), 5.44(s, 1H), 4.54(s, 2H), 3.25-3.64(m, 14H), 
1.81-1.96(m, 2H), 1.40(s, 18H). 13C NMR (100 MHz, CDCl3): δ 157.18, 155.75, 
138.17, 128.34, 128.31, 127.70, 127.60, 79.51, 79.33, 73.18, 70.61, 70.50, 70.33, 
69.42, 66.94, 65.77, 58.96, 43.63, 32.07, 28.36. HRMS (ESI): Calcd. for 
C26H44N2NaO8 [M+Na]+, 535.2990; Found, 535.2990. 
1-((2-((3,4-bis(tert-butoxycarbonylamino)-3-((tert-butyldimethylsilyloxy)methyl)
butoxy)ethoxy)ethoxy)methyl)benzene (3.15)  A solution of alcohol 3.14 (800 mg, 
1.56 mmol), TBSCl (423 mg, 2.80 mmol), and imidazole (234 mg, 3.43 mmol) in 
DMF (5 mL) was stirred at 50°C for 20 h. The mixture was then diluted with EtOAc 
washed with saturated aqueous ammonium chloride solution, water, brine, and dried 
over Mg2SO4. The solvent was evaporated under reduced pressure to afford the crude 
product which was purified by column chromatography using 15% EtOAc/nHexane 
(v/v) to afford 3.15 (743 mg, 1.18 mmol) in 76% yield as a colorless oil. 1H NMR 
(400 MHz, CDCl3): δ 7.29-7.31(m, 5H), 5.46(bs, 2H), 4.53(s, 2H), 3.37-3.80(m, 14H), 
1.86-1.96(m, 2H), 1.40(s, 18H), 0.86(s, 9H), 0.03(s, 6H). 13C NMR (100 MHz, 
CDCl3): δ 157.18, 155.57, 138.77, 128.83, 128.20, 128.06, 79.91, 79.59, 73.73, 71.17, 
71.02, 70.74, 69.97, 67.74, 66.37, 58.85, 45.95, 33.19, 28.90, 26.35, 18.62, -5.07.  
General Procedure A: Removal of Benzyl protecting group: The benzyl protected 
alcohol was dissolved in absolute ethanol (40 mL) and 10% Pd/C (20% wt) was added. 
The mixture was subjected to hydrogenation for 24 h. The catalyst was removed by 
filtration on celite and the solvent evaporated to afford the alcohol in quantitative 
yield. 
General Procedure B: Conversion of alcohol to azide: MsCl (1.1 equiv) was added 
to a solution of alcohol at room temperature. The solution was cooled to -78 °C with 
liquid nitrogen and Et3N (1.1 equiv) was slowly added via a syringe. After being 
stirred for 3 h, the solution was diluted with 10ml CH2Cl2 and washed with water, 
brine, dried (MgSO4). CH2Cl2 was evaporated completely (very important, to avoid 
the formation of explosive diazidomethane in the next step) and the residue was 
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dissolved in DMF. Sodium azide (1.5 equiv) was added to the solution, which was 
then heated to 70°C for 15 h. After being cooled to room temperature, water was 
added and the mixture was extracted with AcOEt. The combined organic layers were 
washed with water, dried over MgSO4, filtered and evaporated. The crude product 
was purified by flash column chromatography. 
General Procedure C: Conversion of azide to amine: To a solution of the azide in 
ethanol (15 ml) 10% Pd/C (10% wt) was added. The reaction mixture was cooled to 
0°C and bubbled with hydrogen gas at pressure of 2 bar for 5 h. The catalyst was 
filtered off and the filtrate was concentrated under reduced pressure to yield a residue 
of the amine as colorless oil. 
2-(2-(3,4-bis(tert-butoxycarbonylamino)-3-((tert-butyldimethylsilyloxy)methyl)b
utoxy)ethoxy)ethan-1-ol (3.16) Prepared according to General Procedure A. Starting 
with 3.15 (0.62 g, 1 mmol) the alcohol was obtained as a colorless oil (0.51 g, 96%). 
1H NMR (400 MHz, CDCl3): δ 5.48-5.58(m, 2H), 3.87(d, 1H, J = 9.6Hz), 
3.49-3.72(m, 13H), 1.88-2.03 (m, 2H), 1.41-1.43(m, 18H), 0.89(s, 9H), 0.05(s, 6H). 
13C NMR (100 MHz, CDCl3): δ 156.56, 155.08, 79.02, 78.83, 72.62, 70.35, 67.18, 
66.11, 61.73, 58.32, 45.54, 32.55, 28.39, 25.82, 18.11, -5.59. HRMS (ESI): Calcd. for 
C25H52N2NaO8Si [M + Na]+, 559.3385; Found, 559.3389. 
1-(2-(3,4-bis(tert-butoxycarbonylamino)-3-((tert-butyldimethylsilyloxy)methyl)b
utoxy)ethoxy)azidoethane (3.17). Prepared according to General Procedure B. 
Starting with 3.16 (0.6 g, 1.12 mmol) the azide was obtained as a clear oil (0.5 g, 
79%): 1H NMR (400 MHz, CDCl3): δ 5.41(bs, 2H), 3.80(d, 1H, J = 12Hz), 
3.37-3.65(m, 13H), 1.91-2.01(m, 2H), 1.39-1.41(m, 18H), 0.87(s, 9H), 0.03(s, 6H). 
13C NMR (100 MHz, CDCl3): δ 156.90, 155.30, 79.28, 79.10, 70.76, 70.45, 70.27, 
67.53, 66.16, 58.50, 50.89, 45.70, 32.91, 28.62, 28.60, 26.05, 18.34, -5.36. HRMS 
(ESI): Calcd. for C25H51N5NaO7Si [M + Na]+, 584.3450; Found, 584.3453. 
2-(2-(3,4-bis(tert-butoxycarbonylamino)-3-((tert-butyldimethylsilyloxy)methyl)b
utoxy)ethoxy)ethanamine (3.18) Prepared according to General Procedure C. 
Starting with azide 3. 17 the amine was obtained as a clear oil (0.38 g, 80%): 1H NMR 
(400 MHz, CDCl3): δ 5.44-5.48(m, 2H), 3.82(d, 1H, J = 12Hz), 3.37-3.59(m, 11H), 
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2.84(s, 2H), 1.81-1.91(m, 2H), 1.38-1.40(m, 18H), 0.86(s, 9H), 0.02(s, 6H). 13C NMR 
(100 MHz, CDCl3): δ 156.92, 155.27, 79.25, 79.02, 73.56, 70.40, 70.37, 67.43, 66.17, 
58.52, 45.67, 41.96, 32.85, 28.59, 26.03, 18.31, -5.38. HRMS (ESI): Calcd. for 
C25H53N3NaO7Si [M + Na]+, 558.3545; Found, 558.3546. 
Diethyl2-(2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethyl)-2-(tert-butoxycarbonylamino)
malonate (3.19) To a solution of diethyl 2-(N-(tert-butoxycarbonyl)amino)malonate 
(1.2 g, 4.27 mmol) in THF (30mL) was added NaH (60% in mineral oil, 170 mg , 
4.25 mmol) and iodide 3.7 (1.0 g, 2.85mmol) at room temperature, The resulting 
solution was refluxed for 10 h. After evaporation of the solvent under reduced 
pressure, the crude product was purified by column chromatography over silica gel 
with n-hexane/EtOAc (v/v, 5/1) as the eluent to afford a colorless oil (1.3 g, 92%). 1H 
NMR (400 MHz, CDCl3): δ 7.33-7.34(m, 5H), 6.09(s, 1H), 4.55(s, 2H), 4.13-4.26(m, 
4H), 3.48-3.64(m, 10H), 2.59(s, 2H), 1.42(s, 9H), 1.23(t, 6H, J = 7Hz). 13C NMR 
(100 MHz, CDCl3): δ 168.36, 154.10, 138.32, 128.38, 127.73, 127.60, 80.08, 73.25, 
70.60, 70.49, 70.30, 69.50, 66.38, 64.61, 62.24, 32.92, 28.26, 13.95. MS-ESI: m/z 
520.2(calcd. for C25H39NNaO9: 520.25) [(M + Na)+]. HRMS (ESI): Calcd. for 
C25H39NNaO9 [M + Na]+, 520.2517; Found, 520.2512. 
2-amino-2-(2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethyl)malonamide (3.23) To a 
solution of diester 3.19 (1.0 g, 2 mmol) in DCM (10 mL) was added trifluoroacetic 
acid (5 mL). The resulting mixture was stirred at room temperature for 3 h. After 
removal of volatile material, the residue was dissolved in MeOH (10 ml). 25% aq 
NH3 (10 ml) was slowly added and the mixture was stirred at room temperature for 20 
h. After this time, the solvent was evaporated to leave a white solid residue, which 
was dissolved in CH2Cl2 and washed with water. The organic phase was dried, 
filtered and concentrated and the residue was purified by column chromatography 
over silica gel with EtOAc as the eluent to afford the diamide 3.23 as a colorless 
oil(0.52 g, 76%).1H NMR (400 MHz, CDCl3): δ 7.83(bs, 2H), 7.26-7.34(m, 5H), 
6.43(bs, 2H), 4.55(s, 2H), 3.53-3.65(m, 10H), 2.57(bs, 2H), 2.21(t, 2H, J=5.6Hz). 13C 
NMR (100 MHz, CDCl3): δ 175.53, 138.18, 128.37, 127.76, 127.62, 73.21, 70.53, 
70.35, 70.29, 69.45, 68.01, 64.82, 32.45. MS-ESI: m/z 340.2 (calcd. for 
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C16H26N3O5:340.19)[(M + H)+]. HRMS (ESI): Calcd. for C16H26N3O5 [M + H]+, 
340.1867; Found, 340.1866. 
1-((2-((3,4-bis(tert-butoxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)
butoxy)ethoxy)ethoxy)methyl)benzene (3.24) To a stirred solution of lithium 
aluminium hydride (LiAlH4) (0.56 g, 14.76 mmol) in THF (33 ml) at 0 oC was added 
diamide 3.23 (1 g, 2.95 mmol) in THF (7 ml) via a syringe. The mixture was allowed 
to warm to room temperature and refluxed for 24 hours, after which time it was 
quenched with water (0.7 mL), 15% aqueous NaOH (0.7 ml), and water (1.8 mL) 
again. The resulting suspension was filtered through celite and evaporated to afford a 
colorless syrup that was used in the next step without purification. To a mixture of 
above residue and NaHCO3 (0.76 g, 9.0 mmol) in H2O (12 mL) was added Boc 
anhydride (1.97 g, 9.0 mmol) in dioxane (12 mL). The mixture was stirred for 24 h at 
room temperature. After this time, the solution was diluted with water and extracted 
with CH2Cl2. The organic phase was dried, filtered and concentrated to leave a crude 
product, which was purified by column chromatography using 25% EtOAc/hexanes 
as the eluent. Evaporation of the solvent afforded 3.24 as a colorless oil (0.9 g, 50%). 
1H NMR (400 MHz, CDCl3): δ 7.27-7.28(m, 5H), 5.57-5.65(m, 3H), 4.50(s, 2H), 
3.52-3.62(m, 10H), 3.31-3.32(m, 2H), 3.18-3.20(m, 2H), 1.90(t, 2H, J = 6 Hz), 
1.34-1.38(m, 27H). 13C NMR (100 MHz, CDCl3): δ 157.64, 155.70, 138.73, 128.85, 
128.20, 128.08, 79.87, 79.36, 73.72, 71.08, 70.95, 70.59, 69.97, 67.42, 59.63, 44.70, 
33.20, 28.88, 28.86. HRMS (ESI): Calcd. for C31H53N3NaO9 [M + Na]+, 634.3674; 
Found, 634.3670. 
2-(2-(3,4-bis(tert-butoxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)b
utoxy)ethoxy)ethan-1-ol (3.25) Compound 3.25 was prepared from 3.24 according to 
General Procedure A, quantitative yield, colorless oil. 1H NMR (400 MHz, CDCl3): δ 
5.60-5.72(m, 3H), 3.52-3.67(m, 10H), 3.17-3.38(m, 4H), 1.90(s, 2H), 1.34-1.38(m, 
27H). 13C NMR (100 MHz, CDCl3): δ 157.39, 155.42, 80.01, 79.76, 72.78, 70.52, 
70.19, 67.14, 61.88, 59.37, 44.40, 32.91, 28.53, 28.50. HRMS (ESI): Calcd. for 
C24H47N3NaO9 [M + Na]+, 544.3205; Found, 544.3205. 
1-(2-(3,4-bis(tert-butoxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)b
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utoxy)ethoxy)azidoethane (3.26) Compound 3.26 was prepared from 3.25 according 
General Procedure B. yield 84%; colorless oil; 1H NMR (400 MHz, CDCl3): δ 
5.55-5.66(m, 3H), 3.53-3.64(m, 8H), 3.16-3.40(m, 6H), 1.92(s, 2H), 1.36-1.40(m, 
27H). 13C NMR (100 MHz, CDCl3): δ 157.33, 155.37, 79.65, 79.10, 70.63, 70.20, 
70.12, 67.16, 59.31, 50.79, 44.34, 32.90, 28.54, 28.52. HRMS (ESI): Calcd. for 
C24H46N6NaO8 [M + Na]+, 569.3269; Found, 569.3267. 
2-(2-(3,4-bis(tert-butoxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)b
utoxy)ethoxy)ethanamine (3.27) Compound 3.27 was prepared from 3.26 according 
to General Procedure C. yield 75%; colorless oil; 1H NMR (400 MHz, CDCl3): δ 
5.71-5.76(m, 3H), 3.22-3.59(m, 12H), 2.96(s, 2H), 1.94(s, 2H), 1.36-1.40(m, 27H). 
13C NMR (100 MHz, CDCl3): δ 157.53, 155.54, 79.75, 79.21, 70.52, 70.22, 67.25, 
59.33, 44.40, 44.18, 32.91, 28.61, 28.59. HRMS (ESI): Calcd. for C24H49N4O8[M + 
H]+, 521.3545; Found, 521.3546. 
Diethyl2-(tert-butoxycarbonylamino)-2-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)mal
onate (3.20) Compound 3.20 was prepared from 3.19 according to General Procedure 
A, quantitative yield, colorless oil. 1H NMR (400 MHz, CDCl3): δ 6.02(s, 1H), 
4.06-4.16(m, 4H), 3.61(t, 2H, J = 4.5Hz), 3.37-3.45(m, 8H), 2.47(s, 2H), 1.31(s, 9H), 
1.15(t, 6H, J = 7Hz). 13C NMR (100 MHz, CDCl3): 168.40, 154.13, 80.15, 72.45, 
70.24, 66.30, 64.59, 62.31, 61.73, 32.90, 28.24, 13.92. HRMS (ESI): Calcd. for 
C18H33NNaO9: [M + Na]+, 430.2048; Found, 430.2047. 
diethyl2-(2-(2-(2-azidoethoxy)ethoxy)ethyl)-2-(tert-butoxycarbonylamino)malona
te (3.21) Compound 3.21 was prepared from 3.20 according to General Procedure B. 
yield 77%; colorless oil; 1H NMR (400 MHz, CDCl3): δ 6.02(s, 1H), 4.10-4.22(m, 
4H), 3.34-3.59(m, 10H), 2.53(s, 2H), 1.37(s, 9H), 1.19(t, 6H, J = 7Hz). 13C NMR 
(100 MHz, CDCl3): 168.47, 154.20, 80.25, 70.63, 70.35, 70.00, 66.59, 64.72, 62.36, 
50.84, 33.00, 28.35, 14.05. MS-ESI: m/z 455.2 (calcd. for C18H32N4NaO8: 455.21) 
[(M + Na)+]. HRMS (ESI): Calcd. for C18H32N4NaO8: [M + Na]+, 455.2112; Found, 
455.2110. 
diethyl2-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-2-(tert-butoxycarbonylamino)malon
ate (3.22) Compound 3.22 was prepared from 3.21 according to General Procedure C. 
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yield 75%; colorless oil; 1H NMR (400 MHz, CDCl3): δ 6.04(s, 1H), 4.10-4.20(m, 
4H), 3.42-3.48(m, 8H), 2.83(s, 2H), 2.52(s, 2H), 2.18(s, 2H), 1.36(s, 9H), 1.19(t, 6H, 
J = 7Hz). 13C NMR (100 MHz, CDCl3): 168.48, 154.23, 80.25, 72.99, 70.33, 70.29, 
66.48, 64.73, 62.39, 41.80, 33.02, 28.37, 14.06. MS-ESI: m/z 407.2(calcd. for 
C18H35N2O8:407.24) [(M + H)+]. HRMS (ESI): Calcd. for C18H35N2O8: [M + H]+, 
407.2388; Found, 407.2391. 
Ethyl4-(2-(2-(benzyloxy)ethoxy)ethoxy)-2-(tert-butoxycarbonylamino)-2-(hydrox
ymethyl)butanoate (3.28) To a solution of 3.19 (510 mg, 1.02 mmol) in THF (12 
mL), a solution of LiOH monohydrate (64 mg, 1.52 mmol) in H2O (6 mL) was added 
dropwise at 0 ◦C. The reaction mixture was warmed to room temperature and stirred 
for 24 h. the mixture was acidified and extracted with EtOAc. The organic layer was 
washed with water, dried (MgSO4) and concentrated in vacuo to give the crude 
product which was directly used in the next step without purification. 
N, N-Diisopropylethylamine (DIPEA) (210 ul, 1.20mmol) was added to a stirred 
suspension of above carboxylic acid (0.48 g, 1.02 mmol) and BOP (0.68 g, 1.53 mmol) 
in 6 ml of THF at room temperature, The resulting solution was stirred for 10 min, 
then NaBH4 (57.9 mg, 1.53 mmol) was added. After stirring overnight, the solvent 
was evaporated and the residue was taken up in diethyl ether and washed with 5% 
HCl, saturated NaHCO3 and brine, then dried (MgSO4) and evaporated to give a 
colorless oil, which was chromatographed on silica gel (n-hexane : ethyl acetate = 2 : 
1) to afford 12 as a colourless oil(0.25 g, 54%).1H NMR (400 MHz, CDCl3): δ 
7.25-7.26(m, 5H), 5.93(s, 1H), 4.48(s, 2H), 4.15(q, 2H, J = 7Hz), 3.49-3.91(m, 12H), 
2.09-2.18(m, 2H), 1.35(s, 9H), 1.18(t, 3H, J = 7Hz). 13C NMR (400 MHz, CDCl3): δ 
173.20, 155.81, 138.73, 128.85, 128.21, 128.09, 80.26, 73.74, 71.15, 70.85, 70.80, 
69.95, 67.52, 66.81, 63.89, 62.01, 33.07, 28.80, 14.60. HRMS (ESI): Calcd. for 
C23H37NNaO8 [M + Na]+, 478.2411; Found, 478.2413. 
Ethyl4-(2-(2-(benzyloxy)ethoxy)ethoxy)-2-(tert-butoxycarbonylamino)-2-((tert-b
utyldimethylsilyloxy)methyl)butanoate (3.29) To a solution of 3.28 (0.46 g, 1.01 
mmol) in DMF (6 mL) were added TBSCl (0.23 g, 1.5 mmol) and imidazole (0.10 g, 
1.5 mmol), and the mixture was stirred for 20 h. After this time, the mixture was 
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diluted with water then extracted with ethyl acetate three times. The combined 
organic phase was dried, filtered and concentrated to leave a crude brown oil. This oil 
was purified by column chromatography using a 15% EtOAc/hexanes gradient as the 
eluent. Evaporation of the solvent afforded the O-protected compound 3.29 as a 
colorless oil (0.5 g, 87%) 1H NMR (400 MHz, CDCl3): δ 7.29-7.30(m, 5H), 5.72(s, 
1H), 4.52(s, 2H), 4.08-4.18(m, 3H), 3.53-3.76(m, 11H), 2.30-2.33(m, 1H), 
2.02-2.06(m, 1H), 1.39(s, 9H), 1.23(t, 3H, J=7Hz), 0.81(s, 9H), 0.03(s, 6H). 13C NMR 
(400 MHz, CDCl3): δ 172.91, 154.72, 138.80, 128.83, 128.20, 128.05, 79.44, 73.74, 
71.12, 70.99, 70.75, 69.95, 67.22, 65.43, 63.91, 61.86, 31.64, 28.90, 26.20, 18.62, 
14.61, -5.12. HRMS (ESI): Calcd. for C29H52NO8Si [M + H]+, 570.3457; Found, 
570.3459. 
Ethyl2-(tert-butoxycarbonylamino)-2-((tert-butyldimethylsilyloxy)methyl)-4-(2-(
2-hydroxyethoxy)ethoxy)butanoate (3.30) Prepared according to General Procedure 
A from 3.29. The desired alcohol was obtained as a white solid(quantitative yield). 1H 
NMR (400 MHz, CDCl3): δ 5.71(s, 1H), 4.04-4.15(m, 3H), 3.63-3.70(m, 3H), 
3.40-3.50(m, 8H), 2.62(s, 1H), 2.27-2.30(m, 1H), 1.98-2.04(m, 1H), 1.35(s, 9H), 
1.19(t, 3H, J = 7Hz), 0.76(s, 9H), 0.07(s, 6H). 13C NMR (400 MHz, CDCl3): δ 173.04, 
154.72, 79.52, 72.88, 70.78, 70.70, 67.13, 65.43, 63.91, 62.27, 61.97, 31.61, 28.89, 
26.18, 18.61, 14.57, -5.15. HRMS (ESI): Calcd. for C22H45NNaO8Si [M + Na]+, 
502.2807; Found, 502.2812. 
2-(2-(2-(3-(tert-butoxycarbonylamino)-3-((tert-butyldimethylsilyloxy)methyl)-4-e
thoxy-4-oxobutoxy)ethoxy)ethoxy)acetic acid (3.31) To a stirred solution of alcohol 
3.30 (0.63 g, 1.32 mmol) in dry THF (40 mL) was added sodium iodoacetate (0.35 g, 
1.68 mmol) and NaH (67 mg, 1.68 mmol, 60% oil dispersion) at 0 ◦C. The reaction 
was allowed to warm to room temperature and stirred overnight. The mixure was 
diluted with water and acidified with 5% HCl. The aqueous phase was saturated with 
sodium chloride and extracted with EtOAc three times. The combined organic layers 
were dried over MgSO4, filtered and concentrated. The residue was purified by flash 
chromatography over silica gel to yield carboxylic acid 3.31 (0.48 g, 67% yield) as a 
colourless oil. 1H NMR (400 MHz, CDCl3): δ 5.70(s, 1H), 4.10-4.16(m, 5H), 
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3.45-3.70(m, 11H), 2.30-2.33(m, 1H), 2.03-2.07(m, 1H), 1.39(s, 9H), 1.23(t, 3H, J = 
6.8Hz), 0.80(s, 9H), 0.04(s, 6H). 13C NMR (400 MHz, CDCl3): δ 172.51, 154.27, 
79.15, 71.35, 70.49, 70.13, 69.97, 68.92, 66.73, 64.96, 63.45, 61.49, 31.06, 28.41, 
25.70, 18.13, 14.13, -5.56. MS-ESI: m/z 538.2 (calcd. for C24H48NO10Si:538.30) [(M 
+ H)+]. 
8.4 Synthesis and characterization of compounds in Chapter 4 
Compound 4.1-4.2, 4.7-4.8 were prepared according to the literature method.(105) 
(S)-benzyl 2-(benzyloxycarbonylamino)-6-(methylsulfonyloxy)hexanoate (4.9). To 
a stirred solution of 4.8 (2g, 5.4 mmol) and H3CSO2Cl (0.466 mL, 6 mmol) in CH2Cl2 
(10 mL) cooled to -78 °C, NEt3 (0.797 mL, 6 mmol) was slowly added. The mixture 
was allowed to come to r.t., and stirring was continued for 3 h. The solution was 
diluted with 10 mL CH2Cl2, washed with H2O, dried over MgSO4, and evaporated. 
The crude product was purified by flash column chromatography (33% Et2O in 
hexane) to give 7 as a pale yellow oil (2.3 g, 5.12 mmol, 95%). Rf =0.77 (SiO2, TLC, 
Et2O). 1H NMR (400 MHz, CDCl3): δ 7.26(s, 10H), 5.61(d, 1H, J=8Hz), 5.02-5.13(m, 
4H), 4.34(d, 1H, J = 5.2Hz), 4.03(t, 2H, J= 6.2 Hz), 2.81(s, 3H), 1.32-1.78(m, 6H). 
13C NMR (100 MHz, CDCl3): δ172.68, 156.58, 136.89, 135.91, 128.59-129.26, 70.12, 
67.66, 67.44, 54.28, 37.66, 32.27, 29.02, 21.84.  Anal. Calcd. for C22H27NO7S: C, 
58.78; H, 6.05; N, 3.12. Found: C, 58.39; H, 5.99; N, 3.04. MS-ESI: m/z 472.1(calcd. 
472.15) [(M + Na)+]  
(S)-benzyl 2-(benzyloxycarbonylamino)-6-iodohexanoate (4.10) Sodium iodide 
(0.64 g, 4.26 mmol) was added to a solution of mesylate 4.9 (1.6 g, 3.6 mmol) in 
2-butanone (30 ml) at room temperature. The reaction was stirred at 80°C for 3 h. 
After this time, the solvent was evaporated in vacuo to near dryness and the residue 
was partitioned between EtOAc and water. The organic extract was washed with 10% 
Na2S2O3, dried over Na2SO4, and concentrated in vacuo. The crude product was 
purified by flash chromatography eluting with hexane/ethyl acetate (5:1) to give 4.10 
as a colorless oil (1.44 g, 83%). 1H NMR (400 MHz, CDCl3): δ 7.30(s, 10H), 5.45(d, 
1H, J = 8Hz), 5.15-5.20(m, 4H), 4.45-4.50(m, 1H), 3.13(t, 2H, J = 6.8Hz), 
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1.71-1.90(m, 4H), 1.38-1.48(m, 2H). 13C NMR (100 MHz, CDCl3): δ 172.15, 155.88, 
136.26, 135.27, 128.70, 128.59, 128.44, 128.24, 128.14, 67.27, 67.06, 53.71, 32.76, 
31.53, 26.03, 6.08. HRMS (ESI): Calcd. for C21H24INNaO4 [M + Na]+, 504.0642; 
Found, 504.0638. 
(S)-tert-butyl 6-acetoxy-2-(benzyloxycarbonylamino)hexanoate (4.3) To a solution 
of 4.2 (3.5 g, 12.5 mmol) and sodium acetate (1.03 g , 12.5 mmol) in acetic acid (90 
ml) was added sodium nitrite (2.8 g, 40.6 mmol) at room temperature. After stirring 
for 6 h at 40 °C, the reaction mixture was concentrated in vacuo and the pale yellow, 
oily residue was used in the next reaction without further purification. 
To a solution of the carboxylic acid prepared above in t-BuOH (80 mL) was added 
4-Dimethylaminopyridine (0.49 g, 4 mmol) and Boc2O (4.36 g, 20 mmol). After 
stirring for 24 h, the reaction mixture was concentrated and the residue was purified 
via silica gel column chromatography eluting with 25% EtOAc/hexanes to give 4.3 
(2.5 g, 53%) as a colorless oil. 1H NMR (400 MHz, CDCl3): δ 7.38-7.39(s, 5H), 
5.35(d, 1H, J = 8Hz), 5.14(s, 2H), 4.26-4.30(m, 1H), 4.07(t, 2H, J = 6.5Hz), 2.06(s, 
3H), 1.67-1.86(m, 4H), 1.36-1.49(m, 11H). 13C NMR (100 MHz, CDCl3): δ 171.10, 
155.83, 136.36, 128.73, 128.52, 128.31, 128.16, 128.10, 82.12, 66.88, 64.09, 54.19, 
32.54, 28.22, 27.99, 27.92, 21.57, 20.95. MS-ESI: m/z 402.2 (calcd. for 
C20H29NNaO6:402.19) [(M + Na)+]. HRMS (ESI): Calcd. for C20H29NNaO6 [M + 
Na]+, 402.1887; Found, 402.1890. 
(S)-tert-butyl 2-(benzyloxycarbonylamino)-6-hydroxyhexanoate (4.4) To a stirred 
solution of 4.3 (1.3 g, 3.43 mmol) in methanol (15 mL) was added 1.4 M K2CO3 (1.25 
g, 9 mmol) in H2O. The resulting solution was stirred vigorously at rt for 12 h. 
Methanol was removed under vacuum, and the resulting aqueous solution was 
extracted with CH2Cl2. The organic layer was then dried over anhydrous magnesium 
sulfate and concentrated under vacuum to provide compound 4.4 as a yellow oil (1.04 
g, 90%):. 1H NMR (400 MHz, CDCl3): δ 7.25-7.31(s, 5H), 5.48(d, 1H, J = 8Hz), 
5.05(s, 2H), 4.18-4.23(m, 1H), 3.55(t, 2H, J = 6.2Hz), 2.26(s, 1H), 1.55-1.78(m, 4H). 
1.36-1.41(m, 11H). 13C NMR (100 MHz, CDCl3): δ 171.8, 156.12, 136.46, 128.56, 
128.18, 128.14, 82.08, 66.91, 62.29, 54.41, 32.63, 32.19, 28.05, 21.49. HRMS (ESI): 
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Calcd. for C18H27NNaO5 [M + Na]+, 360.1781; Found, 360.1777. 
(S)-tert-butyl2-(benzyloxycarbonylamino)-6-(methylsulfonyloxy)hexanoate (4.5) 
Mesylate 4.5 was prepared from 4.4 according to the preparation of 4.9: yield 95%. 
1H NMR (400 MHz, CDCl3): δ 7.23-7.26(m, 5H), 5.26(d, 1H, J = 8Hz), 5.01(s, 1H), 
4.09-4.18(m, 3H), 2.88(s, 3H), 1.59-1.75(m, 4H), 1.36-1.39(m, 11H). 13C NMR (100 
MHz, CDCl3): δ 171.78, 156.37, 136.84, 129.03, 128.68, 128.60, 82.82, 69.97, 67.40, 
54.54, 37.87, 32.78, 29.16, 28.48, 21.62. MS-ESI: m/z 438.3 (calcd. for 
C19H29NNaO7S: 438.16) [(M + Na)+]. HRMS (ESI): Calcd. for C19H29NNaO7S [M + 
Na]+, 438.1557; Found, 438.1558. 
(S)-tert-butyl 2-(benzyloxycarbonylamino)-6-iodohexanoate (4.6) Iodide 4.6 was 
prepared from 4.5 according to the preparation of 4.10: yield 92%. 1H NMR (400 
MHz, CDCl3): δ 7.25-7.29(m, 5H), 5.37(d, 1H, J = 8Hz), 5.04(s, 2H), 4.19-4.20(m, 
1H), 3.07-3.10(m, 2H), 1.59-1.78(m, 4H), 1.40(s, 11H). 13C NMR (100 MHz, CDCl3): 
δ 171.87, 156.32, 136.91, 129.02, 128.63, 128.59, 82.69, 67.35, 54.59, 33.34, 32.22, 
28.55, 26.38, 6.85. HRMS (ESI): Calcd. for C18H26INNaO4 [M + Na]+, 470.0799; 
Found, 470.0800.  
(7S)-8-benzyl1-ethyl 2-(tert-butoxycarbonylamino)-7-(benzyloxycarbonylamino)- 
2-cyan ooctanedioate (4.16). Na (0.046 g, 2 mmol) was dissolved in abs. ethanol, 
and ethyl 2-(tert-butoxycarbonylamino)-2-cyanoacetate (0.46 g, 2 mmol) was added, 
the mixture was stirred at 60°C for 30 min. After cooling to r.t., ethanol was removed 
under vacuum, the residue dissolved in DMSO (5 mL), mesylate 4.9 (0.67 g, 1.5 
mmol) was added and the resulting solution stirred at 70 °C for 10 h. DMSO was 
removed under high vacuum and the residue dissolved in EtOAc. The solution was 
washed with water, brine, dried over MgSO4 and concentrated in vacuo. Purification 
on a silica gel column with EtOAc/hexane provided 4.16 (0.66 g, 76 %) as a colorless 
oil. Rf = 0.24 (SiO2, TLC; hexane/EtOAc, 2/1). 1H NMR (400 MHz, CDCl3): δ 7.26(s, 
10H), 5.41(d, 1H, J = 7.6Hz), 5.04-5.11(m, 4H), 4.33(s, 1H), 4.22(t, 2H, J = 7Hz), 
1.58-1.96(m, 4H), 1.38(s, 9H), 1.18-1.31(m, 7H). 13C NMR (100 MHz, CDCl3) δ 
172.00, 166.89, 155.85, 153.73, 136.09, 135.12, 128.03-128.59, 116.77, 81.60, 67.17, 
66.97, 63.39, 57.88, 53.47, 36.23, 32.10, 28.03-28.15, 24.49, 23.31, 14.11. Anal. 
calcd. for C31H39N3O8: C, 64.01; H, 6.76; N, 7.22. Found: C, 63.92; H, 6.68; N, 7.18. 
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MS-ESI: m/z 582.4 (calcd. 582.27) [(M + H)+] 
(7S)-8-benzyl1-ethyl 2-(tert-butoxycarbonylamino)-7-(benzyloxycarbonylamino)- 
2-((tert-butoxycarbonylamino)methyl)octanedioate (4.17). Boc2O (0.87 g, 4 mmol) 
was added to a solution of 4.16 (1.20 g, 2 mmol) in dry MeOH of 0° C followed by 
NiCl2·6H2O(0.048 g, 0.2 mmol). NaBH4 (0.606 g, 16 mmol) was then added in small 
portions over 30 min. The resulting mixture was allowed to warm to r.t. and left to stir 
for a further 2 h. The mixture was filtered through celite and the filtrate evaporated to 
dryness in vacuo. The residue was taken up in EtOAc, washed with water, brine, dried 
over MgSO4 and concentrated. Flash chromatography on silica gel column eluting 
with EtOAc/hexane provided 4.17 (0.96 g, 70%) as a colorless oil. Rf = 0.4 (SiO2, 
TLC; hexane/EtOAc, 2/1). 1H NMR (500 MHz, CDCl3): δ 7.24(s, 10H), 5.42(s, 1H), 
5.35(d, 1H, J=7.5 Hz), 5.04-5.11(m, 4H), 4.82(s, 1H), 4.31(s, 1H), 4.11(d, 2H, 
J=6.5Hz), 3.60(m, 2H), 1.57-1.99(m, 4H), 1.41(s, 18H), 1.06-1.20(m, 7H). 13C NMR 
(125 MHz, CDCl3)  δ 172.45, 172.16, 155.80, 155.60, 154.11, 136.17, 135.21, 　
127.99-128.52, 79.60, 79.32, 66.99, 66.84, 63.51, 61.84, 53.72, 44.47, 32.23, 
28.15-28.21, 24.91, 23.07, 13.96. Anal. Calcd. for C36H51N3O10: C, 63.05; H, 7.50; N, 
6.13. Found: C, 62.90; H, 7.23; N, 6.00. MS-ESI: m/z 708.5 (calcd. 708.35) [(M + 
Na)+]. 
(2S)-2-amino-7-(tert-butoxycarbonylamino)-7-((tert-butoxycarbonylamino)meth
yl)-8-ethoxy-8-oxooctanoic acid (4.18). 30 mg of 10% Pd/C was added to an 
anhydrous EtOH (15 mL) solution of 4.17 (0.27 g, 0.4 mmol). H2 was then bubbled 
through the solution for 2 days at r.t. The solution was filtered with celite to remove 
the catalyst and the solvent removed by rotary evaporation. The residue was purified 
by C18 RP chromatography (1:1 CH3OH/H2O) to give 4.18 (0.16 g, 88 %) as a white 
solid. 1H NMR (400 MHz, CDCl3): 7.94 (s, 1H), 5.73 (s, 1H), 5.15 (s, 1H), 4.12 (d, 
1H, J = 6Hz), 3.57 (m, 3H), 1.41 (s, 18H), 1.18-1.82 (m, 11H). MS-ESI: m/z 484.4 
(calcd. 484.27)[(M + Na)+]. HRMS (ESI): Calcd. for [M + H]+, 462.2815; Found, 
462.2804. 
(2S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-7-(tert-butoxycarbonylamino
)-7-((tert-butoxycarbonylamino)methyl)-8-ethoxy-8-oxooctanoic acid (4.19). 
Compound 4.18 (0.6g, 1.3 mmol) was dissolved in dioxane (4 mL) and a 5% aqueous 
solution of Na2CO3 (8 mL). The reaction mixture was immersed in an ice bath and a 
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solution of FmocCl (0.336 g, 1.3 mmol) in dioxane (4 mL) was added. The solution 
was allowed to warm to r.t. and stirred for 3 h. The solvent was evaporated under high 
vacuum and the resulting material was purified on a silica gel column eluting with 
CHCl2/MeOH. Compound 4.19 was received as a white solid (0.77 g, 87%). Rf =0.3 
(SiO2, TLC; CH2Cl2/MeOH, 30:1). 1H NMR (400 MHz, CDCl3): δ 7.26-7.77 (m, 8H), 
5.53 (s, 1H), 4.89 (s, 1H), 4.19-4.50 (m, 5H), 3.68 (m, 2H), 1.41 (s, 18H), 1.25-2.10 
(m, 11H). 13C NMR (100 MHz, CDCl3): δ 175.64, 172.61, 156.12, 155.88, 154.65, 
143.92, 143.76, 141.30, 127.70, 127.08, 125.14, 119.96, 80.14, 79.94, 79.58, 67.07, 
63.56, 62.02, 53.74, 47.16, 44.55, 32.08, 28.31, 25.01, 23.10, 14.09. MS-ESI: m/z 
682.5 (calcd. 682.34)[(M - H)-] HRMS (ESI): Calcd. for [M + Na]+, 706.3315; Found, 
706.3314. 
(7S)-8-tert-butyl1-methyl7-(benzyloxycarbonylamino)-2-(tert-butoxycarbonylam
ino)-2-cyanooctanedioate (4.11) Methyl 2-(tert-butoxycarbonylamino)-2- 
cyanoacetate (0.23 g, 1.07 mmol) was added to a freshly prepared solution of NaOMe 
(59 mg, 1.09 mmol) in MeOH (5 mL) and stirred at 60°C for 30 min. After cooling to 
room temperature, methanol was removed under vacuum, the residue dissolved in 
DMSO  (8 mL), mesylate 4.5 (0.4g, 0.96 mmol) was added and the resulting solution 
stirred at 70°C for 12 h. DMSO was removed under high vacuum and water was 
added, the mixture was extracted with EtOAc. The combined organic phases were 
washed with brine, dried overs MgSO4 and filtered. The filtrate was concentrated in 
vacuo and the residue was purified by flash column chromatography (ethyl 
acetate/hexane = 1/2) to give 4.11 (0.36 g, 70%) as a colorless oil. 1H NMR (500 
MHz, CDCl3): δ 7.22-7.27(m, 5H), 5.28-5.50(m, 2H), 5.00(s, 2H), 4.14(s, 1H), 3.77(t, 
3H), 1.52-1.94(m, 4H), 1.25-1.39(m, 22H). 13C NMR (125 MHz, CDCl3): δ 171.92, 
168.01, 156.52, 154.43, 136.86, 129.13, 128.80, 128.76, 128.72, 117.37, 83.12, 82.95, 
67.57, 58.48, 54.36, 37.07, 33.12, 28.71, 28.58, 28.45, 25.14, 24.03. MS-ESI: m/z 
556.6 (calcd. for C27H39N3NaO8:556.26) [(M + Na)+]. HRMS (ESI): Calcd. for 
C27H39N3NaO8: [M + Na]+, 556.2629; Found, 556.2631. 
(7S)-8-tert-butyl1-methyl7-(benzyloxycarbonylamino)-2-(tert-butoxycarbonylam
ino)-2-((tert-butoxycarbonylamino)methyl)octanedioate (4.12) compound 4.12 
was prepared according to the preparation of 4.17: yield 72%, colorless oil. 1H NMR 
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(400 MHz, CDCl3): δ 7.22-7.28(m, 5H), 5.40(s, 1H), 5.21(s, 1H), 5.02(s, 2H), 4.79(s, 
1H), 4.14(s, 1H), 3.58-3.69(m, 5H), 1.52-1.96(m, 4H), 1.34-1.37(m, 29H), 
1.16-1.18(m, 2H). 13C NMR (100 MHz, CDCl3): δ 173.31, 171.69, 156.01, 155.91, 
154.39, 136.55, 128.68, 128.30, 128.28, 82.21, 80.00, 67.03, 63.97, 54.39, 53.00, 
44.85, 32.87, 28.17-28.49, 25.11, 25.08, 23.57. HRMS (ESI): Calcd. for 
C32H51N3NaO10: [M + Na]+, 660.3467; Found, 660.3466. 
(2S)-tert-butyl2-(benzyloxycarbonylamino)-7,8-bis(tert-butoxycarbonylamino)-7
-(hydroxymethyl)octanoate (4.13) To a solution of 4.12 (180 mg, 0.28 mmol) in 
THF/H2O (2:1, 10 mL) was added LiOH monohydrate (24 mg, 0.57 mmol) at 0 °C. 
The reaction mixture was warmed to rt and stirred for 48 h. The organic solvent was 
evaporated under reduced pressure. The remaining aqueous solution was carefully 
acidified with 1 N HCl and extracted with EtOAc three times. The combined organic 
phases were washed with water, dried over MgSO4 and evaporated under reduced 
pressure to give a yellow oil that was used in the next step without further 
purification. 
To a solution of the crude product in THF (4.0 ml) were added BOP (150 mg, 0.34 
mmol) and DIPEA (59 μl, 0.34 mmol) at room temperature. The mixture was stirred 
for 10 min until it turned yellow, and cooled down to 0°C. Then NaBH4 (15 mg, 0.4 
mmol) was added portion wise. After stirring for 20 h, the reaction mixture was 
concentrated in vacuo and the residue was dissolved in diethyl ether. The resulting 
solution was washed with aqueous potassium bisulfate and brine, dried over MgSO4 
and concentrated. The residue was purified by column chromatography on silica gel 
to give 4.13 as a colorless oil (98 mg, 57%). 1H NMR (400 MHz, CDCl3): δ 
7.30-7.33(m, 5H), 5.28(d, 1H), 5.07(s, 2H), 4.81(bs, 1H), 4.20(s, 1H), 3.23-3.44(m, 
4H), 1.57-1.77(m, 4H), 1.39-1.42(m, 27H), 1.28-1.30(m, 4H). 13C NMR (100 MHz, 
CDCl3): δ 171.81, 156.10, 155.79, 136.55, 128.71, 128.34, 82.21, 80.38, 79.75, 67.09, 
64.79, 59.61, 54.24, 43.88, 33.07, 32.32, 28.21-28.56, 25.58, 22.56. HRMS (ESI): 
Calcd. for C31H51N3NaO9: [M + Na]+, 632.3518; Found, 632.3521. 
(2S)-2-(benzyloxycarbonylamino)-7,8-bis(tert-butoxycarbonylamino)-7-(hydroxy
methyl)octanoic acid(4.14) Compound 4.14 was prepared from 4.13 according to the 
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preparation of 4.22. Yield: 79%. 1H NMR (400 MHz, CDCl3): δ 7.27(s, 5H), 
5.26-5.62(m, 2H), 5.05(s, 2H), 4.25-4.28(m, 1H), 3.24-3.62(m, 4H), 1.60-1.80(m, 3H), 
1.22-1.38(m, 23H). HRMS (ESI): Calcd. for C27H43N3NaO9 [M + Na]+, 576.2892; 
Found, 576.2891. 
(2S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-7,8-bis(tert-butoxycarbonyla
mino)-7-(hydroxymethyl)octanoic acid(4.15) Compound 4.15 was prepared from 
iodide 4.14 according to the preparation of 4.23. Yield: 75%. 1H NMR (400 MHz, 
CDCl3): δ 7.29-7.79(m, 8H), 5.57(bs, 1H), 5.25-5.31(m, 1H), 5.05(bs, 1H), 
4.41-4.44(m, 3H), 4.24(t, 1H. J = 6.8Hz), 3.32-3.50(m, 4H), 1.75-1.92(m, 3H), 
1.30-1.45(m, 23H). MS-ESI: m/z 664.6 (calcd. 664.3) [(M + Na)+]. 
(S)-6-benzyl1,1-diethyl6-(benzyloxycarbonylamino)-1-(tert-butoxycarbonylamin
o)hexane-1,1,6-tricarboxylate (4.24) A solution of iodide 4.10 (0.5 g, 1.04 mmol) 
and diethyl 2-(N-(tert-butoxycarbonyl)amino)malonate (0.44 g, 1.6 mmol) was added 
to a flame-dried flask under nitrogen, then 38 mg of sodium hydride was added with 
vigorous stirring, and the mixture was stirred under reflux for 12 h. After cooling to 
room temperature, the solvent was removed and the residue was taken up in EtOAc. 
The solution was washed with brine, dried (MgSO4), and concentrated. Flash 
chromatography on a silica gel column eluting with 25% EtOAc/hexanes provided 
4.24 (0.59 g, 90%) as a colorless oil. 1H NMR (400 MHz, CDCl3): δ 7.31-7.32(m, 
10H), 5.87(s, 1H), 5.23(d, 1H, J = 8Hz), 5.07-5.13(m, 4H), 4.13-4.36(m, 5H), 2.19(s, 
2H), 1.61-1.77(m, 2H), 1.39(s, 9H), 1.18-1.22(m, 10H). 13C NMR (100 MHz, CDCl3): 
δ 172.43, 168.41, 156.01, 154.04, 136.41, 135.45, 128.29-128.83, 80.34, 67.34, 67.18, 
66.55, 62.55, 62.54, 54.02, 32.73, 28.14, 25.08, 23.31, 14.18. HRMS (ESI): Calcd. for 
C33H44N2NaO10: [M + Na]+, 651.2888; Found, 651.2890. 
(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-7-(tert-butoxycarbonylamino)-
8-ethoxy-7-(ethoxycarbonyl)-8-oxooctanoic acid (4.25) To a solution of 4.24 (0.29 
g, 0.46 mmol) in EtOH (12 mL) was added 10% Pd on carbon (60 mg). The mixture 
was stirred under H2 (1 bar) for 20 h. The catalyst was filtered off, and the solvent 
was removed under reduced pressure. To the residue in acetone (15 ml) was added 
DIEA (87 μl, 0.5 mmol) followed by FmocOSu (0.17 g, 0.5 mmol), After the solution 
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was stirred overnight over night at room temperature, acetone was removed under 
reduced pressure and the residue was purified by silica gel chromatography to yield 
the title compound as a white solid (92% yield). 1H NMR (400 MHz, CDCl3): δ 
7.30-7.79(m, 8H), 5.99(s, 1H), 5.42(s, 1H), 4.23-4.51(m, 8H), 2.28(s, 2H), 
1.72-1.91(m, 2H), 1.46(s, 9H), 1.25-1.29(m, 10H). 13C NMR (100 MHz, CDCl3): δ 
176.91, 168.25, 156.12, 154.03, 143.76, 141.31, 127.72, 127.10, 125.14, 119.96, 
80.26, 67.06, 66.44, 62.43, 53.87, 47.18, 32.37, 32.15, 28.24, 24.98, 23.08, 14.00. 
HRMS (ESI): Calcd. for C33H42N2NaO10: [M + Na]+, 649.2732; Found, 649.2733. 
(S)-6-tert-butyl1,1-diethyl6-(benzyloxycarbonylamino)-1-(tert-butoxycarbonyla
mino)hexane-1,1,6-tricarboxylate (4.20)  Compound 4.20 was prepared from 
iodide 4.6 according to the preparation of 4.24. Yield: 95%. 1H NMR (400 MHz, 
CDCl3): δ 7.27-7.28(m, 5H), 5.84(s, 1H), 5.20(d, 1H, J = 8Hz), 5.02(s, 2H), 
4.08-4.22(m, 5H), 2.18(s, 2H), 1.58-1.76(m, 2H), 1.35-1.37(m, 20H), 1.15-1.18(m, 
8H). 13C NMR (100 MHz, CDCl3): δ 171.67, 168.40, 155.96, 153.99, 136.55, 128.66, 
128.27, 128.23, 82.18, 80.29, 66.99, 66.56, 62.51, 62.49, 54.41, 32.90, 32.59, 28.38, 
28.14, 25.00, 23.37, 14.15. HRMS (ESI): Calcd. for C30H46N2NaO10: [M + Na]+, 
617.3045; Found, 617.3039. 
(7S)-8-tert-butyl1-ethyl7-(benzyloxycarbonylamino)-2-(tert-butoxycarbonylamin
o)-2-(hydroxymethyl)octanedioate (4.21) Compound 4.21 was prepared from 4.20 
according to the preparation of 4.13. Yield: 52%. 1H NMR (400 MHz, CDCl3): δ 
7.28-7.29(m, 5H), 5.43(s, 1H), 5.22(s, 1H), 5.03(s, 2H), 4.15-4.21(m, 4H), 3.71(d, 1H, 
J = 12Hz), 1.58-1.97(m, 4H), 1.37-1.38(m, 20H), 1.20-1.24(m, 5H). 13C NMR (100 
MHz, CDCl3): δ 173.13, 171.98, 156.32, 155.53, 136.85, 129.01, 128.64, 128.59, 
82.58, 80.60, 67.37, 66.28, 65.58, 62.45, 54.69, 32.20, 32.56, 28.80, 28.49, 25.46, 
23.72, 14.64. HRMS (ESI): Calcd. for C28H44N2NaO9 [M + Na]+, 575.2939; Found, 
575.2941. 
(2S)-2-(benzyloxycarbonylamino)-7-(tert-butoxycarbonylamino)-8-ethoxy-7-(hyd
roxymethyl)-8-oxooctanoic acid (4.22) To the above alcohol 4.21 (160 mg, 0.29 
mmol) in 2 mL of CH2Cl2 was added 1 mL of TFA and the mixture was stirred for 2.5 
h at room temperature. Most of the volatile was removed by nitrogen flow. To a 
solution of the residue in dry acetonitrile was added Me4NOH·5H2O (153 mg, 0.85 
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mmol) and 332 mg of Boc2O (186 mg, 0.85 mmol). The resulting mixture was stirred 
for 20 h at room temperature, and concentrated under reduced pressure. The residue 
was diluted with water and extracted with diethyl ether, the aqueous phase was 
acidified with aqueous potassium bisulfate and extracted with ethyl acetate three 
times.The combined organic layers were washed with brine, dried (MgSO4) and 
concentrated by rotary evaporation to provide 106 mg (yield 74%) of 4.22 as clear oil. 
1H NMR (400 MHz, CDCl3): δ 7.31(s, 5H), 5.62-5.64(m, 1H), 5.07(s, 2H), 
4.04-4.34(m, 4H), 3.76-3.78(m, 1H), 1.64-1.82(m, 4H), 1.40-1.41(m, 9H), 
1.22-1.27(m, 7H). HRMS (ESI): Calcd. for C24H36N2NaO9 [M + Na]+, 519.2313; 
Found, 519.2312. 
(2S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-7-(tert-butoxycarbonylamino
)-8-ethoxy-7-(hydroxymethyl)-8-oxooctanoic acid (4.23) To a solution of 4.22(100 
mg, 0.2 mmol) in ethanol (10 ml) was added 10% Pd/C (20 mg) and the solution was 
stirred under hydrogen for 20 h. The reaction mixture was then filtered and the filtrate 
was concentrated under reduced pressure. To a solution of the above residue and 
DIPEA (38 μl, 0.22 mmol) in dry acetone (6 mL) were added Fmoc-OSu (74 mg, 0.22 
mmol) portionwise. After being stirred at room temperature overnight, the reaction 
mixture was concentrated and the residue was then purified by flash chromatography 
on silica gel (eluent: CH2Cl2/MeOH) to afford 91 mg of title compound 4.23 (yield 
78%). 1H NMR (500 MHz, CDCl3): δ 7.22-7.73(m, 8H), 5.41-5.52(m, 2H), 
4.04-4.37(m, 7H), 3.77-3.79(m, 1H), 1.69-2.14(m, 4H), 1.39-1.41(m, 9H), 
1.22-1.26(m, 7H). HRMS (ESI): Calcd. for C31H40N2NaO9 [M + Na]+, 607.2626; 
Found, 607.2632. 
General procedure for synthesis of 4.29 to 4.31. The amine 3.18 or 3.22 or 3.27 was 
dissolved in THF and cooled to 0°C. This solution was treated with the 
Fmoc-Glu-OAll (1.1 eqiv), HOBt (1-hydroxybenzotriazole) (1.2 eqiv), EDC·HCl (1.2 
eqiv), N-methylmorpholine (5 eqiv). The mixture was warmed to room temperature 
and stirring overnight. The solvent was removed in vacuo, and the residue was 
purified using flash column chromatography (silica gel, ethyl acetate/hexanes) to 
afford the desired compound as colorless oil. 
(S)-diethyl2-(2-(2-(2-(4-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-(allyloxy)-
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5-oxopentanamido)ethoxy)ethoxy)ethyl)-2-(tert-butoxycarbonylamino)malonate 
(4.29) (77% yield) 1H NMR (400 MHz, CDCl3): δ 7.28-7.78(m, 8H), 5.87-6.17(m, 
3H), 5.24-5.37(m, 2H), 4.65(d, 2H, J = 5.4Hz), 4.16-4.44(m, 8H), 3.49-3.53(m, 10H), 
2.62(s, 2H), 2.10-2.37(m, 4H), 1.44(s, 9H), 1.25(t, 6H, J = 7.2Hz). 13C NMR (100 
MHz, CDCl3): δ 172.23, 171.77, 168.44, 156.28, 154.10, 144.01, 141.29, 131.61, 
127.68, 127.08, 125.27, 119.94, 118.83, 80.26, 70.10, 70.00, 69.72, 67.10, 66.31, 
65.98, 64.72, 62.35, 53.99, 47.17, 39.38, 32.79, 32.21, 28.23, 27.72, 13.92. MS-ESI: 
m/z 798.3 (calcd. for  C41H56N3O13:798.38) [(M + H)+]. HRMS (ESI): Calcd. for 
C41H55N3NaO13: [M + Na]+, 820.3627; Found, 820.3626. 
(2S)-allyl5-(2-(2-(3,4-bis(tert-butoxycarbonylamino)-3-((tert-butyldimethylsilylox
y)methyl)butoxy)ethoxy)ethylamino)-2-(((9H-fluoren-9-yl)methoxy)carbonylami
no)-5-oxopentanoate (4.30) (83% yield ) 1H NMR (400 MHz, CDCl3): δ 7.23-7.73(m, 
8H), 5.19-5.89(m, 6H), 4.60(d, 2H, J = 5.6Hz), 4.20-4.39(m, 4H), 3.82(d, 1H, J = 8 
Hz), 3.42-3.58(m, 12H)), 1.86-2.18(m, 6H), 1.37-1.39(m, 18H), 0.86(s, 9H), 0.04(s, 
6H). 13C NMR (100 MHz, CDCl3): δ 171.97, 156.93, 156.48, 155.06, 144.22, 144.50, 
131.79, 127.88, 127.29, 125.40, 120.14, 119.09, 79.46, 79.15, 70.44, 70.28, 70.11, 
67.45, 67.31, 66.46, 66.22, 58.41, 54.11, 47.39, 45.82, 39.62, 32.76, 28.63, 26.04, 
18.34, -5.36. HRMS (ESI): Calcd. for C48H74N4NaO12Si [M + Na]+, 949.4965; Found, 
949.4966. 
(S)-allyl5-(2-(2-(3,4-bis(tert-butoxycarbonylamino)-3-((tert-butoxycarbonylamin
o)methyl)butoxy)ethoxy)ethylamino)-2-(((9H-fluoren-9-yl)methoxy)carbonylami
no)-5-oxopentanoate (4.31) (86% yield ) 1H NMR (400 MHz, CDCl3): δ 7.30-7.66(m, 
8H), 5.69-6.06(m, 4H), 5.26-5.38(m, 3H), 4.66(d, 2H, J = 5.6Hz), 4.26-4.45(m, 4H), 
3.27-3.62(m, 14H)), 1.98-2.35(m, 6H), 1.43-1.46(m, 27H). 13C NMR (100 MHz, 
CDCl3): δ 171.80, 157.29, 156.30, 155.30, 143.98, 141.30, 131.56, 127.70, 127.08, 
125.26, 119.95, 118.94, 79.69, 70.22, 69.94, 69.76, 67.12, 66.06, 59.20, 53.89, 47.17, 
44.17, 39.41, 32.72, 32.36, 28.39. HRMS (ESI): Calcd. for C47H69N5NaO13: [M + 
Na]+, 934.4784; Found, 934.4785. 
General procedure for synthesis of 4.29a to 4.31a. To a solution of 4.29 or 4.30, or 
4.31 in THF, tetrakis(triphenylphosphane)palladium(0) (0.2 equiv) was added and 
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N-ethylaniline (10 equiv). After stirring for 30 min at room temperature, THF was 
removed in vacuo and the residue was purified by flash chromatography to afford 
4.29a-4.31a as a white solid. 
(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-(2-(2-(3-(tert-butoxycarbony
lamino)-4-ethoxy-3-(ethoxycarbonyl)-4-oxobutoxy)ethoxy)ethylamino)-5-oxopent
anoic acid (4.29a) (quantitative yield). 1H NMR (400 MHz, CDCl3): δ 7.28-7.78(m, 
8H), 6.01-6.17(m, 2H), 4.21-4.40(m, 8H), 3.49-3.51(m, 10H), 2.18-2.61(m, 6H), 
1.44(s, 9H), 1.26(t, 6H, J = 7.2Hz). 13C NMR (100 MHz, CDCl3): δ 173.92, 168.51, 
156.03, 154.17, 143.96, 141.28, 127.67, 127.09, 125.17, 119.93, 80.46, 70.07, 69.97, 
69.35, 67.02, 66.21, 62.49, 53.61, 47.16, 39.61, 32.74, 32.23, 28.21, 13.90. HRMS 
(ESI): Calcd. for C38H51N3NaO13: [M + Na]+, 780.3314; Found, 780.3319. 
(2S)-5-(2-(2-(3,4-bis(tert-butoxycarbonylamino)-3-((tert-butyldimethylsilyloxy)m
ethyl)butoxy)ethoxy)ethylamino)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-
5-oxopentanoic acid (4.30a) (quantitative yield) 1H NMR (400 MHz, CDCl3): δ 
7.22-7.72(m, 8H), 5.41-5.98(m, 3H), 4.18-4.38(m, 5H), 3.85(d, 1H, J = 8 Hz), 
3.32-3.51(m, 12H)), 1.85-2.13(m, 6H), 1.39-1.45(m, 18H), 0.85(s, 9H), 0.02(s, 6H). 
13C NMR (100 MHz, CDCl3): δ 173.80, 171.37, 156.97, 156.14, 144.16, 144.50, 
127.88, 127.29, 125.38, 120.14, 79.84, 70.2, 69.67, 67.24, 66.65, 58.69, 53.63, 47.38, 
45.99, 39.79, 32.55, 28.64, 26.02, 18.31, -5.38. HRMS (ESI): Calcd. for 
C45H70N4NaO12Si: [M + Na]+, 909.4651; Found, 909.4642. 
(S)-5-(2-(2-(3,4-bis(tert-butoxycarbonylamino)-3-((tert-butoxycarbonylamino)me
thyl)butoxy)ethoxy)ethylamino)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5
-oxopentanoic acid (4.31a) (quantitative yield) 1H NMR (400 MHz, CDCl3): δ 
7.30-7.79(m, 8H), 5.74-6.09(m, 3H), 4.23-4.45(m, 4H), 3.27-3.58(m, 14H), 
1.98-2.45(m, 6H), 1.44-1.46(m, 27H). 13C NMR (100 MHz, CDCl3): δ 174.20, 173.25, 
157.43, 156.16, 143.93, 141.29, 131.56, 127.69, 127.10, 125.18, 119.94, 79.92, 79.31, 
70.09, 69.87, 69.39, 67.08, 59.20, 53.43, 47.15, 44.26, 39.52, 32.62, 32.36, 28.39. 
MS-ESI: m/z 872.3 (calcd. for C44H66N5O13: 872.46) [(M + H)+]. HRMS (ESI): Calcd. 
for C44H65N5NaO13: [M + Na]+, 894.4471; Found, 894.4471. 
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(2R)-3-(4-(2-(2-(3,4-bis(tert-butoxycarbonylamino)-3-((tert-butyldimethylsilyloxy
)methyl)butoxy)ethoxy)ethoxy)phenyl)-2-(((9H-fluoren-9-yl)methoxy)carbonyla
mino)propanoic acid(4.27a) To a solution of triphenylphosphine (0.29 g, 1.12 mmol), 
alcohol 3.16 (0.30 g, 0.56 mmol), and 4.26 (0.25 g, 0.56 mmol) in toluene(5 ml)was 
slowly added diethyl azodicarboxylate (DEAD, 40% in toluene, 0.44 ml ,1.12 mmol) 
with stirring at 0°C. The reaction mixture was stirred for 15 h and concentrated by 
rotary evaporator, the residue was purified by chromatography on silica gel 
(n-hexane/ethyl acetate 3:1) to give 4.27 as a colourless oil, which was used for the 
next step by dissolving it in THF (20 mL), N-methylaniline (0.73 mL, 6.7 mmol) and 
Pd(PPh3)4 (0.06 g, 0.05 mmol) were added to the solution. The mixture was stirred at 
room temperature for 30 min. The solvent was removed under reduced pressure and 
the oily residue was purified by column chromatography (eluent DCM/MeOH, 30:1 
v/v) to afford 4.27a (0.26 g, 50%) as a white solid . 1H NMR (400 MHz, CDCl3): δ 
7.65-6.73 (m, 12H), 5.51(s, 1H), 5.40(s, 1H), 5.27(s, 1H), 4.54-3.98(m, 6H), 
3.72-3.02(m, 12H), 1.82(s, 2H), 1.34(s, 18H), 0.8(s, 6H) . 13C NMR (400 MHz, 
CDCl3): δ 175.0, 158.50, 157.47, 156.33, 155.79, 144.47, 144.37, 141.90, 131.04, 
128.68, 128.29, 127.66, 125.94, 125.67, 120.55, 115.42, 79.91, 79.57, 71.27, 70.81, 
70.41, 68.09, 67.79, 67.66, 59.04, 58.84, 47.78, 46.14, 37.59, 33.33, 29.00, 26.44, 
18.72, -5.01. MS-ESI: m/z 944.5 (calcd. for C49H71N3NaO12Si: 944.47) [(M + Na)+] 
8.5 Synthesis and characterization of compounds in Chapter 5 
2,3,4,6-Tetra-O-acetyl-1-O-[2-(4-methoxy-4-oxo-3-(2,2,2-trifluoroacetamido)-3-((
2,2,2-trifluoroacetamido)methyl)butoxy)ethoxy]-β-D-glucopyranose (5.1) 
β-Glucosepentaacetate (275 mg, 0.705 mmol) and alcohol 3.13 (240 mg, 0.543 mmol) 
were dissolved in anhydrous CH2Cl2 (2.5 mL), then BF3·OEt2 (0.06 mL) was added 
slowly. The reaction mixture was stirred at room temperature for 24 h. and then 
poured into 5% aqueous NaHCO3 (8 mL). The organic layer was separated, washed 
with water and brine, dried (MgSO4) and concentrated. Purification on a silica gel 
column with DCM/Acetone(25:1) provided 5.1 (0.3 g, 72%) as a colorless oil. 1H 
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NMR (500 MHz, CDCl3): δ 8.57(s, 1H), 7.55(s, 1H), 5.19(t, 1H, J=9.5Hz), 5.06(t, 1H, 
J = 9.7Hz), 5.19(t, 1H, J = 9.0Hz), 4.56(d, 1H, J = 8Hz), 4.23(dd, 1H, J = 7.5Hz, J = 
12Hz), 4.11-4.14(m, 2H), 3.58-4.01(m, 15H), 2.21(s, 1H), 1.99-2.07(m, 12H).  13C 
NMR (125 MHz, CDCl3 ) δ 170.73, 157.42(q, 2×COCF3), 116.82(q, 2×COCF3), 72.18, 
70.45, 69.85, 66.64, 62.87, 61.46, 53.21, 42.82, 32.54. HRMS (ESI): Calcd. for 
C28H38F6N2NaO16 [M + Na]+, 795.2018; Found, 795.2018. 
[Re(G1)(CO)3] (5.2a) Lithium hydroxide monohydrate (42 mg, 1 mmol, 10.0 equiv.) 
and water (2.0 mL) were added sequentially to a solution of 5.1 (77 mg, 0.1 mmol) in 
THF (6 mL) at room temperature. The solution was stirred for 18 h. Amberlite IR-120 
(H+) resin was used to neutralize the above solution which was concentrated to afford 
viscous G1 in quantitative yield. To a solution of above residue in water (5 mL) was 
added [NEt4]2[Re(CO)3Br3] (76.8 mg, 0.1 mmol). The mixture was heated to 70˚C for 
5 h. The solvent was then removed in vacuo and the residue was purified by silica gel 
chromatography (EtOAc/MeOH) to afford the product as a white solid (53.4 mg, 
80%). 1H NMR (500 MHz, D2O): δ 4.53(d, 1H, J = 8Hz), 4.10-4.13(m, 1H), 3.96(dd, 
1H, J = 2.5Hz, 12.5Hz), 3.87-3.90(m, 1H), 3.69-3.81(m, 9H), 3.32-3.55(m, 4H). 
2.93-2.98(m, 1H), 2.76-2.82(m, 1H), 2.14-2.18(m, 1H), 2.00-2.04(m, 1H). HRMS 
(ESI): Calcd. for C18H29N2NaO13Re [M + Na]+, 691.1120; Found, 691.1117. 
3,5,6-Tri-O-benzyl-1,2-O-isopropylidene-α-D-glucofuranose (5.3) A solution of 
1,2-O-isopropylidene-a-D-glucofuranose (6 g), sodium hydride (8 g), and 
tetrabutylammonium iodide (catalytic amount) in dry N,N-dimethylformamide (70 
mL) was cooled to 0 °C, and benzyl bromide (8 mL) was introduced dropwise. After 
24 h, when TLC showed that the reaction was complete, the mixture was quenched 
with MeOH before filtered, filtrate evaporated, and the residue purified by column 
chromatography with 1:8 ethyl acetate-hexane as the eluent, giving a colorless syrup 
yield, 10.7g (80%). 1H NMR (200 MHz, CDCl3): δ 7.29-7.27(m, 15H), 5.91(d, 1H), 
4.68(s, 2H), 4.60, 4.49(2d, 2H), 4.31(dd, 2H), 4.13(dd, 1H), 4.08(d, 1H), 4.04(m, 1H), 
3.92(dd, 1H), 3.69(dd, 1H), 1.49(s, 3H), 1.32(s, 3H).  
Methyl 3,5,6-tri-O-benzyl-α-D-glucofuranoside (5.4) A solution of the previous 
syrup (10 g) in methanol (150 mL) was boiled under reflux and stirred with Amberlite 
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IR-120 (H+) ion-exchange resin (60 mL) for 5 days. TLC then showed that the 
starting material had disappeared completely. The suspension was filtered, the filtrate 
evaporated, the residue dissolved in 1: 1 hexane-ethyl acetate, and the mixture 
separated by column chromatography, with 1:3 ethyl acetate-hexane as the eluent, 
giving a colorless syrup yield, 4.2g (44%) 1H NMR (400 MHz, CDCl3): 7.30-7.38(m, 
15H). 5.06(d, 1H, J = 4.4), 4.84(d, 1H, J = 11.5Hz), 4.72(d, 1H, J = 11.5Hz), 
4.57-4.62(m, 4H), 4.36(dd, 1H, J = 4 Hz, 8Hz), 4.27-4.29(m, 1H), 4.07-4.10(m, 2H), 
3.91(dd, 1H, J = 2Hz, 10.5Hz), 3.73(dd, 1H, J = 5.8Hz, 10.5Hz), 3.50(s, 3H). 
Methyl3,5,6-tri-O-benzyl-2-O-[2-(3-(tert-butoxycarbonyl)-3-((tert-butoxycarbon
yl)methyl)-4-methoxy-4-oxobutoxy)ethoxy]-α-D-glucofuranoside (5.5) To a 
solution of methyl 3,5,6-tri-O-benzyl-a-D-glucofuranoside(2) (410 mg, 0.88 mmol) in 
dry DMF (10 mL) in an ice bath was added sodium hydride (69 mg, 2.9 mmol)) under 
N2.  The reaction was stirred for half an hour and a solution of bromide 3.11 (1.2 g, 
2.33 mmol) in DMF (1.2 mL) was added dropwise. The obtained suspension was 
stirred overnight with increasing temperature from 0°C to room temperature. The 
reaction was quenched with MeOH. The organic solvent was removed under vacuum, 
and the residue was extracted with EtOAc. The organic layer was dried with Na2SO4, 
then filtered, concentrated and the product isolated by column chromatography with a 
gradient of CH2Cl2/acetone (25:1) to yield (443 mg, 56%) of 5.5 as a colorless oil. 1H 
NMR (400 MHz, CDCl3) : δ 7.22-7.29(m, 15H), 5.95(s, 1H), 5.02(s, 1H), 4.93(d, J=4 
Hz, 1H), 4.75(d, J=12 Hz, 1H), 4.62(d, J=12 Hz, 1H), 4.54-4.49(m, 4H), 4.29(t, J=8 
Hz, 1H), 4.17(t, J=4 Hz, 1H), 3.99(t, J=8 Hz, 1H), 3.94(t, J=4 Hz, 1H), 3.84(d, J=4 Hz, 
0.4H), 3.82(s, 0.6H), 3.70-3.47(m, 16H), 3.37(s, 3H), 2.22(s, 1H), 2.08(s, 1H), 1.40(s, 
18H). 13C NMR (100 MHz, CDCl3): δ 173.40, 156.08, 154.77, 139.18, 138.86, 138.29, 
128.47, 128.38, 127.77, 127.68, 127.57, 127.50, 101.70, 85.49, 82.00, 79.85, 79.53, 
73.56, 72.75, 72.29, 71.60, 70.78, 70.62, 70.49, 70.40, 67.04, 62.50, 55.62, 52.72, 
44.93, 32.84, 28.50. HRMS (ESI): Calcd. for C48H68N2NaO14 [M + Na]+, 919.4563; 
Found, 919.4562. 
Methyl3,5,6-tri-O-benzyl-2-O-[2-(4-methoxy-4-oxo-3-(2,2,2-trifluoroacetamido)-3
-((2,2,2-trifluoroacetamido)methyl)butoxy)ethoxy]-α-D-glucofuranoside (5.6) 
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Trifluoroacetic acid (4.0 mL) was added dropwise to a solution of 5.5 (0.25 g, 0.28 
mmol) in DCM (10 mL) under nitrogen. The resulting mixture was stirred at RT for 
3h. The volatiles were removed under reduced pressure to give a crude oil which was 
used for the next step without further purification by dissolving it in DCM (15 mL) at 
0°C, To the above solution was added triethylamine (0.2 mL) and trifluoroacetic 
anhydride (0.2 mL), The mixture was stirred at room temperature for 1 h. The solvent 
was removed under reduced pressure and the crude product was purified by flash 
chromatography (CH2Cl2/acetone 20:1) to afford the title compound 5.6 (180 mg, 
73%). 1H NMR (400 MHz, CDCl3) : δ 8.63(bs, 1H), 7.58(bs, 1H), 7.30-7.22(m, 15H), 
4.94(d, J = 3.76 Hz, 1H), 4.75(d, J = 11.67 Hz, 1H), 4.61(d, J = 12 Hz, 1H), 4.52(d, J 
= 12 Hz, 3H), 4.29(t, J = 6 Hz, 1H), 4.17(t, J = 6 Hz, 1H), 4.00-3.55(m, 20H), 3.37(s, 
3H), 2.19-2.12(m, 2H). 13C NMR (100 MHz, CDCl3): δ 171.01, 157.74(q, 2×COCF3), 
139.09, 138.80, 138.22, 127.35-128.49, 114.27(q, 2×COCF3), 101.65, 85.30, 81.93, 
73.52, 72.69, 72.33, 72.31, 71.41, 70.84, 70.65, 70.30, 70.24, 67.08, 63.14, 55.59, 
53.52, 43.20, 32.98. HRMS (ESI): Calcd. for C42H50F6N2NaO12: [M + Na]+, 911.3160; 
Found, 911.3160. 
1,3,4,6-Tetra-O-acetyl-2-O-[2-(4-methoxy-4-oxo-3-(2,2,2-trifluoroacetamido)-3-((
2,2,2-trifluoroacetamido)methyl)butoxy)ethoxy]-β-D-glucopyranose (5.7) 10% 
Pd/C (60 mg) was added to a solution of 5.6 (130 mg, 0.15 mmol) in MeOH (20 ml), 
and the reaction mixture was stirred overnight at room temperature under H2 
atmosphere. Then, the mixture was filtered through celite and solvent removal under 
reduced pressure gave 85 mg (94%) of 5 as a colorless oil that was used in the next 
step without further purification. 
To a solution of above crude product (85 mg, 0.14 mmol) in acidic anhydride (1.9 mL) 
at 0˚C was added trimethylsilyl trifluoromethanesulphonate (25 μL). The reaction was 
allowed to stir for 1 h at 0˚C. After which it was poured into NaHCO3-ice-water and 
extracted with DCM, The organic layer was dried with Na2SO4, then filtered and 
concentrated by rotary evaporation. The product was isolated by flash column 
chromatography using a gradient of CHCl2/acetone to yield 5.7 (66 mg, 61%) as a 
colorless oil. 1H NMR (400 MHz, CDCl3) : δ 8.58(s, 1H), 7.56(s, 1H), 6.12(s, 1H), 
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5.29(m, 2H), 4.54-4.62(m, 2H), 4.10(dd, 1H, J = 12.4, 2.4Hz), 4.02(m, 1H), 3.91(m, 
2H), 3.78(m, 6H), 3.60(m, 7H), 2.26(m, 2H), 2.00-2.16(m, 12H). HRMS (ESI): Calcd. 
for C28H38F6N2NaO16:[M + Na]+, 795.2018; Found, 795.2017. 
[Re(G2)(CO)3] (5.8a) Lithium hydroxide monohydrate (21 mg, 0.5 mmol) and water 
(1.0 mL) were added sequentially to a solution of 5.7 (39 mg, 0.05 mmol) dissolved in 
THF (3.0 mL) at room temperature. After stirring the mixture for 20 h, The solution 
was treated with Amberlite IR-120 (H+) resin and stirred for 2 h. The solution was 
then filtered and evaporated to afford G2 as an oil, which was dissolved in water. 
[NEt4]2[ReBr3(CO)3] (38 mg, 0.05 mmol) was added and the mixture was heated to 
70˚C for 5 h. The solvent was then removed in vacuo and the residue was purified by 
silica gel chromatography to afford the product as a hydroscopic solid (29 mg, 87%). 
1H NMR (500 MHz, D2O): δ 5.27(d, 0.4H, J = 3.5Hz), 4.64(d, 0.6H, J = 8Hz), 4.39(m, 
1H), 3.61-3.99(m, 13H), 3.30-3.42(m, 2H). 2.84-2.88(m, 1H), 2.70-2.73(m, 1H), 
2.07-2.10(m, 1H), 1.93-1.96(m, 1H). Anal. Calcd. for C18H31N2O14Re: C, 31.53; H, 
4.56; N, 4.09. Found: C, 31.39; H, 4.48; N, 3.91. MS-ESI: m/z 691.1 (calcd. for 
C18H29N2NaO13Re 691.11) [(M + Na)+]  
1,2:5,6-di-O-isopropylidene-α-D-glucofuranoside (5.9) To a slurry of D-glucose 
(1.8 g, 10 mmol) in dry acetone (35 mL) was added H2SO4-silica (200 mg). The 
mixture was refluxed for 3 h. Then it was filtered through a pad of Celite and the 
solvent was removed in vacuo and the crude product was purified by silica gel 
comlum to give the target compound 5.9 as a white solid(1.7 g, 65%). 1H NMR (400 
MHz, CDCl3) : δ 5.97(d, 1H, J = 3.6Hz), 4.56(d, 1H, J = 3.6Hz), 4.35-4.40(m, 2H), 
4.20(dd, 1H, J = 6.2Hz, 8.6Hz), 4.11(dd, 1H, J = 2.8Hz, 7.6 Hz), 4.00(dd, 1H, J = 
5.4Hz, J = 8.6Hz), 1.35-1.53(m, 12H). MS-ESI: m/z 283.1 (calcd. for C12H20NaO6 
283.12) [(M + Na)+]. 
3-O-([2-(3-(tert-butoxycarbonyl)-3-((tert-butoxycarbonyl)methyl)-4-methoxy-4-o
xobutoxy)ethoxy])-1,2:5,6-di-O-isopropylidene-α-D-glucofuranoside (5.10) To a 
solution of 0.030 g (0.12 mmol)) of 5.9 in 3 mL of DMF was added 10 mg of NaH 
(0.42 mmol). After stirring this mixture at room temperature for 30 min, a solution of 
bromide 3.11(0.15 g, 0.29 mmol) in 0.5 ml DMF was added. The obtained suspension 
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was stirred overnight with slowly increasing temperature from 0 °C to room 
temperature. The solvent was removed in vacuo and the residue was purified by 
column chromatography (over SiO2 eluting with 2:1 Hexane/EtOAc) gave 5.10 as a 
clear oil (70%). 1H NMR (400 MHz, CDCl3): δ 5.95(s, 1H), 5.82(d, 1H, J = 3.6Hz), 
5.02(s, 1H), 4.53(d, 1H, J = 3.6Hz), 4.25-4.28(m, 1H), 4.04-4.09(m, 2H), 3.93-3.96(m, 
1H), 3.88(d, 1H, J = 2.8Hz), 3.44-3.75(m, 15H), 2.23-2.26(m, 1H), 2.05-2.09(m, 1H), 
1.27-1.45(m, 30H). 13C NMR (100 MHz, CDCl3 ): δ 173.23, 155.90, 154.61, 111.72, 
108.89, 105.24, 82.71, 81.12, 79.69, 79.38, 72.54, 70.47, 70.33, 70.04, 69.92, 67.20, 
62.29, 52.51, 44.71, 32.59, 28.32, 26.80, 26.25, 25.44. HRMS (ESI): Calcd. for 
C32H56N2NaO14: [M + Na]+, 715.3624; Found, 715.3627. 
[Re(G3)(CO)3] (5.11a) Compound 5.10 (21mg, 0.03mmol) was added to a 
trifluoroacetic acid/water (1:1) mixture and the solution was stirred at room 
temperature for 3 h. Concentration of the solution give a yellow oily residue that was 
dissolved in THF:H2O (1:1), Lithium hydroxide monohydrate (4 mg, 0.09 mmol) was 
added and the solution was stirred for 5 h. Amberlite IR-120 (H+) resin was used to 
neutralize the above solution which was concentrated to afford a syrup G3 in 
quantitative yield. To a solution of above syrup in water (2 mL) was added 
[NEt4]2[Re(CO)3Br3] (23 mg, 0.03 mmol). The resulting solution was heated to 70˚C 
for 4 h. The solvent was then removed in vacuo and the residue was purified by silica 
gel chromatography to afford the product 5.11a as a hydroscopic solid (15 mg, 75%).  
1H NMR (400 MHz, D2O): δ 5.17(d, 0.5H, J = 3Hz)), 4.60(d, 0.5H, J = 8Hz), 
4.38-4.41(m, 1H), 3.95-3.97(m, 2H), 3.47-3.86(m, 13H), 2.87-2.90(m, 1H), 
2.70-2.73(m, 1H), 2.07-2.09(m, 1H), 1.94-1.97(m, 1H). HRMS (ESI): Calcd. for 
C18H29N2NaO13Re [M + Na]+, 691.1120; Found, 691.1126. 
Benzyl 2,3,4,6-tetra-O-benzyl-β-D-glucopyranoside (5.12) To a solution of 
powdered KOH (3.5 g, 63.5 mmol) in 4 mL of Me2SO cooled in an ice bath was 
added D-Glucose (1.0 g, 5.6 mmol). BnBr (4.8 mL, 40.3 mmol) was immediately 
added dropwise over a period of 30 min. The reaction was allowed to come slowly to 
room temperature. After stirring for 24 h, the reaction was diluted with 60 mL of cold 
water and then extracted with methyl tert-butyl ether, the combined organics were 
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washed with water, brine, dried (MgSO4) and concentrated. The residue was purified 
by silica gel chromatography (EtOAc/hexane 1:10) to afford the product (2.12 g, 60%) 
as a white solid. 1H NMR (300 MHz, CDCl3): δ 7.37-7.15(m, 25H), 5.02-4.52(m, 
11H), 3.77-3.63(m, 6H). 
Benzyl 6-O-acetyl-2,3,4-tri-O-benzyl-β-D-glucopyranoside (5.13) To a solution of 
5.12 (2.5 g, 4 mmol) in 15 ml Ac2O/HOAc (5:1) was added a solution of freshly fused 
ZnCl2 (2.7 g, 20 mmol) in 15 ml Ac2O/HOAc (5:1), the mixture was stirred at room 
temperature for 90 min, and then water was added, the mixture was extracted with 
dichloromethane three times, and the combined organic phase was washed with 
saturated sodium carbonate, water, brine, dried over Na2SO4, and concentrated to give 
a syrup. Purification by chromatography gave 13 (1.20 g, 52%) as a white solid. 1H 
NMR (400 MHz, CDCl3): δ 7.21-7.32(m, 20H), 4.89-4.94(m, 3H), 4.46-4.84(m, 6H), 
4.35(d, J = 11.6 Hz, 1H), 4.22(dd, J = 12.0 Hz, 4.8 Hz, 1H), 3.61-3.65(m, 1H), 
3.45-3.50(m, 3H), 2.02(s, 3H). MS-ESI: m/z 605.3(calcd. for C36H38NaO7 605.25) 
[(M + Na)+].  
Benzyl 2,3,4-tri-O-benzyl-β-D-glucopyranoside (5.14) A suspension of 5.13(1.19g, 
2mmol) in 15 mL of 0.025 M NaOMe in MeOH was stirred for 10 h. The reaction 
mixture was evaporated to dryness. The residue was dissolved in methyl tert-butyl 
ether and washed with water and brine, dried (Na2SO4), and concentrated. Purification 
by chromatography give 14 (0.96g, 89%) as a white solid. 1H NMR (400 MHz, 
CDCl3): δ 7.30-7.33(m, 20H), 4.66-5.00(m, 8H), 4.62(d, 1H, 8Hz), 3.89-3.92(m, 1H), 
3.68-3.73(m, 2H), 3.60(t, 1H, J = 9 Hz), 3.52(dd, 1H, J = 8Hz, 9Hz), 3.39-3.41(m, 
1H). MS-ESI: m/z 563.3 (calcd. for C34H36NaO6 563.24) [(M + Na)+] 
Benzyl2,3,4,-tri-O-benzyl-6-O-([2-(3-(tert-butoxycarbonyl)-3-((tert-butoxycarbo
nyl)methyl)-4-methoxy-4-oxobutoxy)ethoxy])-β-D-glucopyranoside (5.15) To a 
stirred solution of 5.14 (520 mg, 0.96 mmol) in DMF(10 ml) at 0 °C was added 
sodium hydride (80 mg, 3.33 mmol). The mixture was stirred at room temperature for 
30 min, and then a solution of bromide 3.11(1.55 g, 3.02 mmol) in DMF (1.5 mL) was 
added dropwise. The obtained suspension was stirred overnight with increasing 
temperature from 0 °C to room temperature. The excess of sodium hydride was then 
destroyed by addition of methanol (1.0 ml). The volatiles were removed under 
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reduced pressure, and the residue was taken up into EtOAc and washed with brine, 
dried (MgSO4), and concentrated. Purification by chromatography gave 5.15 as a 
colourless oil(485mg, 52%). 1H NMR (400 MHz, CDCl3) : δ 7.21-7.28(m, 20H), 
5.94(s, 1H), 5.00(s, 1H), 4.60-4.89(m, 8H), 4.46(d, 1H, J = 8Hz), 3.41-3.67(m, 21H), 
2.05-2.19(m, 2H), 1.38(s, 18H). 13C NMR (100 MHz, CDCl3 ): δ 173.39, 156.05, 
154.76, 137.61-138.77, 127.74-128.57, 102.75, 84.85, 82.25, 80.08, 79.82, 79.49, 
75.10, 71.28, 70.72, 70.56, 70.32, 66.25, 62.44, 52.67, 44.87, 32.81, 28.54. 
[Re(G4)(CO)3] (5.16a) Trifluoroacetic acid (1.5 mL) was added dropwise to a 
solution of 5.15 (80 mg, 0.082 mmol) in DCM (4 mL) under nitrogen. The resulting 
mixture was stirred at RT for 5 h. The volatiles were removed under reduced pressure to 
give a crude oil which was dissolved in MeOH (15 ml). To the above solution was 
added 10% Pd/C (100 mg). The reaction mixture was stirred for 24 h at room 
temperature under H2 atmosphere. The suspension was then filtered over a Celite pad 
and concentrated to dryness to afford a colorless oil which was dissolved in THF:H2O 
(1:1), LiOH was added and the solution was stirred overnight. The solution was 
neutralized with Amberlite IR-120 (H+) resin. After removing the resin by filtration, 
the solution was concentrated to afford a syrup G4 (20.0 mg, 0.05 mmol) which was 
dissolved in water (3mL), [NEt4]2[ReBr3(CO)3] (38.4 mg, 0.05 mmol) was added and 
the solution was heated to 70˚C for 5 h. The solvent was then removed in vacuo and 
the residue purified by silica gel chromatography to afford the product as a white 
solid(27.7 mg, 83%). 1H NMR (400 MHz, D2O): δ 4.58(d, 1H, J=8Hz), 4.38-4.40(m, 
1H), 3.90-3.92(m, 1H), 3.80(dd, 1H, J = 2.0 Hz, 11.3Hz), 3.61-3.72(m, 13H). 
2.85-2.89(m, 1H), 2.70-2.74(m, 1H), 2.06-2.10(m, 1H), 1.94-1.98(m, 1H). Anal. 
Calcd. for C18H31N2O14Re: C, 31.53; H, 4.56; N, 4.09. Found: C, 31.80; H, 4.46; N, 
3.99. MS-ESI: m/z 669.1(calcd. for C18H30N2O13Re 669.13) [(M + H)+]  
 
8.6 Synthesis and characterization of compounds in Chapter 6 
BBN analogues synthesis 
Peptides were prepared either on an automated peptide synthesizer or by manual 
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synthesis using Fmoc chemistry. The BBN analogs prepared and characterized were: 
NH2-Lys(Dap)-Gln-Trp-Ala-Val-Gly-His-Leu-Met-CONH2 (N-terminal, L1),  
NH2-Gln-Trp-Ala-Val-Lys(Dap)-Gly-His-Leu-Met-CONH2 (integrated, L2), and 
NH2-Gln-Trp-Ala-Val-Gly-His-Leu-Met-Lys(Dap)-CONH2 (C-terminal, L3). Peptide 
synthesis used traditional Fmoc chemistry with HBTU or HATU activation of the 
carboxylate groups on the reactant for coupling with the N-terminal amino group on 
the growing peptide anchored via the C-terminus to the resin. Rink Amide MBHA 
resin and Fmoc-protected amino acids with appropriate side-chain protection were 
used for the synthesis. A fourfold excess of Fmoc amino acid and two equivalent of 
SAAC 40 were employed for each coupling. The final products were cleaved from the 
resin by a standard procedure using a cocktail containing thioanisol, water, phenol, 
and trifluoroacetic acid in a ratio of 5:5:5:85 and precipitated into methyl-t-butyl ether. 
Crude peptides were purified by preparative HPLC monitored at 278 nm (gradient 
from 0 to 100% solvent B over the course of 60 min). ESI-MS was used to determine 
the molecular constitution of the conjugates. ESI-MS for L1, L2, L3: m/z: 1183.7 [(M 
+ H)+].  
Cyclic RGD peptide (L4) synthesis 
The peptide was synthesized by solid-phase peptide synthesis (SPPS) on 2-chlorotrityl 
chloride resin using Fmoc-strategy. L-glycine was loaded on the 2-chlorotrityl 
chloride resin as a first amino acid. 2-chlorotrityl chloride resin (1g, loading: 
1.56mmol/g) was placed in a sintered glass funnel and the resin was washed and 
swelled twice with dry DMC. Then a solution of Fmoc-Gly-OH (208mg, 0.7mmol) 
and DIEA (0.44ml, 2.8mmol) in dry DCM (10ml) was added immediately to the resin. 
The flask was sealed and the reaction mixture was agitated for 1 hour at room 
temperature. After the coupling reaction, the unreacted sites on the resin was capped 
by washing with a mixture of DCM/MeOH/DIEA (17:2:1) (3×) fellowed by washing 
with dry DCM (3×), dry DMF (2×), dry DCM (2×). Then the resin was dried in 
vacuum. To determine the amino acid loading 1-2 mg of resin were placed in a 
cuvette and 20%(vv) piperidine/DMF was added in order to deprotect Fmoc. The 
OD290 was measured against a blank (20% piperidine/DMF). The amino acid loading 
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was then calculated according to the following equation: Fmoc-loading = 
(OD290(sample)-OD290(blank))/(1.75×mg(resin)). The amount of resin needed for the 
peptide synthesis was calculated. 
Subsequently, Fmoc-Arg(Pbf)-OH, SAAC, Fmoc-D-Tyr(tBu)-OH, and 
Fmoc-Asp(OtBu)  were coupled with HBTU (4 equiv), HOBt (4 equiv) and 
DIEA(10 equiv) in DMF. Cleavage of protected linear peptide from the resin was 
performed without affecting the side chain protecting groups by using a mild 0.8% 
TFA/CH2Cl2 (1:1:8) mixture. Head-to-tail cyclization was carried out in DMF with 
HBTU (4 equiv), HOBt (4 equiv) and DIEA (10 equiv). The side chain protecting 
groups were removed by treatment with trifluoroacetic acid/water/triisopropylsilane 
(TIS)) (95:2.5:2.5) at room temperature for 1.5 h. The reaction mixture was 
concentrated and precipitated with ice-cold ether and purified by preparative HPLC 
monitored at 226nm(Method for L4, L7, L9, L6: Gradient E; L5, L8: Gradient F) 
ESI-MS for L4 m/z: 707.3 [(M + H)+], 354.1 [(M + 2H)2+]; L5: m/z: 909.2 [(M + H)+], 
455.2 [(M + 2H)2+]; L6: m/z: 823.3 [(M + H)+], 412.3 [(M + 2H)2+]; L7: m/z: 824.2 
[(M + H)+], 412.7 [(M + 2H)2+]; L8: m/z: 778.2 [(M + H)+], 389.7 [(M + 2H)2+]; L9: 
m/z: 795.4 [(M + H)+], 398.3 [(M + 2H)2+]. 
Synthesis of Re-peptide conjugates. An excess of (NEt4)2[ReBr3(CO)3] was added 
to 6 mg of an aqueous solution of L1-L9 respectively. The solution was heated at 
70°C for 6-20h (longer times do not reduce the yields) with stirring. Microwave was 
used to speed up the reactions. Quality control of the reaction mixture was done by 
RP-HPLC. The desired product was purified by HPLC, lyophilized and characterized 
by ESI-MS. ESI-MS for 6.1a, 6.2a, 6.3a: m/z: 1425.6 [(M + H)+], 713.3 [(M + 2H)2+]; 
6.7a: m/z: 1121.2 [M–]; 6.8a: m/z: 1093.5 [M+]; 6.9a: m/z: 990.2 [M–]; 6.10a: m/z: 
1094.5 [(M + H)+]. 
[99mTc(OH2)3(CO)3]+ Labeling. The precursor [99mTc(OH2)3(CO)3]+ was prepared 
using an IsoLink® Kit with 1.0–2.5 GBq of Na99mTcO4 in 1-2 ml saline.(154) After 
neutralization to pH = 7 with HCl, quantitative labeling was achieved by mixing an 
aliquot of the [99mTc(OH2)3(CO)3]+ precursor with a 0.1 mM stock solution of L1-L9 
at 90°C for 30 min. Quality control (radiochemical yield and purity determination) of 
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the product was determined by RP-HPLC. The identity was assessed by comparing 
HPLC retention times with the corresponding rhenium compounds (coinjection). 
 
HPLC and MS analysis of peptide conjugates 
 
The HPLC-MS (UV) trace of L1(Nucleodur C18 Column, Gradient A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The HPLC-MS (UV) trace of compound 6.1a(Nucleodur C18 Column, Gradient A) 
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The HPLC-MS (UV) trace of L2 (Nucleosil C18 Column, Gradient A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The HPLC traces of compound 6.2a, 6.2b (Gradient C) 
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Mass Spectrum of compound 6.2a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The HPLC-MS (UV) trace of L3 (Nucleosil C18 Column, Gradient A) 
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The HPLC traces of compound 6.3a, 6.3b (Gradient B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass Spectrum of compound 6.3a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The HPLC trace of compound L4(Gradient D) 
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Mass Spectrum of compound L4, 6.6a 
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